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ABSTRACT 
Biosynthesis and folding of proteins entering the secretory pathway of eukaryotic 
cells is coordinated at the endoplasmic reticulum (ER). Any terminally misfolded 
proteins are sorted for the endoplasmic reticulum associated degradation (ERAD) 
pathway for destruction. Eeyarestatin I (ESI) is a potent inhibitor of certain 
stages of protein biogenesis at the ER including protein translocation across the 
ER and deubiquitination, a late stage of the ERAD process.  
Here several structurally related Eeyarestatins (ES) were synthesised based on 
key structural requirements shown in ESI and the structural activity relationship 
of these compounds both in vivo and in vitro was investigated. Experiments 
conducted included: cytotoxicity to determine toxicity of ES compounds at 
several concentrations; cell microscopy to identify vacuole formation frequently 
exhibited by ESI; SDS page electrophoresis and western blotting for ubiquitin to 
ascertain the extent of accumulation of ubiquitinated protein and indicator of 
inhibition of deubiquitination; a translocation block assay looking to determine 
the inhibitory effect the ES compounds have on translocation of selected proteins 
across the ER membrane; and finally a secretion assay to determine the ES 
compound’s ability to block overall secretion of proteins from cells. Whilst none 
of the “new” analogues seem to be equipotent to ESI in all inhibitory activities, 
inhibitory activity of compounds ES40, ES24 Click meta and ES24 Click para 
appear to be more specific towards DUBs, with ES40 being the most active. 
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CHAPTER 1: INTRODUCTION 
1.1 Protein biosynthesis and quality control 
Proteins are biochemical compounds consisting of one or more polypeptides 
typically folded into a globular or fibrous form, facilitating a biological function (e.g. 
enzymatic, structural, mechanical or cell signalling). Like other biological 
macromolecules such as polysaccharides and nucleic acids, proteins are essential 
parts of organisms and participate in virtually every process within cells.1  
Cells are made up of many organelles contained within a cell membrane including a 
nucleus, ribosomes, rough and smooth endoplasmic reticulum, Golgi apparatus and 
many more, which are separately enclosed in their own lipid bilayers called 
membranes and the space in between filled with cytosol.2  
 
 
Figure 1.1. Simple overview of the secretory pathway in eukaryotic cells (Taken from 
Wellesley college3) This process is broken down into four general steps: Step 1 protein import in the 
ER followed by protein folding; Step 2 ER to Golgi transport in vesicles; Step 3 Intra-Golgi vesicle 
transport and finally Step 4 Post-Golgi transport to the cell exterior, lysosome or vacuoles. The large 
arrow shows the overall flow of proteins through the secretory pathway. 
 
Although the protein synthesis (translation) begins on ribosomes located in the 
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cytosol, proteins can be directed to particular locations within the cell by the 
presence of specific targeting signals. Approximately one third of the proteome is 
predicted to have a signal sequence that will result in targeting to the endoplasmic 
reticulum (ER)4. The endoplasmic reticulum is a network of tubules, vesicles and 
sacs that are interconnected. Proteins may serve specialised functions in the cell 
including protein synthesis, insertion of membrane proteins, sequestration of calcium 
and production of steroids amongst others.2 Most membrane proteins (i.e. proteins 
that are inserted into the membrane) and proteins that are destined to be released 
from cells (secretory proteins) are synthesised at the ER. Once targeted to the ER, 
these proteins are threaded across the ER membrane (a process called translocation) 
as linear polypeptide chains, which then must fold into the correct three-dimensional 
state. Properly folded proteins are recruited into membrane bound vesicles, which 
bud off from the ER and transport them to the Golgi apparatus (Figure 1.1). The 
Golgi acts as a sorting station to deliver secretory and membrane proteins to their 
correct destination within the cell (Figure 1.1). 
However, protein biogenesis is surprisingly inefficient. It has been estimated that 
around 30 % of all newly synthesised proteins are in some way defective and are 
rapidly degraded.5 Errors in transcription and translation can lead to the 
incorporation of incorrect amino acids leading to a polypeptide that is unable to fold 
correctly. Even with the correct sequence of amino acids folding is intrinsically 
error-prone. Furthermore, the efficiency of protein folding can be compromised 
under various situations, including environmental stress or due to genetic mutation. 
Effective removal of these defective proteins and the recycling of their constituent 
amino acids is vital for cellular homeostasis and survival. Defective proteins may 
compete with their functional equivalents for substrate binding or complex 
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formation, thereby engaging in harmful non-native interactions and this ultimately 
can lead to disease.6 Misfolded or damaged proteins may also form toxic aggregates. 
Although the toxicity of aberrant cytosolic proteins is usually restricted to the host 
cell, secretory and transmembrane proteins are released from the cell or exposed at 
its surface thereby posing a greater risk. In particular, they have the potential to 
interfere with cell-to-cell communication, disrupt development and even prevent 
recognition by the immune system.7 This scenario is normally averted by a sequence 
of quality control steps at the site of secretory and membrane protein biogenesis, the 
ER.8 This quality control system monitors protein folding and assembly and prevents 
the forward transport of non-native polypeptides.9 Proteins that are retained by the 
ER quality control are typically degraded by a process called ER-associated 
degradation (ERAD), in which the misfolded protein is transported back into the 
cytosol and degraded by the proteasome.10 Thus, ERAD is an essential mechanism to 
prevent the accumulation of misfolded proteins within the ER.  
 
1.2 Protein synthesis at the endoplasmic reticulum 
1.2.1 Protein targeting and translocation at the endoplasmic reticulum 
Targeting of secretory proteins to the ER is mediated by a hydrophobic signal 
peptide that is typically at the N-terminus of a polypeptide and is usually 15-30 
residues in length.11 Secretory proteins enter the ER lumen through a proteinaceous 
channel, the Sec61 complex embedded in the ER membrane and via either co- 
translational means (i.e. at the same time as translation is occurring) or post-
translational means (i.e. after translation of the polypeptide is completed).9, 11, 12  
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In mammalian cells most proteins appear to be translocated into the ER co-
translationally (Figure 1.2).2, 11 The signal recognition particle (SRP) binds to the 
signal peptide on the N-terminus of the nascent polypeptide when it is exposed from 
the ribosome, causing a pause in translation (Figure 1.2 a).2, 12, 13 The SRP bound 
ribosome then selectively binds to the SRP receptor in the ER membrane (Figure 1.2 
b)), SRP is displaced and the ribosome binds to the translocon. The nascent chain is 
transferred to the Sec61 complex and translation then continues (Figure 1.2 c). As 
the polypeptide is synthesised it is translocated into the ER lumen through the Sec61 
complex using GTP hydrolysis as the energy source to drive protein synthesis.14 The 
signal peptide may be cleaved from the nascent polypeptide by a signal peptidase as 
translation continues, and the mature polypeptide is finally released into the ER 
lumen. 
 
Figure 1.2 Co-translational translocation of polypeptides is mediated by SRP (Modified 
from Alberts et al2). a) SRP binds to the signal peptide on the growing polypeptide chain causing a 
pause in translation; b) The SRP bound ribosome then binds to the SRP receptor in the ER membrane; 
c) SRP is displaced and the ribosome binds to the translocon and translation continues. 
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The simplest transmembrane proteins are targeted in a similar fashion, a signal 
peptide on the amino terminus initiates translocation, but the polypeptide contains an 
extra hydrophobic sequence (orange segment in Figure 1.3), which stops 
translocation across the ER membrane.2 When this stop-transfer segment enters the 
Sec61 translocon and interacts with a putative binding site, translocation stops, the 
translocator opens up and discharges the protein laterally into the lipid bilayer this 
process is known as integration.2, 11, 14 In this case the signal peptide sequence is 
usually cleaved after insertion (Figure 1.3).15  
 
 
Figure 1.3 Simple transmembrane protein after membrane insertion. (Modified from 
Alberts et al2) 
 
Other transmembrane proteins contain a signal sequence embedded further in the 
polypeptide chain. This signal is still recognised by the SRP as for N-terminus signal 
peptides, the difference is that when the translocon releases the polypeptide into the 
lipid bilayer the signal peptide itself serves as the transmembrane anchor. Such 
signal-anchor proteins can orientate in two ways, one with the carboxyl terminus on 
 20 
the lumenal side of the membrane and N-terminus on the cytosolic face and vice 
versa (Figure 1.4).2, 16 The topology depends on the orientation of the signal-anchor, 
which in turn depends on the distribution of nearby charged amino acids.2, 16 
 
 
Figure 1.4. Type I and II orientation of signal sequence and final membrane structure 
after insertion into the ER membrane 
 
Multiple pass transmembrane proteins have several hydrophobic start and stop 
transfer sequences that allow these proteins to achieve their final orientation in the 
membrane.17  
 
1.2.2 Sec61 
The Sec61 complex is an ER membrane complex composed of three major subunits 
(!, ", #; heterotrimeric) that forms a pore through the membrane.11, 18 Figure 1.5 
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shows the structure of the equivalent protein translocation channel in the bacterium 
Escherichia coli (E.Coli). This complex is well conserved and were two of the 
components, SecY and SecE, share sequence and functionality with mammalian 
Sec61! and Sec61#, which together with Sec61" (equivalent to SecG in E.Coli), 
form the Sec61 translocon in the ER membrane.13  
 
 
Figure 1.5. A protein translocator in E. Coli (Taken from Cross et al.13) 
 
Sec61! has a region called the plug that closes the pore when it is inactive (Figure 
1.5, red ribbon). This plug is believed to be displaced when a hydrophobic region of 
a nascent polypeptide interacts with another region of Sec61 denoted the seam, 
thereby allowing translocation of the polypeptide into the ER lumen.2, 14 The plug 
returns to the centre of the Sec61 complex when the nascent polypeptide chain has 
left the pore.14 
 
1.3 Protein folding and quality control at the ER 
After proteins have been translocated into the ER lumen they fold and may undergo 
post-translational modifications, such as the addition of oligosaccharides to specific 
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Asparagine residues (N-glycosylation), disulfide bond formation between cysteine 
residues and assembly with partner subunits (oligomerisation); before being 
packaged into vesicles to be transported to the Golgi for sorting to their final 
destinations. 
 
1.3.1 Chaperones 
As the polypeptide is exposed on the lumenal side of the ER membrane, molecular 
chaperones bind to it and initiate protein folding, oligomerisaton, maturation and 
post-translational modifications, which may include N-glycosylation and disulfide 
bond formation.19 Molecular chaperones are folding catalysts and there are several 
classes including: Heat shock proteins (Hsp’s) including BiP and cofactors, which 
are ATPases involved in initial folding and recognition of non-native proteins; 
Oxidoreductases (e.g. Protein disulfide isomerase (PDI)), which are involved in the 
formation of disulfide bond formation or reduction and lectins (e.g. Calnexin 
(CNX)), which are involved in N-glycosylation. These chaperones are retained in the 
ER by the presence of specific amino acid sequences such as KDEL (Lys-Asp-Glu-
Leu). Most chaperones bind to unfolded proteins, promote folding, In addition, due 
to their ability to recognise signals that are present on unfolded proteins, chaperones 
form an essential part of the quality control system that identifies and retains non-
native proteins in the ER (see below). 
 
1.3.2 N-Glycosylation 
Many proteins are modified by the addition of a core glycan to specific Asparagine 
residues within the consensus sequence. N-linked glycans may be essential for the 
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protein’s function, and also facilitate folding by allowing them to interact with 
specific chaperone proteins in the ER lumen, including calnexin and calreticulin.  
The presence of N-glycans also provides a quality control mechanism for identifying 
proteins that have failed to fold properly. 
 
 
Figure 1.6. N-glycans role in quality control (Modified from Hegde and Ploegh20) 
 
The first glucose on the N-glycan is rapidly removed by glucosidase I (GI) and this 
event is followed by removal of the second glucose by glucosidase II (GII). Lectins, 
Calnexin (CNX) and Calreticulin (CRT), recognise the resulting mono-glucosylated 
N-glycan and bind to the glycoprotein. GII removes the final glucose residue and if 
correctly folded the mature protein can leave the calnexin cycle. If the protein is not 
folded correctly it is recognised by a soluble enzyme known as glycoprotein 
glucosyltransferase (GT). GT reglucosylates misfolded or incompletely folded 
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glycoproteins, which can then rebind calnexin and reinitiate the chaperone-mediated 
protein folding process again.6, 21 If misfolding is terminal then an ER-resident 
mannose trimming enzyme, mannosidase I (ER !ManI), acts upon the core glycan 
and removes one terminal mannose from N-glycans. This generates an 8-mannose 
‘degradation signal’ that is recognised by the ER quality control and ERAD 
machinery.6  
 
1.4 Endoplasmic reticulum associated degradation 
Proteins that are identified by the quality control system as being non-native are 
retained in or returned to the ER and are ultimately degraded via ERAD. ERAD is 
not mediated within the ER lumen but by the cytosolic proteasome, which is a 
mutisubunit protease complex and a major pathway for degradation of proteins. It is 
composed of a barrel shaped core particle, which contains the protease subunits, and 
two lids that control entry into the proteolytic core.4 In order to be degraded by the 
proteasome, misfolded proteins in the ER must therefore be translocated back across 
the ER membrane into the cytosol, a process called retro-translocation.22 
The process of selective protein export from the ER to the cytosol followed by 
proteosomal degradation is known as endoplasmic reticulum associated degradation 
(ERAD).6 This degradation process is responsible for the destruction of both integral 
membrane and lumenal proteins, and is usually selective for non-native proteins. 
Damaged, unfolded or misfolded proteins are targeted for degradation, correctly 
folded ones are spared.23 
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Figure 1.7.  Step by step illustration of the ERAD pathway (Taken from Vembar and 
Brodsky24). a) Protein recognition. Misfolded proteins are recognised by molecular chaperones that 
facilitate their folding; b) Protein targeting. ERAD substrates are targeted to the retro-translocation 
machinery (the retro-translocon) and/or to E3 ligases; c) Retro-translocation initiation. Precisely how 
ERAD substrates are retro-translocated is not known but it is believed that Cdc48(p97) provides the 
driving force for this process; d) Ubiquitination and further retro-translocation. As proteins exit the 
retro-translocon they are polyubiquitinated by E3 ubiquitin ligases; e) Proteasomal targeting and 
degradation. Once a polyubiquitinated substrate is displaced into the cytoplasm, it is recognised by 
receptors in the 19S cap of the 26S proteasome. De-ubiquitinating enzymes (not shown) remove the 
polyubiquitin tag. The substrate is degraded into peptide fragments by the 20S catalytic core of the 
proteasome. 
 
 
The ERAD pathway is a complex multi-step process and intense study over the past 
10-15 years has identified a large number of proteins that participate in the degradation 
of different types of misfolded proteins (or ERAD 'substrates'). In general ERAD can 
be seen to occur in distinct stages these including: Identification or recognition of 
terminally misfolded proteins; Protein targeting to retro-translocation machinery; 
Initiation of retro-translocation and ubiquitination and finally deubiquitination followed 
by proteasomal degradation (Figure 1.7).  
In the case of ERAD, small molecule inhibitors of the pathway are needed in order to 
elucidate the mechanistic detail at the molecular level. 
 
1.4.1 Recognition and targeting 
It is widely believed that chaperones help identify any incorrectly folded proteins for 
ERAD, by the presence of a variety of signals. 
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ER chaperone-like lectins, calnexin and calreticulin, recognise specific N-glycans on 
glycoproteins, formed when glycosylated proteins cannot fold in the ER. Calnexin 
and calreticulin bind to and retain immature glycoproteins and facilitate their folding, 
continuing this cycle until the protein folds correctly. If, however, glycoproteins 
cannot fold correctly within an appropriate timescale, they are targeted for ERAD.19 
In contrast, BiP recognises hydrophobic regions of peptides, approximately 7 
residues in length, that are usually buried inside native proteins, but may be exposed 
on the surface of misfolded/unfolded proteins.25 BiP recognises non-native proteins 
and retains them in the ER, and helps target those that are terminally misfolded to the 
retro-translocation machinery.19 In some cases subsequent interaction with protein 
disulfide isomerase (PDI) is required for ERAD, most likely because the reduction of 
disulfide bonds is required to enable the passage of the misfolded protein back across 
the ER membrane and back to the cytosol.26  
Chaperones also participate in the cellular unfolded protein response; hence if there 
is an accumulation of unfolded proteins then chaperones bind to them causing a 
reduction in the concentration of free chaperones. This reduction is detected by the 
cell and results in the inhibition of global synthesis of new proteins until the 
‘backlog’ is cleared up and the free chaperone concentration again increases.19 
 
1.4.2 Retro-translocation and ubiquitination 
Following identification and targeting, most ERAD substrates require the covalent 
attachment of a chain of ubiquitin molecules in order to be degraded.27 Ubiquitin is a 
small protein approximately 8.5 kDa28 that is covalently attached to target proteins 
by a cascade system of enzymes.29 Polyubiquitination occurs on the cytosolic face of 
the ER membrane and is usually coupled to retro-translocation of the ERAD 
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substrate across the ER membrane. It has been suggested that ubiquitination might 
promote movement of the polypeptide into the cytosol by preventing it slipping back 
into the ER. However, since ubiquitination takes place primarily in the cytosol it 
cannot be directly involved in initiating export of soluble proteins from the ER.  
Precisely how proteins are extracted from the ER is not known, but the Sec61 
complex is one of several possible channels that might mediate protein export out of 
the ER.22 Hence, a number of ERAD substrates can be isolated together with the 
Sec61 complex when the ER membrane is solubilised under mild conditions.30, 31 For 
many ERAD substrates ubiquitin modification takes place after the ER-lumenal N-
terminus of the protein has been made accessible to the ubiquitination machinery on 
the cytosolic face of the ER membrane.6 Both membrane and soluble proteins are 
initially polyubiquitinated and remain membrane associated.  
The ubiquitination system typically consists of E1 (ubiquitin-activating), E2 
(ubiquitin-conjugating), and E3 (ubiquitin-ligating) enzymes.29, 32 In the first step, 
which is catalysed by an E1, the COOH-terminus of ubiquitin is activated in an ATP 
dependent step and covalently linked through a thioester bond to an active-site 
cysteine in the E1. In the second step, ubiquitin is transferred from the E1 to an 
active site cysteine in one of the at least 13 known E2s in mammals. In the final step, 
which is accomplished by the action of an E3 ubiquitin-ligase, ubiquitin is covalently 
linked through an isopeptide bond to a lysine in the target protein or to another 
ubiquitin that has been linked to the target protein. ERAD substrates need to be 
ubiquitinated with at least 4 copies of ubiquitin for the proteasome to recognise them 
for degradation. E3 ligases are generally responsible for determining the substrate 
specificity of ubiquitination reactions. A number of E3 ligases contribute to ERAD, 
and these are believed to be associated with or form part of the retro-translocation 
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machinery. 
As it emerges from the ER membrane, the polyubiquitinated ERAD substrate is 
recognised by a number of ubiquitin-binding accessory proteins that help deliver it to 
the proteasome for degradation.9, 33, 34 These include the ATPase p97, which is 
believed to provide the driving force to extract the proteins from the ER membrane 
(Figure 1.8).35-37 
 
 
Figure 1.8. Protein extraction from the ER membrane (Taken from Tsai 200222) 
 
In order to enter the narrow proteolytic chamber of the proteasome, polyubiquitin 
chains must be removed from the ERAD substrate. This is achieved by the action of 
proteases termed deubiquitinating enzymes (DUBs). Several DUBs have been 
implicated in ERAD38 and two of these appear to be physically associated with p97 
(YOD1 and Ataxin-3).39, 40 Inhibition of p97-associated DUBs activity can block 
degradation of ERAD substrates.38, 39, 41 In addition, DUBs are also found associated 
with the 19S regulatory particle (lid) of the proteasome.4 
The study of ERAD would be helped by the identification of inhibitors, which block 
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particular stages in the pathway. Currently, only proteasome inhibitors, which block 
proteasomal degradation only, are available. 
 
1.5 The Unfolded Protein Response 
ERAD functions to eliminate misfolded proteins from the ER. However, in some 
situations (eg. increased synthesis of mutant proteins, adverse environmental 
conditions, decreased proteasome activity etc.), misfolded or unfolded proteins can 
accumulate. The presence of high levels of unfolded/misfolded proteins in the ER 
lumen activates a signalling pathway known as the unfolded protein response (UPR). 
The function of the UPR is to increase expression of chaperone proteins (thereby 
promoting protein folding), to decrease overall protein synthesis (thereby reducing 
the burden of newly synthesised proteins that require folding), and to increase 
expression of ERAD factors (thereby facilitating degradation of misfolded proteins). 
Together, these mechanisms help to restore homeostasis to the ER. However, if not 
successful, prolonged activation of the UPR can lead to programmed cell death. 
 
1.6 ER function and disease 
Disruption of ER protein folding, ERAD and UPR signalling pathways have been 
observed in a large number of important human diseases, including diabetes mellitus, 
cancer, neurodegeneration, bone and joint disease.42, 43 In addition, many genetic 
diseases are known to be caused by misfolding of particular secretory or membrane 
proteins leading to their premature degradation. In this way, these proteins will not 
be deployed to later compartments, as is the case in cystic fibrosis. The most 
common cause of this disease, is the deletion of phenylalanine at position 508 in the 
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membrane protein CFTR, which inhibits folding of CFTR, leading to recognition and 
degradation by the ERAD system.10 
The ubiquitin proteasome system has emerged as a therapeutic target for cancer 
treatment. For example, the proteasome inhibitor Bortezomib is an anti-cancer drug 
approved for treatment of multiple myeloma and Mantle cell lymphoma.44 
Disruption of ER homeostasis (most likely by blocking ERAD) and activation of the 
UPR is thought to be a major mechanism through which Bortezomib kills cancer 
cells.45, 46 However, because the proteasome functions in many essential cellular 
pathways, in addition to ERAD, it has many additional side effects.47 Thus, there is 
interest in additional, potentially more selective inhibitors of the ubiquitin 
proteasome system and ERAD.  
 
1.7 Small molecule inhibitors of ER function 
The use of small molecules as specific inhibitors of cellular processes has a well-
established potential to provide insights into function and molecular mechanism, and 
can additionally form the basis for therapeutic intervention in disease.48  
Compounds that interfere with ERAD include proteasome inhibitors, ER-
mannosidase I inhibitors and agents that change the redox potential in the ER.6, 49, 50 
Inhibition of ER-mannosidase I stabilises only selected misfolded glycoproteins.49 
Manipulation of redox potential by addition of alkylating reagents, such as diimide 
or N-ethylmaleimide blocks delivery of misfolded proteins from the ER to the 
cytosol, but has limited specificity.50  
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1.7.1 Eeyarestatins 
In order to identify novel small molecule inhibitors Fiebiger et al screened a 
chemical library for compounds that interfere with the US11 mediated degradation of 
a class 1 major histocompatibility complex (MHC), the heavy chain-enhanced green 
fluorescent protein fusion protein (EGFP-HC). Inhibitors of the degradation of 
EGFP-HC molecules cause them to accumulate and thus, increase fluorescence. This 
screen of 16,320 compounds identified two structurally related compounds that 
specifically increased EGFP-HC fluorescence. These were Eeyarestatin I (ESI), 1, 
and Eeyarestatin II (ESII), 2 (Figure 1.9); the inhibitory effect of these compounds 
on ERAD was validated by pulse-chase assays to determine the rate of ER substrate 
degradation in the presence/absence of compounds.  
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Figure 1.9. Structures of Eeyarestatin I and II 
 
ESI was found to be more potent than ESII and ESI also inhibited the degradation of 
another ERAD substrate T-cell receptor ! (TCR!). Fiebiger et al.51 also showed that 
degradation of misfolded proteins from the ER was impaired by the addition of ESI, 
without affecting degradation of cytosolic proteins. This suggested that ES 
compounds interfere with a step that precedes proteasomal degradation. Further 
experiments provided evidence that retro-translocation was inhibited by ESI 
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treatment, suggesting that these compounds block an early stage in the ERAD 
pathway (Figure 1.7b). This makes it a potentially valuable experimental tool with 
which to study the poorly characterised early stages in the ERAD pathway. The 
molecular target of ESI is not known. However, recent studies by Wang and co-
workers41, 52 and Cross and coworkers53 have identified several ESI inhibitory 
targets. Wang found that ESI associates with the p97 enzyme and associated DUBs, 
causing an inhibition of ERAD and an accumulation of polyubiquitinated proteins. 
They determined that ESI is bifunctional and can be divided into two parts: the 
aromatic domain on the “western” side and the nitrofuran domain on the “eastern” 
side. Wang found that the nitrofuran domain interacts with p97 causing the inhibition 
but the aromatic domain associates with the ER membrane allowing access to the 
p97 enzyme.52 From their observation they concluded that simpler membrane 
targeting groups could replace the aromatic domain to enhance membrane-targeting 
specificity. ESI, 1, also disturbs ER homeostasis and has anticancer activities 
resembling that of Bortezomib. Because ESI has the ability to cause ER stress and 
cause the accumulation of polyubiquitinated proteins it therefore has potential as a 
possible anti-cancer drug.52 The study by Cross found that ESI elicits a wide-ranging 
inhibition of co-translational protein translocation into the ER but does not affect the 
spontaneous ability of proteins to integrate into the ER membrane. They suggested 
that because of this, the inhibition of ESI is limited to proteins that require Sec61 for 
translocation and therefore indicating Sec61 as the target for this compound. They 
also discovered that ESI prevents the transfer of a nascent polypeptide from the SRP 
to the Sec61 complex, and suggested that this may be by a direct effect on the Sec61 
complex.53 Cross also showed that ESI inhibits protein secretion from cultured 
mammalian cells by analysing the secretion of pulse-labelled glycoproteins into the 
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media from HepG2 cells treated with ESI. Strikingly, ESI exhibited almost complete 
loss of secretory proteins in the media. Recent work in the High lab shows ESI 
inducing vacuolisation in HeLa cells treated with the compound, however, the reason 
for this phenomenon is still under debate.54 
 
1.7.2 Synthesis of Eeyarestatins 
Syntheses of ESI and various analogues have previously been developed in the 
Whitehead group55, which follow the general route shown in Figure 1.10. The first 
step involves a coupling reaction between glycine methyl ester and 2-chloro-2-
methyl-1-nitrosopropane.  
The following step involves nucleophilic attack of the amine 1 onto various R-
substituted isocyanates to generate a cyclic urea compound. Compounds with R1 the 
same as R2 were prepared using path A, compounds with R1 different to R2 were 
prepared using path B. 
Step 3 involves the transformation of ester group on the cyclic urea compounds to 
the corresponding hydrazide. This was followed by a coupling reaction between the 
hydrazides and (E)-3-(5-nitro-2-furyl) acrylaldehyde. 
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Figure 1.10. General synthesis of Eeyarestatins 
 
All analogues that have been prepared are shown in the tables below, table 1.1 shows 
the symmetrical analogues previously prepared via path A, table 1.2 shows the 
unsymmetrical analogues prepared via path B. ESI and ESII are compounds 1 and 2 
respectively.  
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Entry R1 R2 X 
1 (ESI) 
Cl  Cl  
O 
2 (ESII) 
Cl  Cl  
O 
3 
Cl  Cl  
S 
Table 1.1: Analogues produced by path A 
 
 
Entry R1 R2 X 
4 
Cl  Cl  
O 
5 
Cl  Cl  
O 
6 
Cl  
Cl
 
O 
7 
Cl  Cl  
O 
Table 1.2: Analogues produced by path B 
 
For analogues such as unsymmetrical methyl ester, 6 shown in Figure 1.11, there are 
no commercially available or readily synthesised isocyanates. They can however be 
prepared using carbonyl diimidazole and a corresponding amine. Methyl ester 6 was 
formed in situ from 1,1-carbonyldiimidazole and 2-aminoanthracene. 
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Figure 1.11. Methyl ester precursor to anthracenyl Eeyarestatin  
 
A second set of analogues, also prepared from the hydrazide precursor to ESI, 8, 
using different aldehydes in the final coupling reaction, is shown in Figure 1.12. 
Structures for 9, 10 and 11 are summarised in Table 1.3.  
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Figure 1.12. Alternative aldehydes to create new inhibitors 
 
 
 37 
Entry n R3 
9 1 H 
10 0 NO2 
11 0 H 
Table 1.3. Summary of analogues prepared by aldehyde variation  
 
A third set of analogues has also been prepared in the Whitehead group via the 
nucleophilic substitution by the free hydroxyl group, R1 position in Figure 1.13, of 
Eeyarestatin I and II on sulfonyl chlorides and biotin. Results are summarised in 
Table 1.4. 
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Figure 1.13. Loci for potential structural variation 
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Entry R1 R2 R3 
13 S
O
O
O
 
4-Cl-C6H4 4-Cl-C6H4 
14 
S
O
O
O
N
 
4-Cl-C6H4 4-Cl-C6H4 
15 HN NH
S
O
O
O
H H
 
4-Cl-C6H4 4-Cl-C6H4 
16 HN NH
S
O
O
O
H H
 
C10H7 C10H7 
Table 1.4. Summary of analogues prepared by variation at R1, R2 or R3 
 
A “short form” analogue of the ES compounds has also been prepared (Figure 1.14) 
which shows similar potency to ESI. It was synthesised from methyl phenyl acetate, 
which was converted into its corresponding hydrazide and then coupled with (E)-3-
(5-nitro-2-furyl)acrylaldehyde to give final product 17 . 
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Figure 1.14. “Short form” Eeyarestatin 
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1.7.3 Other inhibitors of translocation - Cotransin 
To date only CAM741 (Figure 1.15) has been identified as a selective inhibitor of 
ER translocation, in the most recent study Harant and co-workers confirmed that 
CAM741 inhibits translocation through the Sec61 complex.56, 57 A similar study by J. 
L. Garrison and co-workers showed the small molecule Cotransin also inhibits 
translocation.58 The compounds bind directly to the Sec61 complex and block its 
activity but the effect of CAM741/Cotransin is limited by substrate specificity, only 
a small subset of precursor proteins are prevented from entering the ER in the 
presence of CAM741.56-60 Whilst the compounds may bind directly, their inhibitory 
effect is determined by the properties of the nascent chain signal sequence.56, 57  
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Figure 1.15. Cyclodepsipeptides 
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CAM741 and Cotransin are analogues of known compound HUN-7293, a cyclic 
heptadepsipeptide, which is a potent inhibitor of “vascular cell adhesion molecule-1” 
(VCAM-1) expression and exhibits anti-inflammatory properties.61  
Cotransin exhibits several interesting features: firstly it contains an unnatural D-
lactic acid residue and secondly, it contains three N-methylated amino acids. Its 
synthesis has been completed in both solution and solid phases: the solution phase 
was a modification of the Boger method used to make HUN-7293;58, 61, 62 solid phase 
synthesis was accomplished by Coin and co-workers starting from the unnatural D-
lactic acid.63 Interestingly it appears that the N-methyl group on the Phe residue, 
highlighted in Figure 1.15, is critical for biological potency since, when removed, the 
compound apparently becomes inactive towards VCAM 1 expression; this 
compound is known as nor-Cotransin.58 
 
1.7.4 Synthesis of HUN-7293 and its analogues 
HUN-7293 is a naturally occurring heptadepsipeptide, which was first isolated in 
1992 from a fungal broth.61, 62 It contains six L-amino acid residues and one D-!-
hydroxy carboxylic acid residue and its stereochemistry was assigned using a 
combination of 1H NMR and X-ray crystallography.64 The Boger research group was 
the first to synthesise this molecule in solution and in the process, they prepared a 
series of analogues.61, 62 
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Figure 1.16 Retrosynthetic analysis of HUN-7293 
 
Boger used a convergent synthesis exploiting the use of the Mitsunobu reaction to 
invert the (R)-2-hydroxy-4-cyanobutyric acid (DGCN) !-centre avoiding 
racemization of the sensitive N-Me-Ala residue. The final macrocyclization between 
N-Me-Leu and a Leucine residue to form the secondary amide proved to be 
unusually effective benefiting from intramolecular H-bonding arrangement of the 
acyclic substrate (Figure 1.16).61 
Boger’s synthesis began with the preparation of amino acid constituents (4R)-5-
propyl-L-leucine (PrLeu), an N1’-methoxy-N-methyl-L-tryptophan (MTO) derivative 
and DGCN.  The PrLeu constituent was synthesised from commercially available 
(R)-(+)-citronellol as shown in Figure 1.17. 
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Figure 1.17. Synthesis of PrLeu constituent 
 
Ozonolysis followed by a Wittig reaction with methylenetriphenylphosphorane 
followed by hydrogenation gave the saturated alcohol 19. Oxidation with Dess-
Martin periodinane (DMP) gave the aldehyde, which then underwent a Strecker 
reaction without further purification giving an 8.6:1 mixture of  (S):(R) 
diastereoisomers. It wasn’t possible to separate the diastereoisomers at this stage but 
they found that after oxidative cleavage with lead acetate the free amine 22 could be 
easily separated from 21 by column chromatography. The stereochemistry was 
confirmed by synthesis of their Mosher derivatives and comparing 1H NMR spectra. 
Hydrolysis of the nitrile to the acid followed by boc protection of the amine under 
standard conditions gave PrLeu 23. 
The MTO constituent was synthesised in two ways: initially a ten-step process 
beginning with phenylacetic acid was used utilising an enantiomeric enzymatic 
hydrolysis of an N-acetate by Acylase I from Aspergillus sp to get the required 
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stereochemistry. A shorter more effective synthesis was developed from L-Abrine 
(Figure 1.18) after the original synthesis was completed. 
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Figure 1.18 Synthesis of MTO constituent 
  
After Fmoc protection and esterification the indole 24 was reduced to the 
corresponding indoline 25. The indoline was then N-oxidised with in situ reoxidation 
and subsequent O-methylation gave indole 26. Finally Fmoc deprotection gave the 
MTO derivative 27.  
The (S)-2-hydroxy-4-cyanobutyric acid (DGCN) constituent was synthesised as 
shown in Figure 1.19, the use of Mitsunobu conditions late in the synthesis of HUN-
7293 allowed the use of the naturally configured L-amino acid as a starting material. 
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Figure 1.19. Synthesis of the DGCN constituent 
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The starting material for this sequence was the Cbz protected L-Glutamine, which 
was converted into the methyl ester then dehydrated using the cyanuricchloride to 
give the desired nitrile 28. Hydrolysis of the methyl ester and removal of the Cbz via 
hydrogenolysis gave the free amino acid 29. Upon treatment with H2SO4 and NaNO2 
this gave the desired DGCN 30. It was also found that dehydration of the methyl 
ester 28 could be accomplished using Ac2O/py and subsequent hydrogenolysis also 
gave the free amino acid 29.  
With these constituents in hand attention turned to the synthesis of the tripeptide and 
the tetrapeptide.  
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Figure 1.20.  Synthesis of the tripeptide 
 
The tripeptide was synthesised as shown in Figure 1.20, from commercially available 
N-Boc-N-Me-Leu, which was treated with isobutene and H2SO4 in dichloromethane 
(DCM) to generate the t-butyl ester. These conditions simultaneously removed the 
Boc group after treatment with HCl-EtOAc to give the HCl salt 31. This was then 
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coupled to N-Boc-PrLeu 23 and the Boc group removed selectively with neat formic 
acid (30 min at rt). Finally coupling to the DGCN component under the same 
coupling conditions yielded the tripeptide 33. 
The tetrapeptide was synthesised in a convergent fashion from two dipeptides 
(Figure 1.21).  
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Figure 1.21. Synthesis of the tetrapeptide 
 
The first dipeptide 34 was prepared from N-Me-alanine methyl ester (N-Me-Ala-
OMe), which was obtained using Olsen’s procedure to N-methylate readily available 
Boc-Alanine.65 Coupling of N-Me-Ala-OMe with N-Boc-PrLeu 23 followed by 
deprotection with HCl-EtOAc gave 34. Dipeptide 35 was prepared by coupling N-
Boc-leucine (N-Boc-Leu) to MTO derivative 27 followed by hydrolysis of the ester 
with LiOH to give 35. The final peptide coupling step with HATU gave a 13:1 ratio 
of diasteroisomers 36:37, which were separated by semi-preparative high 
performance liquid chromatography (HPLC). During further studies into the 
synthesis of analogues for HUN-7293 it was found that using N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDCI), 3-hydroxytriazolo[4,5-
 46 
b]pyridine (HOAt) and 2,6-lutidine in this final step resulted in an increase in ratio 
from 13:1 to 32:1 in favour of diasteroisomer 36.62 
The final steps of the synthesis, shown in Figure 1.22, involved initial hydrolysis of 
the free ester 36 followed by a Mitsunobu displacement with tripeptide 33 to give the 
linear heptadepsipeptide 38. Finally removal of both the Boc and t-butyl protecting 
group and macrocyclization using EDCI, HOAt and NaHCO3 in dimethylformamide 
(DMF) or HATU and collidine in DCM gave HUN-7293, 39, in good yield. 
Interestingly, macrocylisation with EDCI and HOAt without base present afforded 
the epimer at the N-Me-Leucine center labelled * only.62  
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Figure 1.22. Final steps in the synthesis of HUN-7293 
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As previously mentioned, Boger and co-workers synthesised many analogues of 
HUN-7293. It is clear from Figure 1.23 that there is a huge potential for variation in 
its structure. 
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Figure 1.23.  Loci for potential structural variation in HUN-7293 
 
All of the analogues synthesised were tested for inhibition of protein expression of 
both VCAM-1 and inducible cell adhesion molecule-1 (ICAM-1); HUN-7293 
exhibited 24-fold selectivity for VCAM-1 over ICAM-1 expression. The first set of 
analogues to be investigated, shown in Table 1.5, exploited the epimerisation 
resulting from omission of the base in the macrocyclisation. Introduction of an NH 
instead of the O at the X position gave aza-HUN-7293, however this replacement 
caused a reduction in potency towards both VCAM-1 and ICAM-1. It was concluded 
that the stereochemistry of R3 Leucine is important to the properties of HUN-7293. 
Both epimers 40 and 42 caused a reduction in activity but the epimer 40 only caused 
a 2-fold reduction in activity compared to the 10-fold loss in potency of 42. 
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Compound X * 
39 (HUN-7293) O 
O
N
 
40 O 
O
N
 
41 (aza-HUN-7293) NH 
O
N
 
42 NH 
O
N
 
Table 1.5. Summary of analogues prepare by variation at Xand/or * 
 
An alanine scan on HUN-7293 was performed to ascertain the significance of each 
residue on the activity towards inhibition of protein expression of VCAM-1. This 
involved the replacement of each amino acid side chain with a methyl group whilst 
preserving the stereochemistry of the backbone. This replacement, in all cases, led to 
a reduction in potency ranging from 2 fold to 1000 fold. Changes to residue 5 were 
the most significant and residue 1 the least significant. The study also demonstrated 
that a change to R1-R4 increased selectivity towards inhibition of VCAM-1 over 
ICAM-1. Boger suggested that because of these effects then changes to R1 could be 
tolerated whereas changes to all other residues would be more challenging especially 
in the case of R5. 
 The N-methyl groups on residues 3, 5 and 7 also appeared to be significant with that 
on residue 5 the most so. Removal of the N-methyl groups resulted in a significant 
reduction in inhibition (11- and 7-fold in residues 3 and 7 respectively), but the 
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selectivity for VCAM-1 was greatly improved (54- and 180-fold respectively).  
Removal of the N-methyl group in residue 5 resulted in complete loss of inhibition. 
The analogues prepared by the Boger group are summarised in Table 1.6.62 Variation 
of the amino acids at R1, R2, R5, R6 and R7 was carried out and R5 analogues are 
shown in Figure 1.23 for clarity.  
 
Compound R1 R2 R6 R7 
39 (HUN-7293) (CH2)2CN PrLeu PrLeu CH3 
43 (CH2)3CN PrLeu PrLeu CH3 
44 (CH2)2CN (CH2)5CH3 PrLeu CH3 
45 (CH2)2CN CH2CH(CH3)2 PrLeu CH3 
45 epimer (CH2)2CN CH2CH(CH3)2 PrLeu CH3 
46 (CH2)2CN PrLeu (CH2)5CH3 CH3 
47 (CH2)2CN PrLeu CH2CH(CH3)2 CH3 
48 (CH2)2CN PrLeu PrLeu H 
Table 1.6. Summary of analogues prepared by variation at R1, R2, R6 or R7. 
 
 
The synthesis of 43 involved the incorporation of commercially available (S)-5-
cyano-2-hydroxypentanoic acid into the final step of the tripeptide synthesis. The 
analogue showed lower inhibition compared to HUN-7293 but only moderately so. 
The preparation of 44, 45 and 45 epimer involved the incorporation of (S)-
aminooctanoic acid and L-leucine into analogues of 32. Macrocyclisation of the same 
acyclic heptadepsipetide for 45 with EDCI and HOAt without base present afforded 
the epimer. 44 and 45 both showed slightly reduced inhibitory potency but slightly 
enhanced selectivity for VCAM-1. The 44 epimer again had slightly less potency 
towards inhibition but selectivity towards VCAM-1 was increased. The synthesis of 
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46 and 47 involved the incorporation of (S)-aminooctanoic acid, L-leucine and L-
glycine respectively into analogues of dipeptide 34. Analogue 46 showed similar 
potency and selectivity of inhibition of VCAM-1 expression to that of HUN-7293, 
however shortening the chain as in the case of 47 reduced potency 7-fold.  
Preparation of 48 simply involved the substitution of N-methyl alanine for N-methyl 
glycine. This simplification resulted in only slight reduction in inhibition but 
increased the selectivity for inhibition of VCAM-1 over ICAM1-1. 
Since residue 5 was the site that demonstrated the greatest effect on inhibition a more 
thorough investigation of this residue was carried out. The analogues prepared are 
summarised in Figure 1.24.  
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Figure 1.24.  Summary of analogues prepared by variation of residue 5 
 
All of these analogues required the synthesis of the corresponding N-methyl amino 
acid precursors, which was carried out using a procedure described by Coggins and 
Benoiton66 (N-methylation of the corresponding N-Boc carboxylic acid). The N-
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methyl amino acid methyl ester precursor for 56 was obtained directly by reaction of 
(S)-methyl-2-amino-5-(((benzyloxy)carbonyl)(methoxy)amino)pentanoate with 
Ag2O-MeI. The precursors for 50, 53-55 and 58-61 were all available commercially 
as their N-Boc amino acids or their unprotected amino acids. 51 and 52 were 
produced by N-methylation or N-benzylation of the commercially available 
tryptophan derivatives. Preparation of 56 was accomplished by performing a 
Mitsunobu displacement of the primary alcohol derived from reduction of Boc-L-
Glu(Ot-Bu)67 with CbzNHOMe. 49, 57 and 60 were products of hydrogenolysis of 
39 (HUN-7293), 56 and 61 after macrocyclisation. The coupling of 34 with the 
modified 35 was accomplished with EDCI, HOAt and 2,6-lutidine in order to reduce 
epimerisation. Although most of the analogues were less potent than HUN-7293 
some had surprisingly similar potency in particular 54, 55 and 58. 58 showed only 2-
fold less potency than HUN-7293, which led to Boger postulating here that the 
presence and position of hydrophobic aromatic side chains are important. 
Introduction of a more polar group into 58 as in the cases 59-61 substantially reduced 
activity, as did the removal of the methoxy group on HUN-7293 in case 49. 
Incorporation of benzothiophene gave an inhibitor (50) that was nearly equipotent to 
HUN-7293. 
Boger concluded that many of the side chains could be altered without affecting 
potency and even, in some instances, induce improvements in selectivity towards 
VCAM-1 expression inhibition. 
Cotransin, a sister compound to HUN-7293, can be prepared using the same 
synthetic approach to HUN-7293. Garrison and co-workers synthesised Cotransin by 
changing the amino acids at positions R2, R5 and R6 and using readily available L-
lactic acid at R1.58 
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1.8 Click Chemistry.  
Photoaffinity labelling is a powerful tool for identifying protein targets of 
biologically active small molecules, however, the small molecule must retain its 
biological activity after a photo reactive group has been attached.  
MacKinnon et al utilised a strategy using a photo-leucine as a photoaffinity label and 
‘clicking’ on a rhodamine-azide reporter, which in-gel fluorescent scanning revealed 
a major rhodamine labelled protein with an apparent MW of ~50 kDa.68  
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Figure 1.25 Photoaffinity labelling strategy employed by McKinnon et al to identify the 
target of heptadepsipeptide 1 (Taken from McKinnon et al60): Upon treatment with UV 
light the photoleucine loses nitrogen to give the corresponding carbene 63, the carbene 
photocrosslinks to its target protein, which was detected by “clicking” on rhodamine azide reporter.  
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The photoaffinity probe after being irradiated forms a highly reactive species that 
attaches itself irreversibly69 to the target that it blocks. Once attached proteins then 
are denatured: the fluorescent tag is attached using standard “click” chemistry 
conditions at the propargyl unit and subsequent electrophoresis fluorescent scanning 
revealed their major fluorescently labelled target (Figure 1.25). This is another 
possible way to determine the protein channels involved in the ERAD pathway. 
Nature shows a preference for the production of carbon-heteroatom bonds over 
carbon-carbon bonds. Click chemistry takes its cue from nature’s approach 
employing a set of powerful, highly reliable and selective reactions for the rapid 
synthesis of new compounds.70 There is a strict set of criteria that a process must 
meet to be grouped in the click chemistry reaction set. The reaction must be widely 
applicable, be high yielding, have inoffensive side products, which can easily 
removed by non-chromatographic means and must also be stereospecific. The 
process must also have simple reaction conditions, employ readily available starting 
materials, require the use of no solvent or a benign solvent such as water or a solvent 
that is removed easily and isolation of the product must be simple. Reactions 
satisfying all of these criteria are said to be ‘spring loaded’ for the formation of a 
single product. Carbon-heteroatom bond forming reactions comprise the most 
common examples, which include: 
• Cycloadditions of unsaturated species, 1,3-dipolar cycloadditions especially 
but also Diels Alder transformations;  
• Nucleophilic substitutions, particular ring opening of strained systems such as 
epoxides;  
• Carbonyl chemistry of non-aldol type, such as formation of amides, 
hydrazones, oximes, and ureas;  
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• Addition across carbon-carbon multiple bonds, particularly oxidative 
additions such as epoxide formation but also Michael additions.  
The most widely used of all click chemistry reactions is the Huisgen dipolar 
cycloaddition of azides and alkynes. This reaction unites two unsaturated reactants 
and provides fast access to 5-membered triazoles. The uncatalyzed azide-alkyne 
cycloaddition reaction, like all “click” reactions, is thermodynamically very 
favourable.  However, the reaction suffers from two major disadvantages, one being 
the requirement of high temperature and two being the possibility of forming both 
1,4- and 1,5-regioisomers in an equal ratio as shown in Figure 1.26.71 
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Figure 1.26. Uncatalysed click chemistry  
 
In 2002, the copper-catalyzed azide-alkyne cycloaddition was described by 
Sharpless71 and Meldal. The copper catalyst allows the reaction to proceed at rt and 
proceeds regioselectively, with the 1,4-regioisomer being the only product. It is this 
copper catalysed cycloaddition that will be utilised in this project, an example of 
which is shown below in Figure 1.27. 
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Figure 1.27. Copper cataylsed click reaction 
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This copper catalysed azide cycloaddition has been utilised in several drug 
syntheses: Kabiramide C, 64, the triazole analogue of which 65, shown in Figure 
1.28, was found to be as toxic as the precursor itself towards human cervical 
carcinoma cells.72 The alcohol was substituted by an azide and subsequent 
cycloaddition with propargylamine produced the new analogue. 
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Figure 1.28. Structures of Kabiramide C and its triazole analogue 
 
The “click” cycloaddition has also been used for structural variation of Vancomycin, 
an effective way of overcoming the problem of emerging Vancomycin-resistant 
strains of bacteria.73 
Although the “click” cycloaddition reaction is generally very successful many 
chemists are often reluctant to use it due to the fact that potentially explosive azides 
have to be used. Sharpless et al make a note of a general rule of 6: there must be six 
or more carbons or other atoms of similar size per energetic functional group, in this 
case the azide, to make the compound “relatively” safe. It is also noted that azides 
attached directly to olefinic, aromatic or carbonyl moieties are much less stable than 
aliphatic azides.70 It is relatively safe to prepare, use and store azides providing 
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common sense is applied. 
Copper(I) species are powerful catalysts for the formation of 1,2,3-triazoles from 
azides and alkynes. The general thermodynamic instability of Cu(I) however, results 
in easy oxidation to Cu(II) and/or disproportionation to Cu(0) and Cu(II). TBTA, 
tris-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, is a stabilizing ligand for Cu(I) 
and was developed by the Sharpless group in an attempt to improve catalytic 
activity.74  
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Figure 1.29. Structure of TBTA 
 
TBTA, shown in Figure 1.29, protects Cu(I) from oxidation and disproportionation, 
while enhancing its catalytic activity. Reactions are typically carried out with 1-2 
mol % Cu(I) and TBTA without having to exclude oxygen and water. 
 
1.9 Project aims 
Previous work by Cross et al53 and Wang et al52 showed that “eastern” part of the 
structure was essential for activity, ES35 a compound without this arm was inactive 
in all assays. In contrast, a truncated version, 17, lacking the “western” regions was 
able to inhibit translocation in in vitro assays, confirming that this portion of ESI is 
responsible for at least some of the biological activity of ESI. In order to determine 
the structure-activity relationship due to changes to this section of ESI, a series of 
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analogues will be prepared. Previous work in the lab has shown that 17 inhibits 
translocation in in vitro assays but not when added to live cells, suggesting that it is 
unable to cross the plasma membrane of live cells. The preparation of more 
hydrophobic analogues of 17 will be investigated and any changes in the ability of 
these analogues to cross the cell membrane is increased will be determined.  
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Figure 1.30. Structures of the most potent Eeyarestatins in previous studies 
 
As some of the inhibitory effects of ESI are already known, upon completion of 
synthesis, inhibitory activity of some if not all of the analogues will be investigated. 
Bioassays will include: cytotoxicity to determine toxicity of ES compounds at 
several concentrations; cell microscopy to identify vacuole formation frequently 
exhibited by ESI; SDS page electrophoresis and western blotting for ubiquitin to 
ascertain the extent of accumulation of ubiquitinated protein and indicator of 
inhibition of DUBs; a translocation block assay looking to determine the inhibitory 
effect the ES compounds have on translocation of selected proteins across the ER 
membrane; and finally a secretion assay to determine the ES compound’s ability to 
block overall secretion of proteins from cells. 
To identify protein targets of the ES compounds, exploiting photoaffinity labelling, 
the ES compound must retain its biological activity after modification for use with 
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click chemistry fluorophores. A series of ES compounds containing an alkyne for 
click chemistry will be synthesised and subjected to bioassay to determine their 
inhibitory effect before attempting to ascertain which proteins are linked to the 
degradation pathway by photoaffinity labelling. 
Finally, to study the translocation of proteins more closely, Cotransin will be 
synthesised either by solid phase63 methods or using a modification of the Boger 
method. This compound is much less complex to prepare, as the majority of the side 
chains are commercially available as the N-Boc amino acids.  
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Figure 1.31. Residues of HUN-7293 altered during the synthesis of Cotransin 
 
Cotransin, in a similar manner to HUN-7293, can be prepared in 3 stages. The first 
stage, the preparation of fragment 1 (Figure 1.32) involves the exchange of Boc-
PrLeu at the R2 position for Boc-Leucine and DGCN for L-lactic acid in the final 
step. 
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Figure 1.32.  Proposed synthesis of fragment 1 
 
The second stage, the synthesis of fragment 2 (Figure 1.33), exchanges Boc-PrLeu at 
the R6 position for Boc-Leu during the synthesis of dipeptide 1 and N-Me-Phe-OMe 
for R5 MTO derivative during the synthesis of dipeptide 2. 
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Figure 1.33. Proposed synthesis of fragment 2 
 
The final steps in the synthesis, shown in Figure 1.34, will be similar to those for 
HUN-7293 although more optimisation may be necessary. 
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Figure 1.34. Final steps of Cotransin synthesis 
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CHAPTER 2: RESULTS AND DISCUSSION PART 
I: CHEMISTRY 
 
2.1 Synthesis of ESI and ESII. 
2.1.1 ESI 
The synthesis of ESI starts with the generation of 2-chloro-2methyl-1-
nitrosopropane, 66, prepared according to a literature procedure75 by reaction of 2-
methylpropene with isoamyl nitrite at $15 °C and slowly adding concentrated HCl. 
This procedure gave 66 in a 40% yield. 
 
ONO
HCl ON
Cl
66
-10 - -20 oC
2 h
39%  
Figure 2.1. Synthesis of nitrosyl chloride 
 
The next step is a substitution reaction of the chlorine with glycine methyl ester to 
yield the coupled product, 67, in an 80% yield. 
 
ON
Cl
66
H2N OMe
O
HCl
TEA, MeCN
rt, 17 h
80%
HON
H
N
OMe
O
67  
Figure 2.2. Synthesis of glycine methyl ester adduct 
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The next step involves the reaction of the amine, 67, with 2 equivalents of 4-
chlorophenyl isocyanate in tetrahydrofuran (THF) at room temperature (rt); the 
mechanism is shown in Figure 2.3. 
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Figure 2.3. Mechanism for formation of symmetrical disubstituted methyl ester 
 
This reaction happens in similar systems under basic conditions, the imide deriving 
from the isocyanate attacks the oxime to generate the cyclic urea compound 68 after 
proton transfer.76 The second reaction in this case happens so quickly that the linear 
compound is never isolated. The cyclic urea formation occurs in situ and without any 
basic conditions.  
The nucleophilic attack of the hydroxylamine of the cyclic urea 68 is very rapid and 
even the use of 1 equivalent of isocyanate yielded a mixture of mono- and di-
substituted products. This is, inadvertently, a positive result as the disubstituted 
product is required to continue the synthesis of ESI.  
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Once the disubstituted product, 69, had been obtained the next step was to convert 
the methyl ester into its corresponding hydrazide. This was readily accomplished 
using a standard procedure often used in peptide synthesis.77 A 62% aqueous 
solution of hydrazine was used as it had been found in earlier work that this gave the 
best results.55 The reaction was carried out in methanol (MeOH) at rt and gave 
hydrazide 8  (Figure 2.5) in a 63% yield. 
With the hydrazide in hand, the final step was the coupling with (E)-3-(5-nitro-2-
furyl)acrylaldehyde, 70. Before this could be carried out, however, it was necessary 
to prepare the conjugated aldehyde. This was accomplished in a 70% yield via an E-
selective Wittig reaction between 5-nitrofuran-2-carbaldehyde and 
(triphenylphosphanylidene)acetaldehyde in THF at rt.  
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Figure 2.4. Wittig reaction for aldehyde formation 
 
The ylid in the above reaction is stabilised further by the conjugation with the 
aldehyde. The reason for E-stereoselectivity is still debated amongst chemists but 
some argue that the reaction leading to oxaphosphetane in these types of ylids is 
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reversible. This suggests that reversal to starting materials can provide a mechanism 
where anti and syn diastereoisomers of the oxaphosphetane can interconvert. The 
trans-diasteroisomer is thermodynamically more stable with the bulky groups on 
opposing sides of the ring, elimination of Ph3P=O from this oxaphosphetane gives 
the E-alkene. Furthermore, the rate of elimination to the E-alkene should be faster 
than elimination to give the Z-alkene due to the difference steric crowding in their 
respective transition states. The equilibration of both oxaphosphetane 
diasteroisomers via starting materials will replenish supply of the anti 
diastereoisomer and will ultimately give the E-alkene as the major stereoisomer.78 
With the aldehyde 70 in hand, the final step in the synthesis of ESI was undertaken, 
which involved the condensation of 70 with hydrazide 8 in MeOH at rt, which 
proceeded in an 81% yield.  
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Figure 2.5. Final condensation in the synthesis of ESI 
 
ESI was relatively easy to characterise, however, it is very insoluble and acquisition 
of 13C NMR data in deuterated chloroform (CDCl3) was impossible. It was more 
soluble in dimethyl sulfoxide (DMSO) and it was possible to obtain 13C data but in 
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this solvent the compound apparently undergoes cis-trans isomerism, making the 
spectra excessively difficult to assign.  
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Figure 2.6. Some proton signals of ESI in CDCl3: A) numbered structure of ESI; B) proton 
signal at carbon 24; C) proton signal at carbon 25; D) methylene AB quartet 
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Figure 2.6 shows proton signals at alkene carbons 24 (Figure 2.6A) and 25 (Figure 
2.6B) and the CH2 at carbon 21 (Figure 2.6C). It is evident from the J values from 
alkene carbons 24 and 25 (15.5 & 9.4 for C(24)H and 15.5 for C(25)H) the structure 
is predominantly trans, however, there is a small indication of the cis isomer partially 
obscured by the doublet at ~4.1 ppm. 
         
Figure 2.7. Proton signals of ESI in DMSO: A) methylene AB quartet showing cis-trans 
dynamics; B) alkene signals 
 
If the solvent is changed to DMSO, as shown in Figure 2.7A, the relative amount of 
the cis isomer increases suggesting that this system is dynamic. It is not immediately 
obvious which isomer dominates in d6-DMSO, as Figure 2.7B shows, the alkene 
signals at carbons 24 and 25 are covering each other making it difficult to determine J 
values for one isomer over the other. 
 
A
 
B
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2.1.2 ESII 
The synthesis of ESII is almost identical to ESI, the glycine methyl ester adduct, 67, 
synthesised earlier was reacted with 2 equivalents of 1-naphthylisocyanate in THF at 
rt. This gave a 61% yield of the disubstituted ester, 71. 
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Figure 2.8. Synthesis of methyl ester precursor to ESII 
 
This was then converted into its corresponding hydrazide by reacting, 71, with 62% 
hydrazine solution in MeOH at rt with a 55% yield. 
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Figure 2.9. Hydrazide precursor to ESII 
 
The hydrazide was then coupled to the (E)-3-(5-nitro-2-furyl)acrylaldehyde, 70, 
previously synthesised in MeOH at rt; this gave ESII in an 83% yield.  
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Figure 2.10. Final aldehyde condensation to form ESII 
 
ESII proved much more difficult to analyse by NMR spectroscopy, it is apparent that 
ESII is less stable than ESI in chloroform with both cis and trans isomers being 
present giving a complicated spectrum. A well-resolved proton NMR was difficult to 
acquire, even though several solvents were used including d6-acetone and d6-
DMSO. Eventually, a spectrum of the trans isomer as a single entity was finally 
obtained after the addition of a drop of d5-pyridine to CDCl3. Other analytical 
techniques such as mass spectrometry (MS), melting point (Mp) and infra-red (IR) 
were used to confirm the identity of the structure. 
 
2.2 Synthesis of ESI and ESII analogues. 
2.2.1 p-nitrophenyl analogue of ESII 
The p-nitrophenyl analogue of ESII, shown in Figure 2.11, was prepared using the 
same hydrazide used to prepare ESII. The final step was the reaction of this 
hydrazide with p-nitrophenylcinnamaldehyde to give analogue 73. 
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Figure 2.11. Synthesis of p-nitrophenyl ESII 
 
2.2.2 Synthesis of symmetrical ESI analogues 
The focus of this project was mainly targeted toward ESI due to its enhanced activity 
towards ERAD inhibition. The first set of analogues prepared involved small 
changes to the nitrofuran side chain. Figure 2.12 shows the 4 analogues synthesised 
in this context, which were prepared by reacting the hydrazide precursor 8, with their 
corresponding commercially available aldehydes (The ketone precursor for analogue 
74 was prepared using a Wittig reaction). 
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Figure 2.12 Preparation of ESI analogues by aldehyde variation 
 
The p-nitrophenyl analogue of ESI, 75 (ES326), was obtained in 54% yield by 
reaction of hydrazide 8 with p-nitrocinnamaldehyde. The phenyl analogue 76 
(ES328) was obtained after reaction of hydrazide 8 with cinnamaldehyde in a 47% 
yield. The furan analogue 78 (ES47) was prepared by reaction of hydrazide 8 with 2-
furanacrolein in 51% yield. The ketone 74 required for the preparation of analogue 
77 was synthesised via a Wittig reaction between 1-
(triphenylphosphoranylidene)propan-2-one and 5-nitro-2-furaldehyde shown in 
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Figure 2.13. When this ketone was coupled to the hydrazide 8, analogue 77 was 
obtained in a 51% yield. 
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Figure 2.13. Preparation of ketone 
 
All of the analogues exhibited similar dynamics in DMSO to ESI and the 1H NMR 
spectrum of p-nitrophenyl analogue was unobtainable in CDCl3 due to poor 
solubility.  
 
2.2.3 Synthesis of unsymmetrical ESI analogues 
In order to prepare and unsymmetrical disubstituted analogues it was necessary to 
prepare the mono substituted intermediate, 68 (Figure 2.14). Using one equivalent of 
isocyanate this reaction yields a mixture of mono- and di-substituted products and 
reaction conditions needed to be optimised. Earlier work had showed that reasonable 
conditions for the preparation of a mono-substituted product required one equivalent 
of isocyanate and glycine methyl ester in THF at 0 °C until the glycine methyl ester 
had dissolved followed by warming to rt.55 This gave a ratio of 5.5/1/0 mono/di/67 
respectively, easily distinguished between in a 1H NMR spectrum. All of the protons 
are shifted slightly differently, however, the C(3)H is shifted significantly in the two 
molecules. In the mono substituted derivative it is at % 4.65 whereas in the 
disubstituted derivative it is around % 6.18. Purification by flash column 
chromatography gave the mono-substituted intermediate as a single product in 
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average yield of 50%. The maximum yield of 70% was obtained by reacting 68 in 
THF at 0 °C for a further hour after the glycine methyl ester had dissolved then 
warming the reaction to rt. 
Once the mono substituted product had been prepared, it was necessary to introduce 
a second R group in order to yield an unsymmetrical methyl ester; the easiest way to 
accomplish this is to use the appropriate “R-isocyanate”, however, only the 
corresponding amines were available. An unsymmetrical synthesis, not using an 
isocyanate, had been carried out previously in the group using 1,1-
carbonyldiimidazole and an aminoanthracene. (The general mechanism is shown in 
Figure 2.14).55  
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Figure 2.14. CDI mediated introduction of a second R group 
 
Addition of a benzyl amino group under these conditions described was initially 
attempted (Figure 2.15). This, however, proved unsuccessful with the reaction never 
reaching completion and yielding mainly the mono-substituted product at the end of 
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the reaction. Even changing to rt conditions in DCM, as reported by Asato et al79, 
and carrying out the reaction at -20 °C in acetonitrile (MeCN) as reported by 
Bhowruth et al80, failed to yield the desired methyl ester 79.  
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Figure 2.15. Synthesis of unsymmetrical methyl esters 
 
Initial attempts to attach a phenethyl group by carrying out the reaction in THF at 50 
°C for 17 h, gave the desired methyl ester 80 in 70% yield. This reaction required the 
use of 2:1 equivalents of phenethylamine:68 for reaction to go to completion but any 
excess phenethylamine could be readily removed by flash chromatography (2:1, 
petroleum ether (PE):ethyl acetate (EtOAc). On scale up, a drop in yield to 44% was 
observed even after increasing both the reaction time and the temperature. This yield 
was still workable, however, so the conversion into the corresponding hydrazide 
using the same conditions as for the symmetrical ES compounds gave 81 in 55% 
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yield. The final coupling proceeded smoothly to give analogue 82 (Figure 2.16) in 
50% yield. 
 
80
N
N
O
O
NHNHO
HN O
81
NH2
N
N
O
O
NHNHO
HN O
N
O
NO2
Cl Cl
82
NH2NH2.H2O 62%
MeOH, rt, 48 h
55%
H
O
O
NO2
MeOH, rt, 17 h
50%
 
Figure 2.16 Synthesis of “phenethyl Eeyarestatin” 
 
 
2.3 Synthesis of “short form” Eeyarestatins. 
The synthesis of the “short form” analogues of the ESI commences with the 
conversion of commercially available methyl phenyl acetate into its corresponding 
hydrazide as shown in Figure 2.17. This was accomplished using a 62% aqueous 
hydrazine solution in MeOH at rt, to give 2-phenylacetohydrazide, 83, in 65% yield. 
This was then coupled to (E)-3-(5-nitro-2-furyl)acrylaldehyde in MeOH at rt to give 
the short form analogue 17 (ES24), in 66% yield. 
It is essential that the hydrazide used in this reaction is pure as impurities remain in 
the end product after the final reaction. Since the end product, like ESI and ESII, is 
unstable in solution for prolonged periods of time, it cannot be purified by column 
chromatography or recrystallisation. 
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Figure 2.17 Synthesis of a “short form” analogue of ESI (ES24) 
 
Syntheses of the short form analogues, 84 and 85 (shown in Figure 2.18) were 
accomplished by reaction of phenylacetohydrazide 83 with commercially available 
aldehydes 4-nitrocinnamaldehyde and 2-nitrocinnamaldehyde to give 84 and 85 
respectively in identical yields of 89%. 
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Figure 2.18 Synthesis of analogues of “short form” Eeyarestatin 
 
The synthesis of benzoyl analogue 86 (Figure 2.19) was readily accomplished in a 
53% yield by reacting (E)-3-(5-nitro-2-furyl)acrylaldehyde with commercially 
available benzoylhydrazine.  
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Figure 2.19. Synthesis of “short form” benzoyl analogue of ESI  
 
2.4 Preparation of acetylene derivative suitable for click chemistry 
 
2.4.1 Acetylene analogues of ESI 
As has been previously discussed, Click chemistry can be used to remove proteins 
from a cellular system with a small molecule that is known to interact with them. 
Having detailed a working synthesis of unsymmetrical analogues, it was possible to 
prepare a series of acetylenic compounds for application in click chemistry. Three 
were synthesised (from precursors shown in Figure 2.20), in order to assess whether 
they were effective in  “removing” proteins in vitro.   
 
 77 
N N
O
OMe
O
N
Cl
HN
O
HO
87N N
O
OMe
O
N
H
Cl
HO
68
THF, 50 oC, CDI, 17 h, 70%
NH2
NH2
THF, 50 oC, CDI, 17 h, 58%
N N
O
OMe
O
N
Cl
HN
O
HO
88  
Figure 2.20. Synthesis of acetylenic methyl ester precursors 
 
The synthesis of all three analogues was accomplished by initial reaction of the 
appropriate amine (propargyl amine for 87 and 4-ethynylaniline for 88) with cyclic 
urea 68 and CDI, under similar conditions to those used for the unsymmetrical ES 
compounds. Flash column chromatography yielded the unsymmetrical disubstituted 
products 87 and 88 containing the acetylene unit in 70% and 58% yields 
respectively. The conversion into their corresponding hydrazides was attempted with 
a 62% aqueous solution of hydrazine. The hydrazides were obtained in a pure state 
with careful monitoring by TLC. It was found that 2.5 h was sufficient to allow 
isolation of hydrazide 89 in 98% yield. Only 1.5 h was required to give the 
corresponding hydrazide 90 in 94% yield: a longer reaction time resulted in the 
appearance of impurities by TLC analysis. 
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Figure 2.21. Synthesis of acetylenic unsymmetrical Eeyarestatins 
 
The final coupling of hydrazide 89 with aldehydes (E)-3-(5-nitro-2-
furyl)acrylaldehyde and 2-furanacrolein gave analogues 91 and 92 in identical yields 
(49%). Coupling of hydrazide 90 with (E)-3-(5-nitro-2-furyl)acrylaldehyde gave 
acetylenic analogue 93 in a 50% yield. 
A synthesis of the analogue containing a propargyl unit in the “north west” quadrant 
(94 in Figure 2.22) of the ES skeleton was also investigated. Several attempts were 
made under a variety of conditions, including different temperatures, and molar 
ratios of CDI and amine, to obtain the monosubstituted methyl ester 94 (Figure 2.22), 
however, all failed. This may mean that the range of ES compounds accessible is 
limited by the number of available isocyanates.  
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Figure 2.22 Introduction of an acetylenic R-group in the “north west” quadrant of the 
Eeyarestatins failed 
 
Attempts to prepare this target and other related analogues of this type were 
abandoned. 
 
2.4.2 Synthesis of the acetylenic analogue of ESII 
The first step of the reaction sequence leading to the acetylenic analogue of ESII 
involved the reaction of the amine, 67, with one equivalent of 1-naphthyl isocyanate 
to give mono-substituted compound, 95 (Figure 2.23). This reaction, in the first 
instance, was carried out at 0 °C to minimise the formation of the disubstituted 
product, 71. The first attempt at this reaction resulted in no product formation at all 
and stirring the reaction mixture at 0 °C for a relatively short time only resulted in 
the formation of the disubstituted product with some remaining starting material. In 
the second attempt, the reaction mixture was left at 0 °C for 4 h before allowing it to 
warm slowly to rt and this greatly improved the yield of product, 96 to 44%. When 
the reaction was left for longer at 0 °C, this resulted in no improvements in yield. 
Inevitably, some of the undesirable disubstituted product, 72, was formed and careful 
purification by flash column chromatography was necessary. 
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Figure 2.23. Preparation of the monosubstituted naphthyl methyl ester 
 
After finally obtaining the desired product, 95, it was necessary to introduce the 
propargyl unit onto the hydroxylamine. This was accomplished, as described 
previously, using CDI and propargylamine to give methyl ester, 96, in a 44% yield 
after purification by flash column chromatography.  
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Figure 2.24. Synthesis of acetylenic analogue of ESII 
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The next step in the reaction sequence was the conversion of methyl ester, 96, into its 
corresponding hydrazide, 97, which was accomplished using a 62% aqueous 
hydrazine solution in a 92% yield. Careful monitoring by TLC showed that a 
reaction time of 1.5 h was sufficient to allow the isolation of the pure hydrazide.  
The final step in the reaction sequence was the coupling of hydrazide, 97, with (E)-3-
(5-nitro-2-furyl)acrylaldehyde. Despite numerous attempts, this reaction proved to be 
unsuccessful. During initial attempts a solid precipitate formed but unfortunately 
neither the precipitate nor the filtrate showed any sign of the product 98 when 
analysed by NMR or mass spectrometry. The mass spectrum showed peaks at 334 
and 632 by negative ion electrospray, 238 mass units below and 60 mass units above 
the anticipated mass respectively. Additional attempts at this reaction were 
unsuccessful and only starting material was recovered, therefore, this part of the 
project was abandoned. 
 
2.4.3 Synthesis of short click compounds 
There were two questions to be answered by preparing and assaying “short form” 
acetylenic compounds;  
1. Do the “short form” analogues interact with the same proteins as ESI or do 
they have a different effect? 
2. ES24 has trouble getting across the ER membrane. Could adding extra 
hydrophobic groups increase the effect these shorter compounds have on 
cells? 
 After discussion with collaborators compounds 99 and 100 (Figure 2.25) were 
selected due to their extra hydrophobicity and the alkyne that could also potentially 
be used in click chemistry.  
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Figure 2.25. Selected acetylenic “short form” compounds 
 
Both compounds should be accessible from a Sonogashira reaction using their 
corresponding aryl halides.81 With this in mind the commercially available 3-bromo 
and the 4-bromophenylacetic acids were chosen to attempt the synthesis of these 
analogues. Since many of the final compounds had been found to be unstable when 
stored for long periods of time in solution and some hydrazides had been difficult to 
purify, it was decided that the Sonogashira coupling would be attempted on the 
methyl ester precursor. 
The synthesis commenced with esterification of the 3-bromophenylacetic acid 101 
under standard conditions as reported by Davies et al82 to give 102 in a  99% yield. 
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TMS
MeOH, H2SO4
reflux, 18 h
99%
Table 2.1
102 103101  
Figure 2.26 Attempted synthesis of methyl 2-(3-((trimethylsilyl)ethynyl)phenyl)acetate 
 
The Sonogashira reaction of 3-bromo methyl ester 103 proved to be a lot more 
difficult than initially anticipated: Table 2.1 outlines all of the conditions 
investigated. Entry 1 used a procedure by Iwanowicz et al83 who used the same aryl 
bromide as ourselves. This reaction never reached completion, presumably due the 
absence of Cu(I) in the Iwanowicz procedure, CuI catalyses the introduction of the 
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acetylene on the palladium catalyst by substituting for the halide during the 
transmetallation step. Further attempts using the same conditions but with the 
addition of CuI (Entry 2 in table 2.1) did not produce any better results. Following 
this lack of success it was suggested that the temperature may have been too high 
and either product breakdown was occurring or one or both catalysts were being 
adversely affected. Lowering the temperature, however, and changing the molar ratio 
of TMS-acetylene  (Entries 3 and 4 in table 2.1) did not improve yields. Eventually, 
the catalyst was changed to the standard Pd(PPh3)2Cl2 and this resulted in an 
improved ratio of product to starting material but the reaction still lay heavily in 
favour of the latter. Ahmed et al reported that the use of aqueous ammonia as the 
activator instead of TEA furnished cross-coupling reactions in good to excellent 
yields.84 The addition of aqueous NH3 in this case, however, (entry 6) never afforded 
the desired product and after further increasing catalyst loading as well as other 
reaction variables it was concluded that the C-Br on this molecule was resistant to 
cross-coupling conditions. 
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Entry 
Mass 
of ester 
 
Mol% 
of 
catalyst 
 
Catalyst 
 
Activator 
 
CuI 
mol% 
 
Solvent 
 
°C 
 
Equivalents 
of TMS-
acetylene 
 
Ratio of 
103:102 
 
1 50 mg  
10 
 
Pd(PPh3)2(OAc)2 
 
TEA 
 
0 
 
Toluene 
 
100 
 
1.5 
 
1:8 
 
2 50 mg  
10 
 
Pd(PPh3)2(OAc)2 
 
TEA 
 
10 
 
Toluene 
 
100 
 
1.5 
 
1:5 
 
3 50 mg  
10 
 
Pd(PPh3)2(OAc)2 
 
TEA 
 
10 
 
THF 
 
rt 
 
1.5 
 
1:4 
 
4 50 mg  
10 
 
Pd(PPh3)2(OAc)2 
 
TEA 
 
10 
 
THF 
 
rt 
 
2 
 
1:5 
 
5 50 mg  
10 
 
Pd(PPh3)2Cl2 
 
TEA 
 
10 
 
THF 
 
rt 
 
1.5 
 
1:3 
 
6 50 mg  
10 
 
Pd(PPh3)2Cl2 
 
NH3 (aq) 
 
10 
 
THF 
 
rt 
 
1.5 
 
1:5 
 
7 50 mg  
20 
 
Pd(PPh3)2Cl2 
 
TEA 
 
10 
 
THF 
 
rt 
 
1.5 
 
1:5 
 
8 50 mg  
20 
 
Pd(PPh3)2Cl2 
 
TEA + 
Vol inc 
 
20 
 
THF 
 
rt 
 
2 
 
1:5 
 
Table 2.1. Conditions investigated for the Sonogashira reaction of methyl 2-(3-
bromophenyl)acetate 
 
It was then decided to investigate an aromatic Finkelstein reaction in an attempt to 
convert the aryl bromide into the corresponding aryl iodide.85 This reaction again did 
not proceed, the GC trace of the reaction mixture indicating only the presence of 
starting material (Figure 2.27). Following this failure, it was decided to purchase 3-
iodophenylacetic acid in order to investigate the Sonogashira reaction further. 
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Figure 2.27 GC trace of the reaction mixture of the attempted aromatic Finkelstein 
 
The new synthesis began with the esterification of 3-iodophenylacetic acid, 104, 
which proceeded smoothly to give methyl ester 105 in a 95% yield. This was 
followed by the Sonogashira reaction, which was carried out at rt for 18 h. On this 
occasion the reaction was successful and gave an excellent yield of 97% of methyl 
ester 103. This reaction proceeded smoothly using either of the palladium catalysts 
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investigated previously and provided similar yields in both cases and never went to 
completion in the absence of CuI. 
 
O
OMeI
O
OHI
O
OMe
TMS
MeOH, H2SO4
reflux, 18 h
95%
Pd(PPh3)2Cl2 OR Pd(PPh3)2OAc2,
NEt3, CuI, THF, TMS-acetylene, rt
97%105 103104  
Figure 2.28. Sonogashira reaction on the iodo methyl ester 
 
The next step in the synthesis was the removal of the TMS protecting group, which 
was accomplished using tetrabutylammonium fluoride (TBAF) in THF to give 106 in 
a 74% yield. The procedure was that reported by Nagarajan et al who had used this 
on the corresponding para isomer of 103.86 The methyl ester was then converted into 
its corresponding hydrazide 107 using the same conditions as before, however in this 
step an impurity remained even after flash chromatography. This impurity like the 
hydrazide was soluble in MeOH so it was proposed that it might be removed in the 
final step as the ES analogue was expected to precipitate out of solution as the 
reaction proceeded. The final coupling to (E)-3-(5-nitro-2-furyl)acrylaldehyde 
proceeded smoothly yielding the ES analogue 99 in a 53% yield, with no impurities 
apparent in the 1H NMR spectrum, confirming that the impurity in the hydrazide 
could be removed through washing with MeOH during work-up. 
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Figure 2.29. Synthesis of ES24 Click meta 
 
The 4-acetylenic analogue was obtained in a slightly different manner commencing 
with the iodination of methylphenylacetate, 108, as described for phenylacetic acid 
by Waybright et al.87 A test iodination on the methylphenylacetate directly was 
carried out, however, it was found that yield of product was very low so phenylacetic 
acid was then used as starting material.  
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Figure 2.30. Synthesis of the para acetylenic moiety  
 
The first step of the sequence was the hydrolysis of methylphenylacetate, 108, using 
an aqueous solution of LiOH in THF to give phenylacetic acid, 109.88 This was 
followed by the iodination reaction following Waybright’s procedure; this proceeded 
smoothly giving the 4-iodophenylacetic acid, 110, as a single isomer in a 45% yield.  
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The methyl ester 111 was obtained in 95% yield after esterification with MeOH and 
H2SO4 at reflux for 18 h and the subsequent Sonogashira reaction afforded TMS-
acetylene 112 in a 96% yield. 
 
O
OMe
113
O
NHNH2
114
O
H
N
100 (ES24 Click para)
N O NO2
H
O
O
NO2
NH2NH2.H2O 62%
MeOH 1.5 h
99%
MeOH, rt, 18 h
34%
 
Figure 2.31 Synthesis of para acetylenic “short form” analogue 
 
Removal of the TMS group with TBAF gave acetylene 113 in an 83% yield and 
subsequent conversion to the hydrazide 114 followed by coupling to the (E)-3-(5-
nitro-2-furyl)acrylaldehyde proceeded as expected in 99 and 34% yields respectively, 
to give analogue 100. 
 
2.5 Click reactions with alkyne Eeyarestatins. 
The click reaction requires a stable azide to react with the alkyne previously 
synthesised. The Webb group previously prepared a suitable azide, the triethylene 
glycol azide 117 (TEG-N3).89 The first step in their synthesis was the conversion of 
triethylene glycol, 115, into the monotosylate, 116 using tosyl chloride, silver oxide 
and potassium iodide in DCM at 0 °C.89 Further searching of the literature revealed a 
procedure by Feizi et al90 which gave the monotosylate in a better yield 60 – 70% 
(Compared to 50% in the Webb group), therefore, this procedure was used in 
preference. Thus, reaction of triethylene glycol with tosyl chloride in pyridine at 0 °C 
followed by purification by flash column chromatography gave the desired product 
in a 61% yield. 
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Figure 2.32. Synthesis of triethyleneglycol azide 
 
The next step of the synthesis was the nucleophilic substitution of the tosylate with 
the azide, which was accomplished using sodium azide in DMF at elevated 
temperature and furnished triethylene glycol azide (TEG-N3), 117, in a 54% yield. 
With the organic azide now in hand the click reactions of the methyl ester, 87 and the 
alkyne ES, 91, were then attempted. For the more soluble methyl ester 87, a modified 
procedure by Sharpless et al71 was followed using copper sulphate and sodium 
ascorbate to give the 1,4-triazole 118 as the only product. Two equivalents of the 
azide were required for the reaction to go to completion, and after purification by 
flash column chromatography the triazole 118 was obtained in a 93% yield. 
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Figure 2.33. Click reaction on methyl ester 
 
For the methyl ester, 87, it was found that 17 h was sufficient for the reaction to go to 
completion: for the alkyne ES, 91, however, an extended period of time was 
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required, however, after 42 h the reaction was complete and compound 119 was 
isolated in a 90% yield. 
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Figure 2.34. Click reaction on alkyne Eeyarestatin 
 
2.6 Summary 
Tables 2.2 and 2.3 summarise all of the analogues prepared in this project. ES40, 
ES47, ES326, ES328, ES111 were all prepared to determine the effect changes to the 
nitrofuran chain had on inhibition. ESI Click and ESIb Click were both prepared in 
preparation for photoaffinity labelling in an attempt to identify proteins affected by 
these compounds. ES24 Click para and ES24 Click meta were prepared in an attempt 
to improve hydrophobicity so that the “short form” analogues may be able to cross 
the cell membrane. All other analogues were prepared to investigate the activity of 
other “short form” analogues in comparison to activity observed with ES24. 
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Table 2.2. Summary of ESI and ESII analogues prepared 
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Table 2.3, Summary of “short form” Eeyarestatins prepared 
 
With the synthesis of all of these ES compounds completed and the confirmation that 
the click reaction on the alkyne ES proceeds as expected they were then used in 
biological assays to determine their inhibitory activity on ERAD and protein 
translocation. Unfortunately due to time constraints not all of the analogues 
synthesised could be tested, a small selection of compounds that were most similar to 
ESI and ES24 were decided upon and are shown in Chapter 3. The alkyne ES 
 93 
compounds were also used in an attempt to determine which proteins are affected by 
these compounds using a similar click chemistry strategy employed by MacKinnon 
et al.60  
 
2.7 Synthesis of Cotransin 
2.7.1 Solid phase synthesis 
The synthesis of Cotransin can be approached in two ways, either by using the solid 
phase procedure described by Coin63 or in solution by using a modification of the 
Boger method for the synthesis of HUN-7293.58, 62 It was decided that the synthesis 
would be first attempted using solid phase as it was predicted to be less time-
consuming. Figure 2.35 outlines the reaction sequence as reported by Coin this was 
followed in our approach to the target.  
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Figure 2.35. Solid phase synthesis of Cotransin a) H-($)-lac-OH/DIEA/DCM; (b) 
esterification via DIC/NMI; (c) Fmoc removal and coupling with HATU; (d) (i) TBAF 0.15 M in 
DMF, 2 ! 1 min, (ii) MeOH, 15 s, (iii) DCM, 15 s; (iv) Fmoc-MePhe-OH/HBTU/DIEA pre-activated, 
DMF, 20 min; (e) Fmoc removal and coupling with HBTU; (f) acidic cleavage from resin followed by 
HPLC (90:10 H2O:MeOH); (g) cyclisation with HATU/DIEA in DCM (0.5 mM) followed by HPLC 
(90:10 H2O:MeOH).  
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The first step of the synthesis involved coupling of unnatural lactic acid to 2-
chlorotritylchloride resin using N,N-diisopropylethylamine (DIEA) in DCM. This 
resin is usually selected due to its high level of substitution (ideal for shorter 
polypeptides), acid lability and its ability to minimise diketopiperazine (DKP) 
formation.91, 92 They elected to first attach unnatural lactic acid to the resin due to the 
consideration that it cannot form an oxazolone when activated, which would be 
beneficial in the final cyclisation.63, 93 The coupling of lactic acid was followed by 
ester formation with N-Me-alanine using N,N’-diisopropylcarbodiimide (DIC) 
activation and N-methylimidazole (NMI) as a catalyst. This was then followed by 
Fmoc removal with 20% piperidine in DMF and coupling of Fmoc-leucine with 
HATU. The optimal conditions for subsequent removal of the Fmoc group with 
minimal DKP formation had been found to involve two sequential reactions with 
0.15 M TBAF in DMF, for 1 minute each, followed by immediate washing with 
MeOH and DCM for 15 seconds. This was followed by the immediate coupling to 
Fmoc-N-Me-Phe that had been pre-activated with HBTU and DIEA in DMF giving 
the tetradepsipeptide 123. The final three couplings were all accomplished by initial 
removal of the Fmoc group with 20% piperidine in DMF followed by amide bond 
formation with HATU or HBTU. Fmoc removal followed by acidic cleavage from 
the resin and reverse phase HPLC (90:10 H2O:MeOH) gave linear Cotransin 127 in 
only a 3% yield  compared to the 23% yield reported by Coin et al. Further runs were 
monitored by mass spectrometry confirming that all resin-bound intermediates were 
the correct products (NMR cannot be used on the scale used in this procedure). Resin 
loadings were consistent with Coin et al and were confirmed by quantifying the 
piperidine-dibenzylfulvene adduct formed during Fmoc removal using its absorbance 
at 301 nm and entering it into resin loading equation (Eq 1).94 This is achieved by 
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weighing a small amount of resin (W) and reacting with 1 mL of 20% piperidine in 
DMF solution. A small volume (v) of this solution is diluted in 1 mL of 20% 
piperidine in DMF (V) and the UV absorbance at 301 nm taken. 
 
Resin loading (mmol/g) =              Absorbance & V & 103 
             ' & v & W (mg) & cell length (cm) 
 
' = 7800 M$1 cm$1 at 301 nm 
V = dilution volume in µL  
v = Volume of solution diluted in µL 
W = mass of dried resin  
 
Eq 1. Resin loading equation (Taken from Kay et al94) 
 
 
It was concluded that HPLC purification after the acidic cleavage of the linear 
Cotransin from the resin was very inefficient and low yielding. It was therefore 
decided that a solution phase synthesis would be attempted as inexpensive natural 
lactic acid could be used as a starting material and the progress of the reaction 
sequence could be readily monitored by NMR.  
 
2.7.2 Solution phase synthesis of Cotransin 
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Figure 2.36. Synthesis of dipeptides 
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The solution phase synthesis of Cotransin commenced with the preparation of the N-
methyl amino acids N-Me-Ala-OMe (130) and N-Me-Phe-OMe (134) from 
commercially available Boc-alanine, 129, and Boc-phenylalanine, 133, respectively. 
A slightly modified procedure reported by Coggins and Benoiton66 was followed 
using NaH and MeI for methylation followed by HCl in EtOAc (In preference to 
HBr in acetic acid) for removal of the Boc group.  Dipeptide 132 was afforded upon 
reaction of 130 with Boc-leucine, EDCI and HOAt in the presence of NaHCO3 and 
subsequent removal of the Boc group with HCl-EtOAc. Dipeptide 135 was prepared 
from 134 using Boc-leucine, EDCI and HOAt and subsequent hydrolysis of the ester 
using LiOH gave dipeptide 136.  Both dipeptides 132 and 136 were used in the next 
reaction without further purification to generate fragment 2 (Figure 2.37) as a 
mixture of diastereoisomers, separation by HPLC was necessary but due to time 
constraints purification by HPLC was not completed. 
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Unfortunately, due to time constraints it was not possible to investigate the synthesis 
of fragment 1 from commercially available N-Boc-N-Me-leucine (Figure 2.38) and 
all remaining steps in the solution phase synthesis were never completed (See 
conclusions and further work for further details). 
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Figure 2.38. Synthesis of fragment 1 
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CHAPTER 3: RESULTS AND DISCUSSION PART 
II: BIOCHEMISTRY 
 
All biological assays were conducted on a selection of compounds previously 
described in Chapter 2 the majority being shown in Figure 3.1 (See section 3.5 for 
the others). Previous work by Cross et al53 and Wang et al52 showed that the right 
hand part of the structure was essential for activity. ES35 a compound without the 
“eastern” arm was inactive in all assays. In contrast, a truncated version lacking the 
left hand regions was able to inhibit translocation in in vitro assays, confirming that 
this portion of ESI is responsible for at least some of the biological activity of ESI. In 
order to determine the structure-activity relationships due to changes to this section 
of ESI the series of analogues shown in Figure 3.1 was prepared (Structural changes 
compared to ESI are circled in red). Previous work in the lab has shown that ES24 
inhibits translocation in in vitro assays but not when added to live cells, suggesting 
that it is unable to cross the plasma membrane of live cells. The two “short form” 
analogues prepared by the addition of an alkyne are ideal for investigating any 
changes in activity observed if the ability of these analogues to cross the cell 
membrane is increased (Structural changes compared to ES24 are circled in blue). 
 
 100 
N
N
O
NHO
OHN
O
NH
N
O
NO2
Cl
Cl
N
N
O
NHO
OHN
O
NH
N
O
NO2
Cl
Cl
N
N
O
X
NHO
OHN
O
NH
N
Cl
Cl
N
N
O
NHO
OHN
O
NH
N
Cl
Cl
NO2
N
N
O
NHO
OHN
O
NH
NH2
Cl
Cl
O
H
N
N O NO2
O
H
N
N O NO2
O
H
N
N O NO2
N
N
O
NHO
OHN
O
NH
N
O
Cl
Cl
8 (ES35) 1 (ESI)
77 (ES40) 78 (ES47)76 (ES328)
75 (ES326)
17 (ES24) 100 (ES24 Click para)99 (ES24 Click meta)  
Figure 3.1. Selected compounds for biological testing 
 
3.1 Cytotoxcity of ESI analogues 
Cell viability assays can be used to determine the cytotoxicity of potential medicinal 
agents and toxic materials, since those agents would stimulate or inhibit the cell 
viability and growth. The MTT assay is a colorimetric assay developed by 
Mosmann95 for measuring the activity of enzymes that reduce MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to formazan dyes, giving a 
purple colour (Shown in Figure 3.2), the absorbance of which can be measured at 
570 nm.  
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Figure 3.2. Reduction of MTT to formazan 
 
These reductions can only take place when the reductase enzymes are active, and 
therefore conversion is used as a measure of viable (living) cells. This assay was 
used to determine the relative cytotoxicity of the different ES compounds. HeLa cells 
were treated with 2, 4, 8, 16, 32 and 64 µM concentrations of ES35, ESI, ES40, 
ES326, ES328, ES24, ES24 Click para and ES24 Click meta for 18 h and cell 
viability determined by MTT. ES35 and ESI were used as negative and positive 
controls respectively for all biochemical experiments. The same averaged ESI data 
are shown in each graph for comparison.  
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Figure 3.3. Cytotoxicity of ESI, ES35, ES328 and ES40. In a 96-well dish HeLa cells were 
treated with ESI, ES35 and ES40 at concentrations of 2, 4, 8, 16, 32 and 64 µM in triplicate and three 
lanes of DMSO controls at 64 µM and cell viability was determined by MTT. This was repeated with 
ES40 replaced with ES328. The graph shows the quantification normalised against DMSO plus the 
ESI and ES35 result from 3 independent experiments (mean ± SD, n = 3). 
 
ESI reduced the viability of cells at 8 and 16 µM to 79 and 58% respectively. 
Increasing the concentration to 32 and 64 µM cell viability had a minor additional 
effect on cell viability (48 and 42% respectively; Figure 3.3, red line). In contrast, 
ES35 showed little cytotoxicity, and even at 64 µM cell viability was only reduced to 
74% (Figure 3.3, light blue line). ES328 (Has a phenyl ring instead of a nitrofuran) 
resembled ES35, and showed only a slight toxicity even at 64 µM, when cell 
viability was only reduced to 67% (Figure 3.3, yellow line). In contrast, ES40 
(containing a methyl on the nitrofuran arm) was more potently cytotoxic than ESI, 
and  caused a greater reduction in cell viability at lower concentrations (Figure 3.3, 
light green line). Even at 4 µM, cell viability was reduced to 74%, whilst at 8 and 16 
µM a reduction of cell viability to 55 and 46% respectively was observed. Again, a 
levelling off of the cytotoxic effect was observed at concentrations of 32 and 64 µM. 
This levelling off indicates that not all of the HeLa cells die after the 18 h period, and 
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indicates that even at the maximum concentrations used, cell viability does not reach 
zero. 
 
 
Figure 3.4. Cytotoxicity of ES47 and ES336. In a 96-well dish HeLa cells were treated with 
ESI, ES35 and ES47 at concentrations of 2, 4, 8, 16, 32 and 64 µM in triplicate and three lanes of 
DMSO controls at 64 µM and cell viability was determined by MTT. This was repeated with ES47 
replaced with ES326 the graph shows the quantification normalised against DMSO plus the ESI result 
from 3 independent experiments (mean ± SD, n = 3). The ES35 result has been omitted for clarity. 
 
ES326 exhibited a similarly low toxicity compared to ES35, and even at 64 µM of 
this compound, cell viability remained at 86% (Figure 3.4, green line). Although 
ES47 showed little toxicity at low concentrations (< 8 µM), higher concentrations 
("16 µM) did affect cell viability (Figure 3.4 purple line), and at 32 and 64 µM, 
ES47 exhibited cell toxicity similar to ESI and ES40. Thus, the dose response curve 
of ES47 was shifted to the right by comparison with ESI (Figure 3.4, red line.). 
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Figure 3.5, Cytotoxicity of ES24, ES24 Click meta and ES24 Click para. In a 96-well dish 
HeLa cells were treated with ESI, ES35 and ES24 at concentrations of 2, 4, 8, 16, 32 and 64 µM in 
triplicate and three lanes of DMSO controls at 64 µM and cell viability was determined by MTT. This 
was repeated with ES24 and ES35 replaced by ES24 Click para and ES24 Click meta. The graph 
shows the quantification normalised against DMSO plus the ESI result from 3 independent 
experiments (mean ± SD, n = 3). The ES35 result has been omitted for clarity. 
 
Next, the three “short form” compounds (ES24, ES24 Click para and ES24 Click 
meta) were examined. ES24 is essentially the nitrofuran arm of ESI with a 
hydrophobic group attached to allow cell permeability. As previously discussed it 
inhibits translocation in in vitro assays but not when added to live cells, suggesting 
that it is unable to cross the plasma membrane of live cells. By comparison to ESI, 
ES24 showed little cytotoxicity. However, at highest concentrations, there was some 
loss of cell viability.  The click versions, ES24 Click meta and para were both 
slightly more toxic to cells, with ES24 Click meta having the largest effect (Figure 
3.5, light green line) and ES24 being the least potent (Figure 3.5, pink line). At 32 
µM cell viability was slightly affected by all three compounds again with ES24 Click 
meta being slightly more potent and ES24 being the least potent. At 64 µM cell 
viability was dramatically reduced in all 3 compounds but in the case of ES24 Click 
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para in particular cell viability was reduced to 35%, which was lower than ESI at the 
same concentration.  
In summary, ES40 was more toxic than ESI, particularly at lower concentrations (i.e. 
dose response curve shifted to left). ES47 was relatively non-toxic at lower 
concentration, but showed similar toxicity to ESI at concentrations above 16 µM. All 
three “short form” compounds showed no toxicity at low concentrations but had high 
toxicity above 64 µM and finally ES326, ES328 and ES35 all showed little or no 
toxicity at all concentrations investigated. 
 
3.2 Effect of ES compounds on cell morphology 
Previous experiments in the High group revealed that treatment with ESI causes 
dramatic changes in the subcellular morphology of HeLa cells. In particular, the ER 
forms large vacuolar structures throughout the cytoplasm.54 This vacuolisation can 
be visualised by phase contrast microscopy, thus providing a simple assay for the 
cellular activity of ESI compounds. Although the underlying causes of the changes in 
ER structure are not known, the vacuolisation resembles paraptosis, a system of 
programmed cell death in which empty spaces form in the cell cytoplasm and the 
mitochondria swells, causing the cell to lose viability.96 Interestingly, paraptosis can 
be induced by perturbing the ubiquitin proteasomal system97 such as that caused by 
treatment with DUB inhibitors. Therefore, vacuolisation may reflect the ability of 
ESI to induce ER-stress and/or to disrupt the ubiquitin proteasome system.  
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DMSO                 ESI 
      
PSII                 ES35 
         
ES40                 ES326 
Figure 3.6. Effect of ES compounds on subcellular morphology images from 
Eeyarestatin treated HeLa cells: HeLa cells were plated into 6-well dishes and treated with PSII 
(10 µM), ESI, ES35, ES40, ES326, ES328, ES47, ES24, ES24 Click para or ES24 Click meta at 8 µM 
at 37 °C for 8 h. After this time pictures of the live cells were taken using an Olympus IX51 Inverted 
microscope. Blue arrows indicate vacuole formation. 
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ES328                 ES47 
      
ES24      ES24 Click meta 
 
ES24 Click para 
Figure 3.6 continued. Effect of ES compounds on subcellular morphology images from 
Eeyarestatin treated HeLa cells: HeLa cells were plated into 6-well dishes and treated with PSII 
(10 µM), ESI, ES35, ES40, ES326, ES328, ES47, ES24, ES24 Click para or ES24 Click meta at 8 µM 
at 37 °C for 8 h. After this time pictures of the live cells were taken using an Olympus IX51 Inverted 
microscope. Blue arrows indicate vacuole formation. 
 
 
In the presence of the solvent control, DMSO, HeLa cells displayed a typical 
appearance by phase contrast microscopy, with the nucleus, plasma membrane and 
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various organelles being visible (Figure 3.6, top left panel). When cells were treated 
with ES35, the cells showed no evidence of vacuolisation therefore providing a 
comparison for inactive versus active compounds (Figure 3.6, row 2, right panel). 
However, treatment with 8 µM ESI for 8 h, resulted in the appearance of prominent 
vacuoles in most of the cells (Figure 3.6, top right panel, blue arrows). In contrast, 
the majority of compounds did not cause vacuolisation in HeLa cells (Figure 3.6, 
rows 3, 4 and 5). Surprisingly, even ES40, which was more toxic than ESI in the 
MTT assay, did not induce vacuolisation after 8 h treatment (Figure 3.6, row 3 left 
panel). In fact, only ES24 Click para of the “short form” analogues showed any 
evidence of vacuolisation after 8 h, but this was only observed in a very small 
proportion of the cells.  
 
 
      
ESI, 8 µM, 16 h             ES40, 8 µM, 16 h 
Figure 3.7. Vacuole formation after 16 hour treatment: HeLa cells were plated into 6-well 
dishes and treated with ESI, ES40, ES24, ES24 Click para or ES24 Click meta at 8 µM at 37°C for 16 
h. After this time pictures of the live cells were taken using an Olympus IX51 Inverted microscope 
(images from ES24 and both ES24 Click compounds are omitted). Blue arrows indicate vacuole 
formation. 
 
 
 
The lack of effect of the compounds was unexpected given their cytotoxcity, 
particularly so for ES40, which showed greater toxicity than ESI in the MTT assays. 
 109 
Since the MTT assays were performed after 16 h of treatment, the morphology of  
the cells was also examined after 16 h treatment with the compounds in case 
vacuolisation occurred after more prolonged treatment. However, only ES40 showed 
increased evidence of vacuoles after this time (Figure 3.7, right panel), and this effect 
was minor compared to ESI, with vacuoles observed only in approximately 20% of 
cells treated with ES40 for 16 h. 
 
 
ES47 16 µM 
Figure 3.8. Vacuolisation was observed in ES47 treated cells at 16 µM: HeLa cells were 
plated into 6-well dishes and treated with ES47 at 16 µM at 37 °C for 8 h. After this time pictures of 
the live cells were taken using an Olympus IX51 Inverted microscope (images from ES24 and both 
ES24 Click compounds are omitted). Blue arrows indicate vacuole formation. 
 
ES47 showed a dramatic decrease in cell viability at concentrations greater than 16 
µM thus a further experiment was run at 16 µM to determine if this was a factor in 
this ES compound’s ability to induce vacuolisation. The increase of concentration to 
16 µM induced vacuolisation in HeLa cells (Figure 3.8) but not as severe as in ESI 
treated cells. 
Thus, the ability to induce vacuolisation was not apparent for most of the ES 
analogues, even under conditions (concentration and length of treatment) when they 
caused substantial loss of cell viability. Interestingly, ES40, which was more toxic to 
cells than ESI at 8 µM, induced less vacuolisation and this occurred more slowly 
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than when cells were treated with ESI. These results suggest that vacuolisation is not 
simply a result of cell death, and may be related to particular action(s) of ESI in cells.  
 
3.3 Accumulation of polyubiquitin conjugates 
ESI has been shown to inhibit the activity of one or more DUBs that function to 
remove ubiquitin chains from ubiquitinated proteins.41 As a result, treatment of cells 
with ESI leads to the accumulation of polyubiquitinated proteins that can be detected 
by SDS-PAGE and Western blotting with anti-ubiquitin antibodies.41 This provides 
an assay to assess the ability of ESI and the new ES compounds to inhibit DUBs. 
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Figure 3.9. Accumulation of Ubiquitinated proteins in HeLa cells treated with 
Eeyarestatins: Top left panel: Confluent HeLa cells were treated for 8 h with ES compounds at 8 
µM or 16 µM as indicated, and lysates analysed by SDS-PAGE and immunoblotting with anti-
polyubiquitin and anti tubulin antibodies followed by infra-red labelled secondary antibodies; Top 
right panel: due to a blemish on original immunoblot the same cell samples that had been treated with 
ES40, ES24, ES24 Click para and ES24 Click meta at 8 µM were analysed again by SDS-PAGE and 
immunoblotting; Bottom panels: Levels of !-Tubulin were specifically analysed by immunoblotting 
of cell samples; (B) The intensity of the ubiquitin signal was quantified using pixel counting in the 
Odyssey software and normalised relative to the intensity of the tubulin loading control. The 
normalised ubiquitin signal was then expressed as a percentage of that in the DMSO treated control 
cell lysate. 
 
B 
A 
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In lysates of cells treated with DMSO as a solvent control, very little 
polyubiquitinated material was detected (Figure 3.9 A, top panel, lane 1). Similarly, 
ES35 treated cells contained low levels of high molecular weight ubiquitinated 
material. By contrast, treatment of cells with PSII, a proteasomal inhibitor,98 caused a 
marked accumulation of a range of high molecular weight polyubiquitinated proteins 
that were visible as a smear at the top of the polyacrylamide gel (Figure 3.9 A, top 
panel, lane 2). ESI treatment for 8 h also causes an accumulation of 
polyubiquitinated material (Figure 3.9 A top panel, lane 3). In line with its effect on 
cell viability and ER vacuolisation, ES40 also resulted in a large accumulation of 
polyubiquitin conjugates (Figure 3.9 A, top panel, lane 9). In fact, at 8 µM, ES40 
appeared to have a greater effect on accumulation of polyubiquitinated protein than 
ESI. Although less dramatic, treatment with ES24, ES24 Click para and ES24 Click 
meta also increased levels of polyubiqutinated proteins (Figure 3.9 A, right panel, 
lanes 10 – 12). This was also apparent when the signal intensity of the polyubiquitin 
conjugates was quantified and expressed relative to that of the DMSO control 
(Figure 3.9 B). This analysis also revealed that ES328 and ES47 both caused a slight 
accumulation of polyubiquitinated proteins (Figure 3.9 A, top panel, lanes 6, 7 and 
8). The effect of ES47 was concentration dependent, ES326 did not appear to cause 
any accumulation of polyubiquitinated proteins above what was seen in DMSO 
treated cells (Figure 3.9 A, top panel, lanes 5, 7 and 8). 
Again, the general SAR / trend observed in the cytotoxicity and vacuolisation assays 
was also seen in the ability of ES compounds to induce accumulation of 
polyubiquitinated proteins. Thus, ES40 was the most active of the analogues, whilst 
ES326 and ES328 were essentially inactive in this assay. ES47 again exhibited some 
activity, that was concentration dependent, and the short form ES24, ES24 Click para 
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and ES24 Click meta all caused a slight accumulation of polyubiquitin conjugates, 
with ES24 Click para being the most effective. Interestingly, ES40 induced even 
greater accumulation of polyubiquitin conjugates than ESI, suggesting that this 
version of ES may be a more effective DUB inhibitor. In contrast, ES40 had a less 
pronounced effect on vacuolisation, suggesting that vacuolisation may not be directly 
related to target inhibition of DUBS in the ubiquitin proteasome system. 
 
3.4 ER protein translocation 
In addition to inhibiting the activity of DUB enzyme(s), ESI has been shown to block 
Sec61 mediated protein translocation across the ER membrane.53 Two separate 
assays were employed in order to determine the ability of the new ESI compounds to 
block post-translational and co-translational translocation. In both cases, HeLa cells 
were first treated with the ES compounds for 1 h before being semi-permeabilising 
with low concentrations of digitonin. Semi-permeabilisation selectively 
permeabilises the plasma membrane, leaving the cellular organelles, such as the ER 
and Golgi network intact.99 These semi-permeablised cells were then used as a 
source of ER membranes for in vitro translocation of radiolabelled substrate proteins. 
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3.4.1 Post-translational translocation 
 
 
Figure 3.10. Post-translational translocation of procecropin (ppCec) in HeLa cells 
treated with Eeyarestatins: (A) In vitro translated 35S Methionine/Cysteine labelled ppCec was 
added to semi-permeabilised cells that had been treated with ES compounds at 8 µM for 1 h. The cells 
were washed and the 35S Methionine/Cysteine labelled ppCec was analysed by SDS-PAGE and 
phosphorimaging; (B) Quantification by pixel counting using AIDA software was used to determine 
the relative processing of pCec normalised relative to the intensity of ppCec. The normalised signal 
was then expressed as a percentage of that in the DMSO treated control cell lysate (mean ± SEM, n = 
3). Differences in the block of post-translational translocation of ppCec were assessed for statistical 
significance using 2-tailed t-tests with equal variance assumed (p<0.05 ** very significant). 
 
A 
B 
** 
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The first experiment investigated the effect on post-translational translocation of pre-
procecropin (ppCec), which due to its small size is translocated across the ER 
membrane in a post-translational manner.100 Thus, 35S ppCec was translated in vitro, 
and then the radiolabelled protein added to semi-permeablised cells that had been 
treated with the various compounds. Translocation was determined by the amount of 
N-glycosylated procecropin, since the addition of N-linked oligosaccharides to 
proteins occurs in the lumen of the ER. Thus, a reduction in the amount of the N-
glycosylated form generated is indicative of an inhibition of translocation of ppCec 
across the ER. Translation of ppCec was completed in the presence of 35S labelled 
Methionine/Cysteine and the translation reaction was added to ES-treated semi-
permeable HeLa cells. In untreated cells a major band of un-glycosylated ppCec is 
observed with a minor band of a higher molecular weight form, which represents N-
glycosylated pCec. Treatment with DMSO or PSII did not alter the amount of N-
glycosylated pCec produced (Figure 3.10 A, lanes 1 and 2), showing that these 
compounds did not affect translocation of ppCec. In cells treated with ESI however, 
there was a clear decrease in the amount of N-glycosylated pCec that was generated 
more than 50% of the ppCec was prevented from translocating into the ER (Figure 
3.10 A, lane 3). Quantification of the amount of N-glycosylated protein produced 
revealed that the N-glycosylated pCec levels were 50% lower in ESI treated cells, 
consistent with previous observations.53 Interestingly, ES40 showed no significant 
block in translocation of this substrate (Figure 3.10 A, lane 9). ES35, ES326, ES328, 
ES24, ES24 Click para and ES47 at 8 µM and 16 µM did not cause a block in 
translocation of this substrate (Figure 3.10 A, lanes 4 – 8, 10 and 11). ES24 Click 
meta caused a slight block of approximately 20% in translocation of this substrate 
(Figure 3.10 A, lane 12).  
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3.4.2 Cotranslational translocation 
 
  
Figure 3.11. Co-translational translocation of prolactin in HeLa cells treated with 
Eeyarestatins: (A) Pre-prolactin (pPL) was translated in vitro in the presence of semi-permeabilised 
HeLa cells that had been treated with ES compounds at 8 µM for 1 h. The cells were harvested and 
analysed by SDS-PAGE and phosphorimaging; (B) Quantification by pixel counting using AIDA 
software was used to determine the relative processing of cleaved prolactin normalised relative to the 
non-cleaved pPL. The normalised signal was then expressed as a percentage of that in the DMSO 
treated control cell lysate (mean ± SEM, n = 3). Differences in the block of post-translational 
translocation of ppCec were assessed for statistical significance using 2-tailed t-tests with equal 
variance assumed (p<0.05 * significant, ** very significant). 
 
B 
A 
** 
* 
* 
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Co-translational translocation was determined by measuring the cleavage of a second 
protein, preprolactin (pPL). Following translocation across the ER, the signal 
sequence of pPL is removed, leading to the production of a smaller protein, providing 
a marker for entry into the ER. In order to allow co-translational translocation, 
mRNA encoding pPL was translated in the presence of ES-treated semi-
permeabilised cells. In this way, the radiolabelled pPL could be translocated across 
the ER membranes as it was being translated. This assay is more challenging and 
therefore only the most interesting compounds were used in this case. PSII and ESI 
were used as the negative and positive controls respectively. In cells treated with 
PSII there was a major band representing pPL, and also a more rapidly migrating 
product that represents PL lacking its signal sequence, and had therefore been 
translocated across the ER membrane. Treatment with ES35 did not alter the extent 
of pPL processing, showing that it did not block co-translational translocation of 
pPL into the ER (Figure 3.11 A, lane 3). In contrast, ESI reduced the level of pPL 
cleavage by approximately 65%, consistent with previous work showing that this 
compound effectively inhibits translocation of pPL into the ER (Figure 3.11 A, lane 
2). In addition, ES40 and to a lesser extent the ES24 Click para caused a slight block 
in co-translational translocation of this substrate (Figure 3.11 A, lanes 4 – 6). ES24 
Click meta did not cause a block in co-translocational translocation of this substrate. 
In summary, none of the compounds were as effective as ESI in inhibiting 
translocation in vitro. This was unexpected, particularly for ES40 given its 
apparently activity in terms of cytotoxicity and accumulation of polyubiquitin 
conjugates. 
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3.5 Protein secretion 
The ER is a major site of synthesis for both membrane integrated and secretory 
proteins. Thus, an alternative way to observe the inhibitory effect of these 
compounds on protein import/translocation at the ER was to measure how they affect 
the overall secretion of proteins from cells. It has previously been shown that ESI 
inhibits the secretion of proteins from HepG2 cells.53 This hepatocyte (liver) derived 
cell line secretes a large number of abundant glycoproteins, which can be detected by 
metabolic labelling with 35S. In this assay, HepG2 cells were incubated with 35S-
methione/cysteine to allow synthesis of 35S labelled proteins being translated (the 
‘pulse’ period). The 35S-methione/cysteine was removed and cells were grown for a 
further 1.5 h in the presence of non-radioactive amino acids.  During this time (the 
‘chase’ period), 35S labelled secretory proteins synthesised during the pulse were 
trafficked through the secretory pathway, and released into the media.  Radiolabelled 
proteins in the cells and media were visualised by SDS-PAGE and phosphorimaging. 
HepG2 cells treated with DMSO as a solvent control during both the pulse and chase 
periods secreted a large number of radiolabelled proteins in the media. This was 
taken to represent a profile of proteins normally secreted from the cells (Figure 
3.12A, lower panel, lane 1). A similar profile of protein secretion was observed in 
cells treated with 8 µM ES35 (Figure 3.12A, lower panel, lane 3). In contrast, when 
cells were treated with Brefeldin A  (Bref A), a fungal metabolite which blocks ER-
Golgi trafficking,102 very few proteins were secreted (Figure 3.12A, lower panel, 
lane 2), despite efficient labelling of total cellular proteins (Figure 3.12A, upper 
panel, lane 2). Consistent with previous work, treatment of cells with ESI also 
markedly reduced the quantity of several secretory proteins in the media.53 Treatment 
with ES40 and ES24 Click meta, also resulted in the reduction of several secretory 
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proteins in the media (Figure 3.12A, lower panel, lanes 5 and 11), without obviously 
altering the labelling of total cellular proteins (Figure 3.12A, upper panel, lanes 5 and 
11). However, the effect of these compounds was not as dramatic as ESI. In contrast, 
ES326, ES328, ES47, ES24 and ES24 Click para had no detectable effect on 
secretion of radiolabelled proteins (Figure 3.12A, lower panel, lanes 6 – 10) 
 
 
Figure 3.12A Protein secretion from HepG2 cells that have been treated with 
Eeyarestatins: Upper panel: Confluent HepG2 cells were pulse-labelled with 35S met/cys for 60 min 
in the presence of 8 µM, ESI compounds,  5µg/mL Bref A or 10 µM DMSO. They were then chased 
in absence of 35S for 1.5 h. At the end of the chase, the media was retained and TCA preciptated and 
the cells lysed in SDS-PAGE sample buffer. Samples of the cell lysate (upper panel) and TCA 
precipitated media (lower panel) were analysed by SDS-PAGE and phosphorimaging. Levels of !-
Tubulin in cell lysates were analysed by immunoblotting (middle panel). 
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Figure 3.12B Quantification of protein secretion from HepG2 cells that have been 
treated with Eeyarestatins: Each lane of the TCA precipitated media was quantified by pixel 
counting using AIDA software and then normalised to the corresponding signal from the cell extract 
this signal was the expressed as a percentage relative to the DMSO control; 
 
 
In order to analyse the secretion of specific proteins directly, the TCA precipitated 
media of the treated HepG2 cultures was subjected to western blotting with 
antibodies to two well-characterised secretory proteins !1-anti-trypsin (!1-AT) and 
albumin.  Significant amounts of both proteins were secreted by DMSO treated cells 
(Figure 3.13A, upper and middle panels, lane 1), whilst treatment with Bref A 
resulted in a dramatic reduction in the levels of !1-AT and albumin secreted into the 
media (Figure 3.13A, upper and middle panels, lane 2).53 In line with its effect on 
global protein secretion, ES40 also inhibited secretion of !1-AT and albumin, albeit 
to a lesser extent than ESI (Figure 3.13A, upper and middle panels, lane 5). 
Strikingly, cells treated with ES24 Click para and ES24 Click meta effectively 
blocked !1-AT secretion, to a similar extent as ESI (Figure 3.13A, upper panel lanes 
3, 10 and 11), with the para compound showing slightly lower effect than the meta 
compound. However, the effect of these compounds on albumin secretion was not as 
strong compared to ESI (Figure 3.13A, middle panel, lanes 3, 10 and 11).  
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Figure 3.13A Secretion of !1-AT and albumin from HepG2 cell. TCA precipitated media 
was analysed by SDS-PAGE and western blotting with anti-!1-AT (upper panel), anti-albumin 
(middle panel). To control for cell number, cell lysates were western blotted with anti-tubulin (lower 
panel). 
 
 
Although ES326, ES328, ES47, ES24 did not obviously reduce secretion of these 
proteins (Figure 3.13 A, upper and middle panels, lanes 6, 7, 8 and 9), quantification 
of the signal intensity showed that whilst they do not affect the secretion of !1-AT 
(Figure 3.13B), but ES326, ES328, ES47 and ES24 all slightly reduced secretion of 
albumin Figure 3.13C). 
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Figure 3.13B Secretion of !1-AT from HepG2 cell. The bands for !1-AT, as indicated, were 
quantified by pixel counting using Odyssey software and then normalised to tubulin signal this signal 
was the expressed as a percentage relative to the DMSO control.  
 
 
Figure 3.13C Quantification of the secretion of albumin from HepG2 cell. The 
phosphorimage bands for albumin, as indicated, were quantified by pixel counting using Odyssey 
software and then normalised to the tubulin signal. This signal was then expressed as a percentage 
relative to the DMSO control. 
 
Importantly, the metabolic labelling of total cellular proteins did not appear to be 
affected by treatment with any of the compounds (Figure 3.12A, top panel, all lanes). 
Thus, an effect on protein synthesis is unlikely to account for the reduction of 
proteins found secreted into the media. Together these results suggest that ES40, 
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ES24 Click para, ES24 Click meta all induce a wide-ranging inhibition of protein 
secretion from cultured HepG2. In contrast, ES326, ES328, ES47 and ES24 appear 
to have little if any effect. Thus, the structure-activity relationship observed in this 
assay was generally similar to that observed for polyubiquitination, with ES40 being 
the most active (after ESI) and the click 24s having a smaller effect. ES40 seems to 
be less active than ESI in terms of blocking secretion and translocation but more 
effective in inducing accumulation of polyubiquitin conjugates. Therefore, the effect 
of these compounds to induce accumulation of polyubiquitins in HEPG2 cells was 
investigated. 
 
 
Figure 3.14A. Accumulation of polyubquitinated proteins in HepG2 cells: Top panel: 
HepG2 cells treated with ES compounds at 8 µM for 8 h were harvested and ubiquitin levels analysed 
by SDS-PAGE and immunoblotting; lower panel: Levels of tubulin were specifically analysed by 
immunoblotting of cell samples. 
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Figure 3.14B. Quantification of the accumulation of polyubquitinated proteins in 
HepG2 cells: Ubiquitin bands were quantified by pixel counting using Odyssey software and 
normalised to the Tubulin signal this was the expressed as a percentage compared to the DMSO 
control 
 
In order the ascertain whether the compounds cause accumulation of 
polyubiquitinated proteins in other cell lines the same ubiquitin assay described 
previously was repeated on this cell line. Using the same cells from the secretion 
assay ubiquitin levels were analysed by SDS-PAGE and immunoblotting.  
In cells treated with DMSO as a solvent control and Bref A there was no 
accumulation of polyubiquitinated proteins as expected (Figure 3.14A, top panel, 
lanes 1 and 2). ESI as expected caused an accumulation of high molecular weight 
polyubiquitinated proteins (Figure 3.14A top panel, lane 3). ES40 caused a greater 
accumulation of polyubiquitinated proteins compared to ESI (Figure 3.14A, top 
panel, lane 5).  However, in HepG2 cells, both ES24 Click compounds caused a 
larger accumulation of polyubiquitinated proteins than ESI, in contrast to what was 
observed in HeLa cells (Figure 3.14A, top panel, lanes 10 and 11). 
In summary, the results were similar to those observed in HeLa cells, with ESI 
causing a marked accumulation of polyubiquitin conjugates compared to ES35. It 
was again observed that ES40 was more effective than ESI. 
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3.6 Click chemistry 
As previously discussed in Chapter 1, MacKinnon et al rhodamine labelled a protein 
with an apparent MW of ~50 kDa using a photo-leucine as a photoaffinity label and 
‘clicking’ on a rhodamine-azide reporter to an alkyne on the same small molecule 
that had bound its target (Figure 1.25). 
This is a useful way to determine targets associated with small molecule inhibitors, 
thus a series of click compounds were prepared in an attempt to determine targets 
associated with the ES compounds (Figure 3.16) 
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Figure 3.16. Structures of Eeyarestatins for use in biological click chemistry assay 
 
ESI Click was initially tested by the High lab for its ability to inhibit cotranslational 
translocation of signal peptide peptidase (SPP) when added directly to ER derived 
microsomal membranes. The results showed that in vitro treatment of microsomes 
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with ESI Click resulted in a similar level of inhibition of translocation to ESI (Figure 
3.17, lane 8).   
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Figure 3.17. Translocation of SPP in ER microsomes treated with Eeyarestatins 
(Provided by McKibbin et al54): In vitro translated 35S Methionine/Cysteine labelled SPP was 
added to ER microsomes that had been treated with 500 µM of the compounds ES35, ESI, ESII, 
ES24, or ESI Click for 1 h on ice. The ER microsomes were washed and the 35S Methionine/Cysteine 
labelled SPP was analysed by SDS-PAGE and phosphorimaging; 
 
Thus, this compound could potentially be used to identify the molecular targets of 
ESI. As a first step towards this, the ability of several different ES Click compounds 
(ES35 Click, ESI Click, ES47 Click or ESIB Click; Structures in Figure 3.16) to 
covalently bind to proteins in ER derived microsomes was examined. ER 
microsomes were treated with the different ES compounds, and incubated for 1 h to 
allow them to react with potential target protein(s) in the microsomes. Subsequently, 
cycloaddition using the commercially available Alexa 488 azide fluorophore (Shown 
in Figure 3.19) was performed, in order to allow visualisation of the ESI. Samples 
were separated by SDS-PAGE and the Alexa 488 fluorescence visualised using 
fluorescence scanning. 
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Figure 3.18. Click reaction in Eeyarestatin treated ER microsomes: ER microsomes were 
treated with 250 µM ES35 Click, ESI Click, ES47 Click or ESIB Click for 1 h on ice before 
performing cycloaddition of Alexa Fluor 488 azide in situ for 1 h at rt. After the addition of 6& sample 
buffer the reactions were analysed by SDS-PAGE and fluorescence scanning. Top panel 10 s 
exposure indicates “clicked” proteins; Lower panel 1 s exposure indicates click reaction completion. 
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Figure 3.19. Alexa 488 azide  
 
A range of different Alexa 488 labelled species were observed in microsomes treated 
with ES35 Click (Figure 3.18, upper panel, lane 1). These most likely represent 
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proteins that had been modified with ES35, and thus labelled with the fluorophore 
following the click reaction. 
 ESI Click and ES47 Click also appeared to target a similar range of proteins, though 
with noticeably lower efficiency (Figure 3.18, lanes 2 and 3). Thus, under these in 
vitro conditions (ER derived membranes and high concentrations of ESI compounds) 
it is impossible to determine which proteins might be targeted by ESI. ESIB Click 
did not clearly label any species (Figure 3.18, lane 4), this may be due to the lower 
reactivity of the alkyne. Since the phenyl alkyne Click reaction is significantly 
slower than for an aliphatic alkyne, it is possible that no reaction with the 
fluorophore occurred in this time frame, thus, none of the targets of this compounds 
could be identified. ES35 actually seems to modify more proteins than ESI, 
suggesting that the experimental conditions need to be altered in order to selectively 
detect the ESI specific targets (Eg The use of live cells may be required). 
 
 3.7 Summary 
Table 3.2. Summary of results of all biological assays investigated: $  negative results, + 
slightly positive result, ++ positive result, +++ exceptionally positive result, ! assay not completed. 
Assay 
 
 Translocation Secretion 
Compound MTT Vacuolisation Poly-ubiquitin 
Post-
translational 
Co-
translational Overall !1-AT Albumin 
ES35 # # # # # # # + 
ESI +++ +++ +++ +++ +++ +++ +++ +++ 
ES40 +++ + +++ + + + ++ ++ 
ES326 # # # # ! # # + 
ES328 # # # # ! # # + 
ES47 8 µM # # + # ! # # + 
ES47 16 µM + + + + ! ! ! ! 
ES24 + # + + ! # # + 
ES24 Click 
para + # ++ + + $ ++ ++ 
ES24 Click 
meta + # ++ + + + ++ ++ 
CAM741 ! ! ! ! ! # # # 
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CHAPTER 4: CONCLUSIONS AND FURTHER 
WORK. 
4.1 Eeyarestatins 
None of the new analogues investigated were equipotent with or more potent than 
ESI in all inhibitory activities, however ES40 appeared to be more potent than ESI in 
terms of cytotoxicity and inducing accumulation of polyubiquitin conjugates and 
both ES24 Click compounds displayed similar activity to ESI when inducing 
accumulation of polubiquitin conjugates. Interestingly, none of the ‘new’ ES 
compounds appeared to induce vacuolisation as observed ESI treated cells. Even 
ES40, which had exhibited the most potent activity of all the new analogues, did not 
show any significant vacuolisation. Some compounds affected secretion of albumin 
but not !1-AT, which was unexpected as it indicates that there may be some 
selectivity in the ability of ES326, ES328 and ES24 to inhibit translocation. ES326 
and ES328 (containing phenyl rings instead of furan rings) only had a slight effect on 
the secretion of albumin confirming that the nitrofuran is a vital structural 
requirement for activity of the ES compounds (although other possibilities could be 
explored). ES47 without the nitro group showed a concentration effect in the 
accumulation of polyubiquitin and vacuolisation assays but this effect was not as 
significant as ESI at 8 µM suggesting that the nitro group may also be a structural 
requirement for activity of the ES compounds.  ES40 was more toxic than ESI 
towards HeLa cells and caused a higher accumulation of polyubiquitin conjugates 
compared to ESI in both HeLa and HepG2 cells but was less effective at blocking 
translocation in vitro, or protein secretion from live cells. The structure-activity 
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relationship appears to be different for these activities, suggesting different reactive 
groups may be involved in inhibiting DUBs vs translocation. Thus, ES40 may be a 
better DUB inhibitor than ESI but less effective inhibitor of translocation. This was 
surprising as the only difference was the addition of a methyl group to the nitrofuran 
arm. More significant changes to this arm, such as in analogue 144 where the 
Michael acceptor has been removed, might help determine the reactive groups 
involved in the inhibition of DUBs and therefore identify the mode of action of these 
inhibitors. Figure 4.1 shows the proposed structures of new analogues that would 
determine the effect the Michael acceptor has on the activity of ES compounds.  
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Figure 4.1. Proposed structures to determine the requirement of the Michael acceptor 
in Eeyarestatins 
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The results observed in the “short form” ES compounds were particularly interesting. 
In previous work ES24 had difficulty crossing the cell membrane, however, the 
addition of hydrophobic groups increased the ability of these “short form” 
compounds to induce accumulation of polyubiquitin conjugates particularly in 
HepG2 cells. The changes to ES24 structure were only minor thus new targets can be 
synthesised to explore ES24 activity in more detail. Some examples of possible 
targets are shown in Figure 4.2 and are currently under study in the Whitehead lab. 
These analogues were selected to further investigate the addition of different 
functional groups on activity 149 and 150 to investigate further addition of 
hydrophobic groups, 151 to investigate the addition of electronegative groups and 
finally 152 to investigate the addition of a pyridine.  
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Figure 4.2. Possible targets to explore “short form” activity in more detail 
 
The IC50 values would give an exact toxicity of these compounds and the MTT assay 
could be used again to determine these. To achieve this drug treatments need to 
occur over a longer time period, such as 72 h, so that cell viability reaches zero and 
over a wider range of concentrations.  
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As previously discussed the click chemistry reaction needs to be repeated to optimise 
the conditions for confirmation of the result. If optimisation is successful then the 
proteins that interact with the ES compounds can be determined. 
 
4.2 Cotransin 
As previously discussed the synthesis of fragment 1 of Cotransin was not completed. 
Further work would involve the esterification of N-Boc amino acid 139 with 
isobutene to give ester 140. This would then be followed by the amino acid coupling 
to Boc-Leu under standard conditions to give the dipeptide 141. The final two steps 
would involve the selective removal of the Boc group using neat formic acid 
followed by the coupling to the natural lactic acid using EDCI and NaHCO3 to give 
fragment 1, 143. 
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Figure 4.3. Synthesis of fragment 1 a precursor to Cotransin 
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The HPLC of fragment 2 and the hydrolysis using LiOH to give 137 would need to 
be completed for the coupling of fragment 1 to fragment 2 via the Mitsunobu 
reaction. This reaction would invert the stereochemistry of the lactic acid to give the 
required linear heptadepsipeptide 153. Then reaction with TFA to remove both the 
Boc and t-Butyl protecting groups and final cyclisation with either EDCI, HOAt and 
NaHCO3 or HATU and collidine would hopefully furnish Cotransin. 
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Figure 4.4 Final steps in the synthesis of Cotransin 
 
Once complete Cotransin can then be used in the assays completed here to determine 
its inhibitory activity compared to ESI and CAM741. 
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CHAPTER 5: EXPERIMENTAL 
5.1 General procedures 
 
Structures 
All chemical structures and chemical names were generated using ChemDraw Ultra 
v12.0. 
Chromatography 
Column chromatography was performed using silica gel (Sigma-Aldrich) 40 – 63 µm 
60 Å treated with solvent system used in individual procedures. The eluents are 
specified in individual procedures. 
Infra – Red Spectroscopy 
Recorded as KBr discs using an ATI Mattson genesis series FT-IR instrument or 
Perkin Elmer FT-IR system or taken as a solid state on Perkin Elmer FT-IR or 
Bruker Alpha P FT-IR instrument. Absorption maxima ((max) are recorded in 
wavenumbers (cm$1). 
Mass spectrometry 
Mass spectrometry was carried out by the staff in the Mass Spectrometry Laboratory, 
School of Chemistry, at the University of Manchester, using Micromass Platform II 
(ES and LCMS), Waters QTOF (HRMS and LCMS) and Thermo Finnigan 
MAT95XP (HRMS and GCMS) spectrometers. Only molecular ions, fractions from 
molecular ions and other major peaks are reported as mass/charge (m/z) ratios. 
Reported mass values are within ± 5 ppm mass units for electrospray and ±10 ppm 
for HRMS. 
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Melting Points 
Recorded on a Sanyo Gallenkamp MPD350 heater. 
Nuclear Magnetic Resonance 
1H and 13C NMR spectra were acquired using Bruker Avance 500, Bruker Avance 
400, and Bruker Avance 300 spectrometers. 1H and 13C assignments were supported 
by 1H COSY, DEPT and HMQC.  
Chemical shifts (%H) are quoted in parts per million (ppm) to the nearest 0.01 ppm 
and referenced to TMS to the nearest 0.1 Hz. Data is reported in the format: 
Chemical shift, integration, multiplicity. Chemical shifts (%C) are reported in ppm to 
the nearest 0.01 ppm and referenced to the solvent peak. 
Optical rotation 
[!]D measurements are given in units of 10$1 deg cm2 g$1 and were recorded on an 
AA-100 polarimeter (Optical activity limited). 
Solvents 
DCM was dried over calcium hydride; THF was distilled from sodium 
benzophenone ketyl under nitrogen atmosphere; PE Bp 40-60 °C was distilled before 
use. Deionised water was obtained from a Millipore Elix 5. 
Solvents were evaporated on a Büchi RE111 rotary evaporator equipped with a 
Büchi 461 water bath. 
 
All chemicals were handled in accordance with safety instructions. All reactions 
were carried out with exclusion of water in an inert nitrogen atmosphere using a 
nitrogen balloon. All glassware was pre-dried in an oven at 110 °C and cooled in a 
dessicator prior to use. 
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5.2 Preparation of Eeyarestatins. 
5.2.1 Symmetrical Eeyarestatins. 
 
2-Chloro-2-methyl-1-nitrosopropane. (66) 
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2-methylpropene (16 mL, 10 g, 178.2 mmol) was condensed into a 3-necked round 
bottomed flask cooled to -30 °C and equipped with a cold finger at $78 °C. The 
temperature was allowed to rise until $15 °C and then iso-amyl nitrite (24 mL, 178.2 
mmol) was added. Cold concentrated HCl (15 mL) was then added drop-wise and the 
mixture allowed to stir for 2 h at $10 °C. After this time the bath was cooled to $20 
°C without stirring. The resulting precipitated solid was collected by filtration, 
washed with cold MeOH ($15 °C, 30 mL) and dried under vacuum to give the title 
compound as a colourless solid (8.67 g, 39%).  Mp 100–101.8 °C [lit.101 104–105 
°C]; (max (evaporated film)/cm$1 3030 (w), 2981 (w, C-H), 2963 (w, C-H), 2863 (w, 
C-H), 1460 (m, N=O); 1H NMR (300 MHz, CDCl3) % 4.70 (2H, s, C(2)H2), 1.76 (6H, 
s, C(3)H3 & C(4)H3); 13C NMR (125 MHz, CDCl3) % 66.3 (C(2)), 65.8 (C(1)), 31.2 
(C(3) & C(4)),  
 
 
 
 137 
Methyl-2-[(2-hydroxyamino-1,1-dimethylethyl)amino]acetate. (67) 
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Glycine methyl ester hydrochloride (5.17 g, 41 mmol) was added, under an 
atmosphere of nitrogen, to a solution of 2-chloro-2-methyl-1-nitrosopropane, 66 (5.0 
g, 41 mmol) in freshly distilled MeCN (82 mL). Freshly distilled triethylamine (8.3 
mL, 82 mmol) was then added drop-wise. The reaction mixture was allowed to stir at 
rt for 17 h and then quenched by the addition of a saturated aqueous solution of 
sodium bicarbonate (40 mL). The organic material was extracted into DCM (4 & 50 
mL) and the combined organic layers were washed with brine (40 mL), dried over 
magnesium sulfate and concentrated under reduced pressure to yield the title 
compound as a colourless solid (5.747 g, 80%). Mp 86.0–86.9 °C; (max (evaporated 
film)/cm$1 3292 (m, O-H), 3163 (m, N-H), 3081 (m, C-H), 2977 (m, C-H), 2874 (m, 
C-H), 2798 (m, C-H), 1750 (s, C=O); 1H NMR (300 MHz, CDCl3) % 7.28 (1H, s, 
C(4)H), 3.73 (3H, s, CO2CH3), 3.39 (2H, s, C(2)H2), 1.27 (6H, s, C(5)H3 & C(6)H3); 
13C NMR (125 MHz, CDCl3) % 172.7 (C(1)), 154.8 (C(4)), 54.1 (C(3)), 52.0 
(CO2CH3), 44.7 (C(2)), 25.2 (C(5) & C(6)); m/z (+ve ion electrospray) 197 
([M+Na]+, 100%), (Found 197.0899, C7H14N2NaO3 ([M+Na]+), requires 197.0897). 
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Methyl 2-(3-(4-chlorophenyl)-4-(3-(4-chlorophenyl)-1-hydroxyureido)-5,5-
dimethyl-2-oxoimidazolidin-1-yl)acetate. (69) 
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A solution of 4-chlorophenyl isocyanate (1.01 g, 5.75 mmol) in freshly distilled THF 
(2 mL) was added under an atmosphere of nitrogen to a solution of oxime, 67 (0.57 
g, 2.87 mmol) also in freshly distilled THF (14 mL). The resulting solution was 
stirred at rt for 17 h and was then concentrated under reduced pressure. The product 
was crystallised from DCM, collected by filtration, washed with diethyl ether (20 
mL) and dried. The filtrate was concentrated under reduced pressure and the 
crystallisation procedure was repeated a further three times. Combination of the four 
batches of crystallised product gave the title compound as a colourless solid (1.03 g, 
65%). Mp 217.5–218.8 °C; (max (solid state)/cm$1 3320 (m, O-H), 3285 (m, N-H), 
2980 (w, C-H), 1735 (s, C=O), 1695 (s, C=O), 1672 (s, C=O), 1590 (m, Ar C=C), 
1526 (s, Ar C=C), 1494 (s, Ar C=C); 1H NMR (500 MHz, CDCl3) % 8.14 (1H, brs, 
NH or OH), 7.94 (1H, brs, NH or OH), 7.66 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.53 (2H, 
d, J 8.8 Hz, 2 & Ar-CH), 7.28–7.24 (4H, m, 4 & Ar-CH), 6.18 (1H, s, C(4)H) 4.40 
(1H, d, J 18.1 Hz, , C(21)HaHb), 3.59 (1H, d, J 18.1 Hz, , C(21)HaHb), 3.58 (3H, s, 
CO2CH3), 1.36 (3H, s, C(19)H3 or C(20)H3), 1.30 (3H, s, C(19)H3 or C(20)H3); 13C 
NMR (75 MHz, CDCl3, some signals are coincident) % 172.6 (C(22)), 156.8 (C(2) or 
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C(12)), 155.8 (C(2) or C(12)), 137.2 (Ar-C), 136.9 (Ar-C), 129.1 (Ar-CH), 128.9 
(Ar-C), 128.8 (Ar-CH), 128.2 (Ar-C), 121.0 (Ar-CH), 120.3 (Ar-CH), 74.7 (C(4)), 
59.0 (C(5)), 53.0 (CO2CH3), 40.6 (C(21)), 26.4 (C(19) or C(20)), 19.3 (C(19) or 
C(20)); m/z-($ve ion electrospray) 483.4 ([M$H]$, (37Cl, 37Cl), 15%), 481.4 ([M$H]$, 
(35Cl, 37Cl), 83 %), 479.5 ([M$H]$, (35Cl, 35Cl), 100%), (+ve ion electrospray) 507 
([M+Na]+, (37Cl, 37Cl), 10%), 505 ([M+Na]+, (35Cl, 37Cl), 60%), 503 ([M+Na]+, 
(35Cl, 35Cl), 100%); (Found 503.0847, C21H2235Cl2N4NaO5 ([M+Na]+), requires 
503.0859). 
 
3-(4-Chlorophenyl)-1-(3-(4-chlorophenyl)-1-(2-hydrazinyl-2-oxoethyl)-5,5-
dimethyl-2-oxoimidazolidin-4-yl)-1-hydroxyurea. (8) 
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An aqueous solution of hydrazine (62%, 1.18 mL, 24 mmol) was added to a solution 
of imidazolidinone, 69 (0.567 g, 1.18 mmol) in MeOH (6 mL). The reaction mixture 
was stirred at rt for 48 h and then cooled to 0 °C. The resulting precipitate was 
collected by filtration, washed sequentially with cold MeOH (10 mL) and diethyl 
ether (10 mL) and dried to yield the title compound as a colourless solid (0.358 g, 
63%). Mp 197.5–199 °C; (max  (solid state)/cm$1 3304 (m, O-H), 3085 (m, N-H), 
3029 (m, C-H), 1700 (s, C=O), 1649 (m, Ar C=O), 1647 (m, Ar C=O), 1591, (m, Ar 
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C=C), 1527 (s, Ar C=C), 1493 (s, Ar C=C); 1H NMR (500 MHz, CD3OD) % 7.68 
(2H, d, J 8.8 Hz, 2 & Ar-CH), 7.46 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.33 (2H, d, J 8.8 
Hz, 2 & Ar-CH), 7.28 (2H, d, J 8.8 Hz, 2 & Ar-CH) 6.12 (1H, s, C(4)H), 4.08 (1H, d, 
J 17.3 Hz, C(21)HaHb), 3.82 (1H, d, J 17.3 Hz, C(21)HaHb), 1.41 (3H, s, C(19)H3 or 
C(20)H3), 1.35 (3H, s, C(19)H3 or C(20)H3); 13C NMR (125 MHz, CD3OD, some 
signals are coincident) % 171.5 (C(22)), 159.0 (C(2) or C(12)), 158.5 (C(2) or C(12)), 
138.8 (Ar-C), 138.4 (Ar-C), 130.3 (Ar-C), 130.0 (Ar-C), 129.9 (Ar-CH), 129.8 (Ar-
CH), 123.4 (Ar-CH), 122.6 (Ar-CH), 77.1 (C(4)), 61.1 (C(5)), 42.4 (C(21)), 25.7 
(C(19) or C(20)), 19.4 (C(19) or C(20)); m/z ($ve ion electrospray) 483 ([M$H]$, 
(37Cl, 37Cl), 10%)  481 ([M$H]$, (35Cl, 37Cl), 65%) 479 ([M$H]$, (35Cl, 35Cl), 100%), 
(+ve ion electrospray) 507 ([M+Na]+, (37Cl, 37Cl), 8%), 505 ([M+Na]+, (35Cl, 37Cl), 
55%), 503 ([M+Na]+, (35Cl, 35Cl), 100%); (Found 479.0998, C20H2135Cl2N6O4 ([M-
H]$), requires 479.1007). 
 
(E)-3-(5-Nitro-2-furyl)acrylaldehyde. (70) 
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A solution of 5-nitrofuran-2-carbaldehyde (1.067 g, 7.56 mmol) in freshly distilled 
THF (1 mL) was added drop-wise under an atmosphere of nitrogen to a solution of 
(triphenylphosphanylidene)acetaldehyde (2.3 g, 7.56 mmol) in freshly distilled THF 
(50 mL) at rt. The reaction mixture was allowed to stir at rt for 2 h and then 
concentrated under reduced pressure. Purification by flash column chromatography 
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(SiO2; Et2O:PE, 3:1) yielded the title compound as an orange solid (1.056 g, 70%). 
Mp 114–116 °C [lit.102 110–116 °C]; (max (evaporated film)/cm$1 3150 (w, C-H), 
3133 (w, C-H), 1686 (s, C=O), 1629 (m, C=C), 1519 (s, C=C), 1470 (s, C=C); 1H 
NMR (300 MHz, d6-DMSO) % 9.70 (1H, d, J 7.6 Hz, CHO), 7.79 (1H, d, J 4.0 Hz, 
C(6)H), 7.7 (1H, d, J 15.9 Hz, C(3)H), 7.43 (1H, d, J 4.0 Hz, C(5)H), 6.75 (1H, dd, J 
15.9 & 7.6 Hz, C(2)H); 13C NMR (100 MHz, d6-DMSO) % 193.6 (C(1)), 152.3 
(C(7)), 152.3 (C(4)), 136.4 (C(3)), 130.4 (C(2)), 118.1 (C(5)), 114.6(C(6)). 
 
3-(4-Chlorophenyl)-1-[3-(4-chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(5-
nitrofuran-2-yl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-
hydroxyurea (ESI). (1) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (63 mg, 0.377 mmol) was added under an 
atmosphere of nitrogen to a solution of acyl hydrazide, 8 (0.180 g, 0.377 mmol) in 
freshly distilled MeOH (2 mL). The resulting solution was stirred at rt for 17 h and 
then concentrated under reduced pressure. The product was crystallised from DCM, 
collected by filtration, washed with cold DCM (10 mL) and pentane (10 mL) and 
dried yielding the title compound as a yellow solid (0.191 g, 81%). Mp 211–213 °C; 
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(max (solid state)/cm$1 3382 (w, O-H), 3124 (w, N-H), 2983 (m, C-H), 2890 (w, C-H), 
1707 (m, C=O), 1669 (s, C=O), 1519 (s, C=C), 1494 (s, C=C); 1H NMR (500 MHz, 
CDCl3) % 9.85 (1H, brs, NH or OH), 9.42 (1H, brs, NH or OH), 7.68 (2H, d, J 8.8 
Hz, 2 & Ar-CH), 7.65 (1H, brs, NH or OH), 7.38 (2H, d, J 9.1 Hz, 2 & Ar-CH), 7.30–
7.26 (3H, m, C(23)H & 2 & Ar-CH), 7.18 (1H, d, J 3.7 Hz, C(28)H),  7.16 (2H, d, J 
8.8 Hz, 2 & Ar-CH), 6.95 (1H, dd, J 15.5 & 9.4 Hz, C(24)H), 6.34 (1H, d, J 3.7 Hz, 
C(27)H), 6.13 (1H, s, C(4)H), 5.47 (1H, brd, J 15.5 Hz, C(25)H), 4.78 (1H, d,  J 18.3 
Hz, C(21)HaHb), 4.11 (1H, d, J 18.3 Hz, C(21)HaHb), 1.43 (3H, s, C(19)H3 or 
C(20)H3), 1.30 (3H, s, C(19)H3 or C(20)H3); 13C NMR (100 MHz, d6-DMSO, two 
isomers, some signals are coincident) % 169.8 (C=O), 165.3 (C=O), 161.0 (C=O), 
156.9 (Ar-C), 156.4 (Ar-C), 155.7 (Ar-C), 155.6 (Ar-C), 154.9 (Ar-C), 154.8 (Ar-
C), 151.4 (Ar-C), 151.4 (Ar-C), 147.0 (Ar-C), 143.8(Ar-CH), 138.3 (Ar-C), 138.1 
(Ar-C), 138.0 (Ar-C), 130.1 (Ar-CH), 128.6 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-
CH), 128.3 (Ar-CH), 126.5 (Ar-C), 126.3 (Ar-C), 126.2 (Ar-C), 124.0 (Ar-CH), 
123.9 (Ar-CH), 123.3 (Ar-CH), 121.5 (Ar-CH), 121.3 (Ar-CH), 120.1 (Ar-CH), 
120.0 (Ar-CH), 119.8 (Ar-CH), 119.2 (Ar-CH), 115.4 (Ar-CH), 115.4 (Ar-CH), 
113.4 (Ar-CH), 74.4 (C(4)H, major isomer) , 74.3 (C(4)H, minor isomer), 58.8 (C(5), 
minor isomer), 58.6 (C(5), major isomer), 40.25 (C(21)), 26.8 (C(19) or C(20), major 
isomer), 26.4, (C(19) or C(20), minor isomer) 19.3 (C(19) or C(20), major isomer), 
19.1 (C(19) or C(20), minor isomer);  m/z ($ve ion electrospray) 632 ([M$H]$, (37Cl, 
37Cl), 15%), 630 ([M$H]$, (35Cl, 37Cl), 70%), 628 ([M$H]$, (35Cl, 35Cl), 100%), (+ve 
ion electrospray); (Found 628.1123, C27H2435Cl2N7O7 ([M$H]$), requires 628.1120). 
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Methyl 2-(4-(1-hydroxy-3-(naphthalen-1-yl)ureido-5,5-dimethyl-3-(naphthalen-
1-yl)-2-oxoimidazolidin-1-yl)acetate. (71) 
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A solution of 1-naphthyl isocyanate (1.01 g, 5.75 mmol) in freshly distilled THF (2 
mL) was added under an atmosphere of nitrogen to a solution of oxime, 67 (0.57 g, 
2.87 mmol) also in freshly distilled THF (14 mL).  The reaction mixture was stirred 
at rt for 15 h when residual solvent was removed under reduced pressure.  The 
product was crystallised from DCM, collected by filtration, washed with diethyl 
ether (20 mL) and dried under vacuum.  The filtrate was concentrated under reduced 
pressure and the crystallisation procedure was repeated a further three times.  
Combination of the crystallised material yielded the title compound as a colourless 
solid (0.921 g, 61%).  Mp 199–200 °C; (max (solid state)/cm$1 3436 (w, O-H), 3054 
(brw, N-H), 2839 (brw, C-H), 1749 (s, C=O), 1658 (s, C=O), 1535 (s, C=C); 
1) *+R (500 MHz, CDCl3) % 8.17 (1H, brs, NH or OH), 8.08 (1H, brd, J 7.9 Hz, 
Ar-CH), 7.99 (1H, brs, NH or OH), 7.92 (1H, brd, J 6.7 Hz, Ar-CH), 7.87–7.78 (4H, 
m, 4 & Ar-CH), 7.61–7.59 (2H, m, 2 & Ar-CH), 7.52–7.55 (1H, m, Ar-CH), 7.50–
7.44 (5H, m, 5 & Ar-CH), 7.35–7.32 (1H, m, Ar-CH), 6.19 (1H, s, C(4)H), 4.69 (1H, 
d, J 18.2 Hz, C(29)HaHb), 3.88 (3H, s, CO2CH3), 3.79 (1H, d, J 18.2 Hz, 
C(29)HaHb), 1.71 (3H, s, C(27)H3 or C(28)H3), 1.49 (3H, s, C(27)H3 or C(28)H3); 
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13C NMR (125 MHz, CDCl3, some signals are coincident) % 173.9 (C(30)), 156.1 
(C(2) and C(16) coincident), 134.6 (Ar-C), 134.0 (Ar-C), 132.1 (Ar-C), 131.1 (Ar-
C), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 127.4 (Ar-C), 126.7 (Ar-CH), 
126.0 (Ar-CH), 125.8 (Ar-CH), 125.6 (Ar-CH), 125.5 (Ar-CH), 125.1 (Ar-CH), 
120.9 (Ar-CH), 120.0 (Ar-CH), 77.6 (C(4)), 59.2 (C(5)), 53.2 (CO2CH3), 40.5 
(C(29)), 25.8 (C(27) or C(28)), 20.3 (C(27) or C(28)); m/z ($ve ion electrospray) 511 
([M$H]$, 100%): (+ve ion electrospray) 535 ([M+Na]+, 100%). (Found 535.1949, 
C29H28N4NaO5 ([M+H]+), requires 535.1952). 
 
1-(1-(2-Hydrazinyl-2-oxoethyl)-5,5-dimethyl-3-(naphthalen-1-yl)-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-(naphthalen-1-yl)urea. (72) 
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An aqueous solution of hydrazine (62%, 0.88 mL, 23 mmol) was added to a solution 
of imidazolidinone 71 (451 mg, 0.88 mmol) in MeOH (4.5 mL).  The reaction mixture 
was stirred at rt for 48 h and then cooled to 0 °C.  The resulting precipitated solid 
was collected by filtration and washed sequentially with cold MeOH (10 mL) and 
diethyl ether (10 mL).  The filtrate was concentrated under reduced pressure and the 
residual solid was recrystallised at rt from DCM/diethyl ether (1:1), washed with 
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cold MeOH and diethyl ether and then combined with the first batch of precipitate 
to yield the title compound as a colourless solid (248 mg, 55%). Mp 195–197 °C; 
(max (evaporated film)/cm$1 3390 (m, O-H), 3271 (brm, N-H), 3054 (m, N-H), 2971 
(m, C-H), 2857 (brw, C-H), 1686 (s, C=O), 1596 (m, C=C), 1520 (m, C=C), 1495 (s, 
C=C); 1H NMR (500 MHz, CD3OD) % 8.12 (1H, brs, NH or OH), 7.98 – 7.95 (3H, 
m, 3 & Ar-CH), 7.80 (1H, d, J 8.2 Hz, Ar-CH), 7.68 (1H, d, J 8.2 Hz, Ar-CH), 7.61–
7.52 (4H, m, 4 & Ar-CH), 7.45–7.30 (5H, m, 5 & Ar-CH), 6.99 (1H, d, J 7.2 Hz, Ar-
CH), 6.10 (1H, s, C(4)H), 4.12 (1H, d, J 16.9 Hz, C(29)HaHb), 3.96 (1H, d, J 16.9 
Hz, C(29)HaHb), 1.70 (3H, s, C(27)H3 or C(28)H3), 1.61 (3H, s, C(27)H3 or 
C(28)H3); 13C NMR (CD3OD: 75 MHz, some signals are coincident) 171.8 (C(30)), 
161.3 (C(2) or C(16)), 160.7 (C(2) or C(16)), 136.2 (Ar-C), 135.7 (Ar-C), 134.0 (Ar-
C), 132.7 (Ar-C), 131.0 (Ar-C), 129.9 (Ar-CH), 129.8 (Ar-CH), 129.2 (Ar-CH), 
128.0 (Ar-CH), 127.6 (Ar-CH) 127.5 (Ar-CH), 127.2 (Ar-CH), 127.1 (Ar-CH), 126.9 
(Ar-CH), 126.4 (Ar-CH), 124.3 (Ar-CH), 123.6 (Ar-CH), 79.7 (C(4)), 61.5 (C(5)), 
42.6 (C(29)), 26.5 (C(27) or C(28)), 20.5 (C(27) or C(28)); m/z – ($ve ion 
electrospray) 511 ([M$H]$, 100%), (+ve ion electrospray) 535 ([M+Na]+, 100%); 
(Found 535.2065, C28H28N6NaO4 ([M+Na]+), requires 535.2064). 
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1-(5,5-Dimethyl-3-(naphthalen-1-yl)-1-(2-((E)-2-((E)-3-(5-nitrofuran-2-
yl)allylidene)hydrazinyl-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-hydroxy-3-
(naphthalen-1-yl)urea (ESII). (2) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (20 mg, 0.120 mmol) was added under nitrogen 
to a solution of acyl hydrazide, 72 (70 mg, 0.137 mmol) in freshly distilled MeOH (1 
mL). The reaction mixture was stirred at rt for 48 h and then concentrated under 
reduced pressure. The residue was recrystallised at rt from EtOAc/diethyl ether 
(1:2), yielding the title compound as a yellow solid (75 mg, 83%). Mp 213–215 °C; 
(max (solid state)/cm$1 3410 (w, O-H), 3267 (m, N-H), 3013 (brm, N-H), 2862 (w, C-
H), 1739 (brs, C=O) 1702 (s, C=O), 1655 (s, C=O), 1626 (m, C=C), 1537 (s, C=C); 
1H NMR (400 MHz, CDCl3 and one drop of d5-Pyridine) % 11.6 (1H, brs, NH or 
OH), 7.97–7.95 (3H, m, 3 & Ar-CH), 7.89–7.87 (1H, m, Ar-CH), 7.81–7.76 (1H, m, 
Ar-CH), 7.71–7.65 (2H, m, 2 & Ar-CH), 7.53–7.45 (10H, m, 10 & Ar-CH), 7.28 (1H, 
d, J 2.9 Hz, C(36)H), 6.86 (1H, dd, J 15.4 & 8.9 Hz, C(32)H), 6.48 (1H, d, J 2.9 Hz, 
C(35)H), 6.32 (1H, s, C(4)H), 5.55 (1H, brs, NH or OH), 5.36 (1H, d, J 17.0 Hz, 
C(29)HaHb), 4.59 (1H, d, J 17.0 Hz, C(29)HaHb)  1.67 (3H, s, C(27)H3 or C(28)H3), 
1.52 (3H, s, C(27)H3 or C(28)H3); 13C NMR (75 MHz, CDCl3 plus d5-Pyridine, 
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some signals are coincident) % 171.5 (C(30)), 166.2 (C(2) or C(16)), 157.3 (C(2) or 
C(16)), 154.0 (C(34)), 147.9 (Ar-C), 133.9 (Ar-C), 133.7 (Ar-C), 132.5 (Ar-C), 
130.0 (Ar-C), 128.8 (Ar-C), 128.0 (Ar-CH), 127.6 (Ar-CH), 126.2 (Ar-CH), 125.9 
(Ar-CH), 125.3 (Ar-CH) 125.0 (Ar-CH), 122.4 (Ar-CH), 121.5 (Ar-CH), 113.0 (Ar-
CH), 110.5 (Ar-CH), 77.2 (C(4)), 59.1 (C(5)),  41.9 (C(29)), 25.8 (C(27) or C(28)), 
19.5 (C(27) or C(28)); m/z ($ve ion electrospray) 660 ([M$H]$, 100%,), (+ve ion 
electrospray) 684 ([M+Na]+, 100%); (Found 660.2199, C35H30N7O7 ([M$H]$), 
requires 660.2212). 
 
1-(5,5-Dimethyl-3-(naphthalen-1-yl)-1-(2-((E)-2-((E)-3-(4-
nitrophenyl)allylidene)hydrazinyl-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-
hydroxy-3-(naphthalen-1-yl)urea (ES111). (73) 
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p-Nitrocinnamaldehyde (40 mg, 0.227 mmol) was added under an atmosphere of 
nitrogen to a solution of acyl hydrazide, 72 (116 mg, 0.16 mmol) in freshly distilled 
MeOH (2 mL). The reaction mixture was stirred at rt for 48 h and concentrated under 
reduced pressure. The resulting solid was collected by filtration, washed with diethyl 
ether (10 mL) and pentane (10 mL) to yield the title compound as a yellow solid 
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(117 mg, 78%). Mp 191.5–193.5 °C; (max (evaporated film)/cm$1 3390 (brw, O-H), 
3195 (brm, N-H), 3048 (m, N-H), 2952 (m, C-H), 2886 (m, C-H), 1685 (s, C=O), 
1597 (m, C=C), 1517 (s, C=C); 1H NMR (400 MHz, d6-DMSO, two isomers) % 11.6 
(brs, NH or OH), 9.2 (brs, NH or OH minor isomer), 9.2 (s, NH or OH major 
isomer), 8.31 – 8.21 (m, Ar-CH), 8.12 – 7.84 (m, Ar-CH), 7.76 – 7.54 (m, Ar-CH), 
7.49 – 7.10 (m, Ar-CH), 6.94 (dd, J 16.3 & 9.8 Hz, C(32)H minor isomer), 5.93, 
(brs, C(4)H  major isomer & C(4)H minor isomer), 5.60 (d, J 16.3 Hz, C(33)H minor 
isomer), 4.46 (d, J 17.9 Hz C(29)HaHb major isomer), 4.31 (d, J 17.9 Hz, C(29)HaHb 
major isomer), 4.07 (partly obscured by solvent peak at 4.04, C(29)HaHb minor 
isomer), 3.97 (d, J 11.1 Hz, C(29)HaHb minor isomer), 1.60 (s, C(27)H3 or C(28)H3 
major isomer & C(27)H3 or C(28)H3 minor isomer), 1.52 (s, C(27)H3 or C(28)H3 
major isomer & C(27)H3 or C(28)H3 minor isomer); 13C NMR (100 MHz, d6-
DMSO, two isomers, some signals are coincident) % 170.4 (C=O), 158.7 (Ar-C), 
148.7 (Ar-C), 148.7 (Ar-C), 147.0 (Ar-C), 146.9 (Ar-C), 146.9 (Ar-C), 142.7 (Ar-
C), 142.6 (Ar-C), 134.1 (Ar-C), 134.1 (Ar-C), 134.0 (Ar-C), 133.7 (Ar-C), 133.7 
(Ar-C), 133.6 (Ar-C), 131.6 (Ar-C), 131.6 (Ar-C), 131.5 (Ar-C), 131.3 (Ar-C), 
131.2 (Ar-C), 131.2 (Ar-C), 131.1 (Ar-C), 129.8 (Ar-CH), 129.8 (Ar-CH), 129.1 
(Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.1 
(Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 126.7 (Ar-C), 126.1 (Ar-
C), 126.0 (Ar-C), 125.9 (Ar-CH), 125.9 (Ar-CH), 125.8 (Ar-CH), 125.7 (Ar-CH), 
125.7 (Ar-CH), 125.6 (Ar-CH), 125.5 (Ar-CH), 124.2 (Ar-CH), 124.1 (Ar-CH), 
123.0 (Ar-CH), 122.6 (Ar-CH), 77.0 (C(4)), 59.6 (C(5) minor isomer), 59.2 (C(5) 
major isomer), 40.6 (C(29) minor isomer), 40.3 (C(29) major isomer), 26.4 (C(27) or 
C(28) minor isomer), 26.3 (C(27) or C(28) major isomer), 20.5 (C(27) or C(28) minor 
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isomer), 20.4 (C(27) or C(28) major isomer); m/z ($ve ion electrospray) 670 
([M$H]$, 100%), (+ve ion electrospray) 694 ([M+Na]+, 100%); (Found 694.2385, 
C37H33N7NaO6 ([M+Na]+), requires 694.2385). 
 
3-(4-Chlorophenyl)-1-[3-(4-chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(4-
nitrophenyl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-
hydroxyurea (ES326). (75) 
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p-Nitrocinnamaldehyde (30 mg, 0.17 mmol) was added under an atmosphere of 
nitrogen to a solution of acyl hydrazide, 8 (75 mg, 0.16 mmol) in freshly distilled 
MeOH (1 mL). The reaction mixture was stirred at rt for 18 h and then concentrated 
under reduced pressure. The product was crystallised from DCM, collected by 
filtration and washed with cold DCM (10 mL) and pentane (10 mL) yielding the title 
compound as a yellow solid (54 mg, 54%). Mp 210.5–211 °C; (max (evaporated 
film)/cm$1 3206 (w), 3166 (w), 3098 (w), 1674 (s), 1590 (m), 1515 (s), 1495 (s); 1H 
NMR (400 MHz, d6-DMSO) % 9.78 (brs, NH or OH minor isomer), 9.76 (brs, NH 
or OH major isomer), 9.33 (brs, NH or OH major isomer & NH or OH minor 
isomer), 8.35 (d, J 8.7 Hz, Ar-CH), 8.28 (d, J 8.7 Hz, Ar-CH), 8.09, (d, J 8.7 Hz, Ar-
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CH), 7.94 (d, J 9.1 Hz, Ar-CH), 7.76 – 7.70 (m, Ar-CH), 7.46 – 7.36 (m, Ar-CH), 
7.33 – 7.25 (m, Ar-CH), 6.16 (brs, C(4)H major isomer & C(4)H minor isomer), 
4.41, (d, J 18.2 Hz, C(21)HaHb major isomer), 4.29 (d, J 18.2 Hz, C(21)HaHb major 
isomer), 4.04 (d, J 16.9 Hz, C(21)HaHb minor isomer), 3.96 (d, J 16.9 Hz, C(21)HaHb 
minor isomer), 1.41 (s, C(19)H3 or C(20)H3 minor isomer), 1.39 (s, C(19)H3 or 
C(20)H3 major isomer), 1.35 (C(19)H3 or C(20)H3 major isomer); 13C NMR (100 
MHz, d6-DMSO, two isomers, some signals are coincident) % 175.5 (C=O), 157.8 
(Ar-C), 157.7 (Ar-C), 157.5 (Ar-C), 156.5 (Ar-C), 156.4 (Ar-C), 150.6 (Ar-C), 142.0 
(Ar-C), 140.3 (Ar-C), 138.3 (Ar-C), 138.1 (Ar-C), 138.0 (Ar-CH), 137.6 (Ar-CH), 
128.4 (Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-CH), 128.1 (Ar-CH), 127.9 (Ar-CH), 
126.3 (Ar-C), 126.3 (Ar-C), 126.2 (Ar-C), 124.2 (Ar-CH), 124.1 (Ar-CH), 124.0 
(Ar-CH), 121.5 (Ar-CH), 121.3 (Ar-CH), 120.1 (Ar-CH), 120.0 (Ar-CH), 119.9 (Ar-
CH), 119.8 (Ar-CH), 74.4 (C(4) major isomer), 74.4 (C(4) minor isomer), 58.6 
(C(5)), 40.3 (C(21)), 26.9 (C(19) or C(20) minor isomer), 26.8 (C(19) or C(20) major 
isomer), 19.3 (C(19) or C(20) major isomer), 19.2 (C(19) or C(20) minor isomer); 
m/z ($ve ion electrospray) 641 ([M$H]$, (35Cl, 37Cl), 30%), 639 ([M$H]$, (35Cl, 
35Cl), 97%); (+ve ion electrospray) 664 ([M+Na]+, (35Cl, 37Cl), 50%) 662 ([M+Na]+, 
(35Cl, 35Cl), 100%); (Found 662.1289, C29H2735Cl2N7NaO6, ([M+Na]+), requires 
662.1292). 
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3-(4-Chlorophenyl)-1-(3-(4-chlorophenyl)-5,5-dimethyl-2-oxo-1-(2-oxo-2-((E)-2-
((E)-3-phenylallylidene)hydrazinyl)ethyl)imidazolidin-4-yl)-1-hydroxyurea 
(ES328). (76) 
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By using the similar procedure described for 75, acyl hydrazide, 8 (150 mg, 0.312 
mmol) and cinnamaldehyde (83 mg, 0.628 mmol) provided the title compound as a 
pale yellow solid (86.3 mg, 47%). Mp 166 – 168 °C; (max (solid state)/cm$1 3555 
(brw, O-H), 3494 (brw, N-H), 3321 (w, N-H), 3233 (brw), 3057 (w, C-H), 2840 
(brw, C-H), 1704 (s, C=O), 1668 (s, C=O), 1650 (m, C=O), 1624 (w, C=C), 1593 
(w, C=C), 1522 (s, C=C), 1494 (s, C=C); 1H NMR (300 MHz, CDCl3) % 9.78 (1H, 
brs, NH or OH), 9.37 (1H, brs, NH or OH), 7.66 (2H, d, J 8.9 Hz, 2 & Ar-CH), 7.53 
(1H, t, J 4.2 Hz, NH), 7.36 (2H, d, J 8.9 Hz, 2 & Ar-CH), 7.31 – 7.19 (6H, m, 5 & 
Ar-CH & C(23)H), 7.09 – 7.02 (4H, m, 4 & Ar-CH), 6.73 (1H, dd, J 16.2 & 9.4 Hz, 
C(24)H), 6.12 (1H, s, C(4)H), 6.00 (1H, d, J 16.2 Hz, C(25)H), 4.76 (1H, d, J 18.5 
Hz, C(21)HaHb), 4.11 (1H, d, J 18.5, C(21)HaHb), 1.41 (3H, s, C(19)H3 or C(20)H3), 
1.32  (3H, s, C(19)H3 or C(20)H3); 13C NMR (75 MHz, d6-DMSO, two isomers, 
some signals are coincident) % 169.7 (C=O), 157.4 (Ar-C), 156.6 (Ar-C), 156.5 (Ar-
C), 155.9 (Ar-C), 155.9 (Ar-C), 155.8 (Ar-C), 155.8 (Ar-C), 149.2 (Ar-C), 149.1 
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(Ar-C), 146.0 (Ar-CH), 139.3 (Ar-CH), 139.2 (Ar-CH), 139.2 (Ar-CH), 138.8 (Ar-
CH), 138.3 (Ar-CH), 138.1 (Ar-C), 137.9 (Ar-CH), 135.9 (Ar-C), 135.9 (Ar-C), 
135.8 (Ar-C), 128.9 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.4 
(Ar-CH), 128.4 (Ar-CH), 127.7 (Ar-CH), 127.7 (Ar-CH), 127.2 (Ar-CH), 127.1 
(Ar-CH), 126.7 (Ar-CH), 127.1 (Ar-CH), 126.7 (Ar-C), 126.6 (Ar-C), 126.5 (Ar-C), 
126.4 (Ar-C), 125.4 (Ar-CH), 125.2 (Ar-CH), 125.2 (Ar-CH), 121.7 (Ar-CH), 121.5 
(Ar-CH), 120.3 (Ar-CH), 120.2 (Ar-CH), 120.2 (Ar-CH), 74.5 (C(4) major isomer), 
74.5 (C(4) minor isomer), 58.9 (C(5) minor isomer), 58.6 (C(5) major isomer), 40.6 
(C(21)), 26.8 (C(19) or C(20) major isomer), 26.3 (C(19) or C(20) minor isomer), 
19.4 (C(19) or C(20) major isomer), 19.0 (C(19) or C(20) minor isomer); m/z ($ve ion 
electrospray) 595 ([M$H]-, (37Cl, 37Cl), 15%), 595 ([M$H]-, (35Cl, 37Cl), 75%), 593 
([M$H]-, (35Cl, 35Cl), 100%), (+ve ion electrospray) 621 ([M+Na]+, (37Cl, 37Cl), 
45%),  619 ([M+Na]+, (35Cl, 37Cl), 45%), 617 ([M+Na]+, (35Cl, 35Cl,), 100%); 
(Found 595.1629, C29H2935Cl2N6O4, ([M+H]+), requires 595.1622). 
 
(E)-4-(5-Nitrofuran-2-yl)but-3-en-2-one. (74) 
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A solution of 5-nitrofuran-2-carbaldehyde (1.067 g, 7.56 mmol) in freshly distilled 
THF (1 mL) was added drop-wise under an atmosphere of nitrogen to a solution of 
(acetylmethylene)triphenylphosphorane (2.41 g, 7.57 mmol) in freshly distilled THF 
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(50 mL) at rt. The reaction mixture was allowed to stir at rt for 2 h and then 
concentrated under reduced pressure. Purification by flash column chromatography 
(SiO2; Et2O:PE, 3:1) yielded the title compound as orange crystals (1.048 g, 83%). 
Mp 115–116 °C, [lit103 114–115 °C]; (max (evaporated film)/cm$1 3147 (w, C-H), 
3124 (w, C-H), 3111 (w, C-H), 3054 (w, C-H), 3040 (w, C-H), 1689 (s, C=O), 1616 
(s, C=C), 1563 (m, C=C), 1523 (m, C=C), 1506 (w); 1H NMR (400 MHz, CDCl3) % 
7.30 (1H, d, J 3.8 Hz, C(7)H), 7.20 (1H, d, J 16.0 Hz, C(3)H), 6.83 (1H, d, J 16.0 
Hz, C(4)H), 6.79 (1H, d, J 3.8 Hz, C(6)H), 2.31 (3H, s, C(1)H3); 13C NMR (100 
MHz, CDCl3) % 196.9 (C(2)), 152.8 (C(5) and C(8)), 129.6 (C(4)), 126.9 (C(3)), 
116.3 (C(6)), 113.4 (C(7)), 28.8 (C(1)); m/z (+ve ion electrospray) 180 ([M$H]$, 
100%); (Found (by +EI) 181.0376, C8H7NO4, ([M]+), requires 181.0370). 
 
3-(4-Chlorophenyl)-1-(3-(4-chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-4-(5-
nitrofuran-2-yl)but-3-en-2-ylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-
yl)-1-hydroxyurea (ES40). (77) 
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Ketone 74 (41 mg, 0.229 mmol) was added to a solution of acyl hydrazide, 8 (100 
mg, 0.208 mmol) dissolved in MeOH under an atmosphere of nitrogen. The reaction 
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mixture was allowed to stir at rt for 18 h or until TLC showed completion. The 
resulting precipitate was filtered and washed with cold MeOH giving the title 
compound as a yellow solid (68 mg, 51%). Mp 178 – 180 °C; (max (evaporated 
film)/cm$1 3218 (brw, O-H), 3142 (brw, N-H), 2970 (w, C-H), 2873 (w, C-H), 2830 
(w, C-H), 1700 (s, C=O), 1684 (s, C=O), 1667 (s, C=O), 1664 (s, C=C), 1653 (s, 
C=C), 1589 (w, C=C), 1559 (w, C=C), 1522 (s, C=C), 1496 (s, C=C); 1H NMR 
(400 MHz, CDCl3) % 8.68 (1H, brs, NH or OH), 8.45 (1H, brs, NH or OH), 8.20 
(1H, brs, NH or OH), 7.66 (2H, d, J 9.0 Hz, Ar-CH), 7.53 (2H, d, J 9.0 Hz, Ar-CH), 
7.37 (1H, d, J 3.8 Hz, C(29)H), 7.25 (4H, m, partly obscured by CDCl3, 4 & Ar-
CH), 7.08 (1H, d, J 16.4 Hz, C(25)H), 6.72 (1H, d, J 16.4 Hz, C(26)H), 6.64 (1H, d, 
J 3.8 Hz, C(28)H), 6.19 (1H, s, C(4)H), 4.73 (1H, d, J 18.2 Hz, C(21)HaHb), 4.15 
(1H, d, J 18.2 Hz, C(21)HaHb), 1.96 (3H, s, C(24)H3), 1.43 (3H, s, C(19)H3 or 
C(20)H3), 1.32 (3H, s, C(19)H3 or C(20)H3); 13C NMR (75 MHz, d6-DMSO, two 
isomers, some signals are coincident) % 170.6 (C=O), 166.0 (C=O),  162.4 (C=O), 
156.7 (Ar-C), 156.5 (Ar-C), 152.6 (Ar-C), 151.3 (Ar-C), 151.2 (Ar-C), 148.1 (Ar-C), 
134.1 (Ar-C), 134.1 (Ar-C), 134.0 (Ar-C), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.3 
(Ar-CH),  126.5 (Ar-C), 126.4 (Ar-C), 126.3 (Ar-C), 121.5 (Ar-CH), 121.4 (Ar-CH), 
120.3 (Ar-CH), 120.2 (Ar-CH), 120.1 (Ar-CH), 119.0 (Ar-CH), 115.5 (Ar-CH), 
115.5 (Ar-CH), 115.3 (Ar-CH), 113.1 (Ar-CH), 113.1 (Ar-CH), 74.5 (C(4) minor 
isomer), 74.5 (C(4) major isomer), 58.6 (C(5) minor isomer), 58.6 (C(5) major 
isomer), 40.9 (C(21) major isomer), 40.8 (C(21) minor isomer), 26.9 (C(19) or C(20) 
major isomer), 26.2 (C(19) or C(20) minor isomer), 19.3 (C(19) or C(20) major 
isomer), 19.3 (C(19) or C(20) minor isomer), 11.5 (C(24)); m/z ($ve ion electrospray) 
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646 ([M$H]$, (37Cl, 37Cl), 25%), 644 ([M$H]$, (35Cl, 37Cl), 70 %), 642 ([M$H]$, 
(35Cl, 35Cl), 100%), (+ve ion electrospray) 670 ([M+Na]+, (37Cl, 37Cl), 20%), 668 
([M+Na]+, (35Cl, 37Cl), 70%), 666 ([M+Na]+, (35Cl, 35Cl), 100%); (Found 666.1251, 
C28H2735Cl2N7NaO7, ([M+Na]+), requires 666.1241). 
 
3-(4-Chlorophenyl)-1-(3-(4-chlorophenyl)-1-(2-((E)-2-((E)-3-(furan-2-
yl)allylidene)hydrazinyl)-2-oxoethyl)-5,5-dimethyl-2-oxoimidazolidin-4-yl)-1-
hydroxyurea (ES47). (78) 
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By using the similar procedure described for 75, acyl hydrazide, 8 (150 mg, 0.312 
mmol) and 2-furanacrolein (76 mg, 0.622 mmol) provided the title compound as a 
pale yellow solid (92.6 mg, 51%). Mp 203 – 204 °C; (max (solid state)/cm$1 3395 (w, 
O-H), 3222 (brw, N-H), 3145 (brw, N-H), 3132 (brw), 3039 (w, C-H), 2979 (w, C-
H) 2974 (w, C-H), 2930 (w, C-H), 1699 (m, C=O), 1680 (s, C=O), 1661 (s, C=O), 
1633 (m, C=C), 1588 (w, C=C), 1550 (s, C=C), 1512 (m, C=C), 1492 (w, C=C); 1H 
NMR (300 MHz, CDCl3) % 9.66 (1H, brs, NH or OH), 8.30 (1H, brs, NH or OH), 
7.77 (1H, brs, NH or OH), 7.65 – 7.43 (3H, m, 3 & Ar-CH), 7.41 – 7.14 (9H, m, 9 & 
Ar-CH), 6.61 (1H, dd, J 16.1 & 9.9 Hz, C(24)H), 6.35 (1H, dd, J 23.6 & 3 Hz, 
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C(28)H), 6.10 (1H, s, C(4)H), 5.79 (1H, d, J 16.1 Hz, C(25)H), 4.75 (1H, d, J 18.7 
Hz, C(21)HaHb), 4.09 (1H, d, J 18.7 Hz, C(21)HaHb), 1.40 (3H, s, C(19)H3 or 
C(20)H3)  1.31 (3H, s, C(19)H3 or C(20)H3); 13C NMR (100 MHz, d6-DMSO, two 
isomers, some signals are coincident) % 169.5 (C=O), 160.0 (C=O), 156.5 (Ar-C), 
155.7 (Ar-C), 155.6 (Ar-C), 153.1 (Ar-C), 151.8 (Ar-C), 151.7 (Ar-C), 148.4 (Ar-
C), 148.2 (Ar-C), 145.3 (Ar-CH), 145.3 (Ar-CH), 145.2 (Ar-CH), 144.4 (Ar-CH), 
144.3 (Ar-CH), 144.2 (Ar-CH), 138.3 (Ar-C), 138.1 (Ar-C), 128.4 (Ar-CH), 128.3 
(Ar-CH), 128.3 (Ar-CH), 128.3 (Ar-CH), 126.3 (Ar-C), 126.2 (Ar-C), 125.7 (Ar-
CH), 122.9 (Ar-CH), 121.3 (Ar-CH), 120.0 (Ar-CH), 119.9 (Ar-CH), 119.8 (Ar-
CH), 112.5 (Ar-CH), 111.6 (Ar-CH), 111.6 (Ar-CH), 74.4 (C(4) both isomers), 58.6 
(C(5) both isomers), 40.2 (C(21)), 26.8 (C(19) or C(20) major isomer), 26.2 (C(19) 
or C(20) minor isomer) 19.3 (C(19) or C(20) major isomer), 18.9 (C(19) or C(20) 
minor isomer); m/z ($ve ion electrospray) 587 ([M$H]-, (37Cl, 37Cl), 10%),  585 
([M$H]-, (35Cl, 37Cl), 65%), 583 ([M$H]-, (35Cl, 35Cl), 100%), (+ve ion 
electrospray) 611 ([M+Na]+, (37Cl, 37Cl), 10%) 609 ([M+Na]+, (35Cl, 37Cl), 60%), 
607 ([M+Na]+, (35Cl, 35Cl), 100%);  (Found 607.1244, C27H2635Cl2N6NaO5, 
([M+Na]+), requires 607.1234). 
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5.2.2 Unsymmetrical Eeyarestatins. 
 
Methyl 2-(3-(4-chlorophenyl)-4-(hydroxyamino)-5,5-dimethyl-2-
oxoimidazolidin-1-yl)acetate. (68) 
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A solution of 4-chlorophenyl isocyanate (768 mg, 5 mmol) in freshly distilled THF 
(6 mL) at 0 °C, was added drop-wise under an atmosphere of nitrogen, to a solution 
of oxime, 67 (870 mg, 5 mmol) also in freshly distilled THF (44 mL) at 0°C. The 
reaction mixture was stirred at rt for 17 h and then concentrated to afford a mixture 
of compounds 68 and 69 (5:1 ratio; 1HNMR). The crude product was purified by 
flash column chromatography (SiO2, PE:EtOAc 2:1) yielding title compound as 
colourless crystals (766 mg, 50%). Mp 147–149 °C; (max (evaporated film)/cm$1 
3366 (brm, O-H), 3248 (m, N-H), 2969 (brm, C-H), 1751 (m, C=O), 1685 (s, C=O), 
1490 (s, C=C); 1H NMR (500 MHz, CDCl3) 7.56 (2H, d, J 9.1 Hz, 2 & Ar-CH), 7.32 
(2H, d, J 9.1 Hz, 2 & Ar-CH), 5.51 (1H, brs, NH), 4.74 (1H, brs, OH). 4.65 (1H, s, 
C(4)H), 4.13 (1H, d, J 17.9 Hz, C(14)HaHb), 3.83 (1H, d, J 17.9 Hz, C(14)HaHb), 
3.76 (3H, s, CO2CH3), 1.42 (3H, s, C(12)H3 or C(13)H3), 1.33 (3H, s, C(12)H3 or 
C(13)H3); 13C NMR (100 MHz, CDCl3, some signals are coincident) 170.8 (C(15)), 
156.2 (C(2)), 136.9 (Ar-C), 129.5 (Ar-C), 129.0 (Ar-CH), 122.9 (Ar-CH), 80.6 
(C(4)), 58.6 (C(5)), 52.4 (CO2CH3), 40.6 (C(14)), 26.3 (C(12) or C(13)), 19.7 (C(12) 
or C(13)); m/z (+ve ion electrospray) 352.1 ([M+Na]+, (37Cl), 30%) 350.1 ([M+Na]+, 
(35Cl), 100%); (Found 350.0874, C14H1835ClN3NaO4 ([M+Na]+), requires 350.0878). 
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Methyl 2-(3-(4-chlorophenyl)-4-(1-hydroxy-3-phenethylureido)-5,5-dimethyl-2-
oxoimidazolidin-1-yl)acetate. (80) 
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1,1-Carbonyldiimidazole (495 mg, 3.05 mmol) was added under an atmosphere of 
nitrogen to a solution of phenethylamine (369 mg, 3.05 mmol) in freshly distilled 
THF (10 mL). The reaction mixture was stirred at 50 °C for 1.5 h then mono-adduct, 
68 (500 mg, 1.52 mmol) was added. The reaction mixture was stirred for a further 17 
h at 50 °C then allowed to cool to rt. Diethyl ether (10 mL) was added and the 
precipitated solid was collected by filtration, washed with diethyl ether (20 mL) and 
pentane (20 mL) and dried under vacuum to yield crude product as a colourless solid 
(526 mg). Purification by flash column chromatography (SiO2, PE:EtOAc, 2:1) 
yielded the title compound as a colourless solid (318 mg, 44%). Mp 182–183 °C; 
(max (evaporated film)/cm$1 3420 (w, O-H), 3330 (w, N-H), 3027 (w, C-H), 2951 (w, 
C-H), 2868 (w, C-H), 1757 (m, C=O), 1739 (m, C=O), 1705 (s, C=O), 1656 (m, 
C=C), 1597 (w, C=C), 1525 (s, C=C), 1496 (s, C=C); 1H NMR (300 MHz, CDCl3) % 
7.50 (2H, d, J 9.1 Hz, 2 & Ar-CH), 7.22 (1H, brt, NH or OH), 7.20–7.13 (5H, m, 5 & 
Ar-CH), 7.05 (2H, d, J 6.6 Hz, 2 & Ar-CH), 6.08 (1H, s, C(4)H), 6.03 (1H, t, J 6 Hz, 
NH), 4.24 (1H, d, J 18 Hz, C(23)HaHb), 3.75 (1H, d, J 18 Hz, C(23)HaHb), 3.73 (3H, 
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s, CO2CH3), 3.51–3.42 (2H, m, C(13)H2), 2.81–2.70 (2H, m, C(14)H2), 1.33 (3H, s, 
C(21)H3 or C(22)H3), 1.29 (3H, s, C(21)H3 or C(22)H3); 13C NMR (100 MHz, 
CDCl3) % 171.9 (C(24)), 158.8 (C(2) or C(12)), 156.7 (C(2) or C(12)), 138.8 (Ar-C), 
137.1 (Ar-C), 128.7 (5 & Ar-CH), 128.4 (2 & Ar-CH), 126.3 (Ar-C), 121.0 (2 & Ar-
CH), 75.3 (C(4)), 58.9 (C(5)), 52.7 (CO2CH3), 41.0 (C(13)), 40.4 (C(23)), 36.1 
(C(14)), 25.5 (C(21) or C(22)), 19.2 (C(21) or C(22)); m/z (-ve ion electrospray) 475 
([M$H]$, (37Cl), 30%), 473 ([M$H]$, (35Cl), 100%), (+ve ion electrospray) 499 
([M+Na]+, (37Cl), 20%), 497 ([M+Na]+, (35Cl), 100%); (Found 475.1743, 
C23H2835ClN4O5 ([M+H]+), requires 475.1740). 
 
1-(3-(4-Chlorophenyl)-1-(2-hydrazinyl-2-oxoethyl)-5,5-dimethyl-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-phenethylurea. (81) 
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An aqueous solution of hydrazine (62%, 0.88 mL, 23 mmol) was added to a solution 
of imidazolidinone, 80 (451 mg, 0.88 mmol) in MeOH (4.5 mL). The reaction mixture 
was stirred at rt for 48 h and then cooled to 0 °C. The precipitated solid was 
collected by filtration and washed with cold MeOH and diethyl ether. The filtrate 
was concentrated under reduced pressure and the residue recrystallised at rt from 
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DCM/diethyl ether (1:1). The resulting solid was collected by filtration, washed with 
cold MeOH and diethyl ether and dried under vacuum. Combination of both batches 
yielded the title compound as a colourless solid (248 mg, 55%). Mp 88–90 °C, (max 
(evaporated film)/cm$1 3321 (brm, O-H), 3078 (w, N-H), 3062 (w, N-H), 3030 (w, 
N-H), 2970 (w, C-H), 2925 (w, C-H), 2873 (w, C-H), 1699 (s, C=O), 1683 (s, 
C=O), 1667 (s, C=O), 1652 (s, C=C), 1524 (s, C=C), 1495 (s, C=C); 1H NMR (500 
MHz CD3OD) % 7.60 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.28 (2H, d, J 8.8 Hz, 2 & Ar-
CH), 7.21 (2H, d, J 6.9 Hz, 2 & Ar-CH), 7.14 (3H, brd, J 7.9 Hz, 3 & Ar-CH), 6.99 
(1H, brt, J 5.9 Hz, NHCH2CH2Ph), 6.00 (1H, s, C(4)H), 4.60 (1H, brs, NOH), 4.07 
(1H, d, J 17.3 Hz, C(23)HaHb), 3.85 (1H, d, J  17.3 Hz, C(23)HaHb), 3.38–3.29 (2H, 
m, C(13)H2), 2.68 (2H, t, J 7.3 Hz, C(14)H2), 1.29 (6H, 2 & s, C(21)H3 & C(22)H3); 
13C NMR (100 MHz, CD3OD) % 171.6 (C(24)), 161.6 (C(2) or C(12)), 158.5 (C(2) 
or C(12)), 140.6 (Ar-C), 138.8 (Ar-C), 130.3 (Ar-C), 130.0 (2 & Ar-CH), 129.9 (2 & 
Ar-CH), 129.6 (2 & Ar-CH), 127.5 (C(18)), 122.9 (2 & Ar-CH), 77.3 (C(4)), 61.1 
(C(5)), 42.6 (C(13)), 42.4 (C(23)), 37.3 (C(14)), 25.7 (C(21) or C(22)), 19.4 (C(21) 
or C(22)); m/z ($ve ion electrospray) 475 ([M$H]$, (37Cl), 25%), 473 ([M$H]$, 
(35Cl), 100%), (+ve ion electrospray) 499 ([M+Na]+, (35Cl), 30%), 497 ([M+Na]+, 
(35Cl), 100%); (Found 497.1684, C22H2735ClN6NaO4 ([M+Na]+), requires 497.1675). 
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1-(3-(4-Chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(5-nitrofuran-2-
yl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-hydroxy-3-
phenethylurea. (82) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (25 mg, 0.147 mmol) was added under nitrogen 
to a solution of acyl hydrazide, 81 (60 mg, 0.77 mmol) in anhydrous MeOH (0.6 
mL). The reaction mixture was stirred at rt for 17 h or until a yellow precipitate 
formed. Diethyl ether was added to allow further precipitation to occur. The solid 
was filtered and washed with Et2O and pentane yielding the title compound as a 
yellow solid (8 mg, 50%). Mp 131–133 °C (dec); (max (evaporated film)/cm$1 3421 
(brm, O-H), 3190 (brm, N-H), 3059 (m, N-H), 2975 (m, C-H), 2929 (m, C-H), 1684 
(s, C=O), 1597 (m, C=C), 1559 (m, C=C), 1520 (s, C=C); m/z ($ve ion electrospray) 
624 ([M$H]$, (37Cl), 25%), 622 ([M$H]$, (35Cl), 100 %), (+ve ion electrospray) 626 
([M+H]+, (37Cl), 30%), 624 ([M+H]+, (35Cl), 100%); (Found 624.1966, 
C29H3135ClN7O7 ([M+H]+), requires 624.1968). 
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5.2.3 Short form Eeyarestatins. 
 
2-Phenylacetohydrazide. (83) 
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An aqueous solution of hydrazine (62%, 3.23 mL, 67 mmol) was added to a solution 
of methyl phenylacetate (500 mg, 3.33 mmol) in MeOH (4 mL). The reaction 
mixture was stirred at rt for 48 h then solvent evaporated under reduced pressure. 
The product was crystallised from diethyl ether, collected by filtration and washed 
with cold MeOH and diethyl ether. The filtrate was concentrated under reduced 
pressure and the crystallisation procedure was repeated a further 3 times. 
Combination of the four batches of crystallised product gave title compound as a 
colourless crystalline solid (323 mg, 65%). Mp 115–117 °C [lit.104 116 °C]; (max 
(evaporated film)/cm$1 3293 (s, N-H), 3180 (m, N-H), 3031 (m, C-H), 1644 (s, C=O), 
1530 (m, C=C); 1H NMR (500 MHz, CDCl3) % 7.38–7.33 (2H, m, 2 & Ar-CH), 
7.33–7.28 (1H, m, Ar-CH), 7.28–7.24 (2H, m, 2 & Ar-CH), 6.77 (1H, brs, NH), 3.85 
(2H, brs, NH2), 3.58 (2H, s, C(2)H2); 13C NMR (400 MHz, CD3OD) % 173.3 (C(1)), 
136.8 (C(6)), 130.2 (2 & Ar-CH), 129.7 (2 & Ar-CH), 128.1 (C(3)), 41.9 (C(2)); m/z 
($ve ion electrospray) 149.2 ([M$H]$, 100%), (+ve ion electrospray) 173.1 
([M+Na]+, 100%); (Found 173.0694, C8H10N2NaO ([M+Na]+), requires 173.0685). 
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2-{2-[3-(5-Nitro-2-furyl)-2-propen-1-ylidene]hydrazino}-2-oxoethylbenzene. (17) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (128 mg, 0.77 mmol) was added under nitrogen 
to a solution of acyl hydrazide, 83 (173 mg, 1.15 mmol) in anhydrous MeOH (4 
mL). The reaction mixture was stirred at rt for 17 h until a yellow precipitate formed. 
The solid was filtered and washed with pentane (3 & 5 mL) yielding the title 
compound (152 mg, 66%) as a yellow solid. Mp 202–204 °C; (max (evaporated 
film)/cm$1 3137 (w, N-H), 3040 (w, C-H), 2971 (brw, C-H), 2857 (brw, C-H), 1747 
(w, C=O), 1667 (s, C=C), 1587 (m, C=C), 1557 (m, C=C), 1504 (s, C=C); 1H NMR 
(300 MHz, CDCl3) % 9.04 (1H, brs, NH), 7.53 (1H, d, J 9.5 Hz, C(3)H), 7.37 – 7.34 
(6H, m, C(8)H and 5 & ArCH), 7.16 (1H, dd, J 15.5 & 9.5 Hz, C(4)H), 6.65  (1H, d, 
J 15.5 Hz C(5)H), 6.64 (1H, brs, C(7)H), 4.03 (2H, s, C(1)H2); 13C NMR (100 
MHz, d6-DMSO, two isomers, some signals are coincident) % 172.4 (C=O major 
isomer), 166.8 (C=O minor isomer), 154.9 (Ar-C), 151.3 (Ar-C), 146.7 (Ar-CH), 
143.5 (Ar-CH), 135.4 (Ar-C), 130.6 (Ar-CH), 130.3 (Ar-CH), 129.5 (Ar-CH), 129.1 
(Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-CH), 126.6 (Ar-CH), 126.4 (Ar-CH), 123.7 
(Ar-CH), 123.1 (Ar-CH), 115.4 (C(7) minor isomer), 115.4 (C(7) minor isomer), 
113.4 (C(8) major isomer), 113.4 (C(8) minor isomer), 41.2 (C(1) minor isomer), 38.5 
(C(1) major isomer);  m/z ($ve ion electrospray) 298 ([M$H]$, 100%), (+ve ion 
electrospray) 322 ([M+Na]+, 100%); (Found 322.0798, C15H13N3NaO4 ([M+Na]+), 
requires 322.0809). 
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(10E)-N’-((E)-3-(4-Nitrophenyl)allylidene)-2-phenylacetohydrazide. (84) 
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p-Nitrocinnamaldehyde (39 mg, 0.2 mmol) was added under nitrogen to a solution of 
2-phenylacetohydrazide (30 mg, 0.2 mmol) in anhydrous MeOH (1 mL). The 
reaction mixture was stirred at rt overnight and then Et2O (5 mL) was added to allow 
further precipitation to occur. The solid was filtered and washed with Et2O (10 mL) 
and pentane (10 mL) yielding the title compound (55 mg, 89%) as a yellow solid. 
Mp 231–233 °C; (max (evaporated film)/cm$1 3061 (brw, N-H), 2947 (m, C-H), 2879 
(w, C-H), 2837 (w, C-H), 1661 (s, C=O), 1593 (m, C=C), 1575 (m, C=C), 1516 (s, 
C=C); 1H NMR (400 MHz, d6-DMSO, two isomers) % 11.65 (s, NH minor isomer), 
11.46 (s, NH major isomer), 8.33 – 8.26 (m, Ar-CH), 8.21 (d, J 8.7 Hz, Ar-CH), 8.02 
(d, J 8.7 Hz, Ar-CH), 7.90 – 7.85 (m, Ar-CH), 7.32 – 7.12 (Ar-CH), 3.91 (s, C(1)H2 
major isomer), 3.54 (s, C(1)H2 minor isomer); 13C NMR (100 MHz, d6-DMSO, two 
isomers some signals are coincident) % 172.2 (C=O major isomer), 166.7 (C=O minor 
isomer), 147.6 (Ar-CH), 146.7 (Ar-CH), 146.7 (Ar-CH), 144.6 (Ar-CH), 144.2 (Ar-
CH), 142.5 (Ar-CH), 142.8 (Ar-C), 136.3 (Ar-C), 136.2 (Ar-C), 135.7 (Ar-C), 135.4 
(Ar-C), 135.4 (Ar-C), 130.0 (Ar-CH), 129.7 (Ar-CH), 129.4 (Ar-CH), 129.1 (Ar-
CH), 129.0 (Ar-CH), 128.3 (Ar-CH), 128.3 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-
CH), 127.9 (Ar-CH), 127.9 (Ar-CH), 126.6 (Ar-CH), 126.5 (Ar-CH), 126.4 (Ar-
CH), 126.3 (Ar-CH), 124.0 (Ar-CH), 124.0 (Ar-CH), 123.9 (Ar-CH), 41.0 (C(1) 
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minor isomer), 38.4 (C(1) major isomer);  m/z ($ve ion electrospray) 308 ([M$H]$, 
100%), (+ve ion electrospray) 332 ([M+Na]+, 100%); (Found 332.1022, 
C17H15NaN3O3, ([M+Na]+), requires 332.1006). 
 
(10E)-N’-((E)-3-(2-Nitrophenyl)allylidene)-2-phenylacetohydrazide. (85) 
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2-Nitrocinnamaldehyde (118 mg, 0.73 mmol) was added under nitrogen to a solution 
of 2-phenylacetohydrazide (100 mg, 0.67 mmol) in anhydrous MeOH (1 mL). The 
reaction mixture was stirred at rt overnight and then Et2O (5 mL) was added to allow 
further precipitation to occur. The solid was filtered and washed with Et2O (10 mL) 
and pentane (10 mL) yielding the title compound (215 mg, 89%) as a yellow solid. 
Mp 218–220 °C; (max (evaporated film)/cm$1 3332 (brw, N-H), 2967 (w, C-H), 1659 
(s, C=O), 1615 (m, C=C), 1569 (w, C=C), 1553 (m, C=C), 1518 (m, C=C); 1H NMR 
(400 MHz, d6-DMSO, two isomers) % 11.63 (s, NH minor isomer), 11.43 (s, NH 
major isomer), 8.04 – 7.94 (m, Ar-CH), 7.86 (d, J 9.3 Hz, Ar-CH), 7.71 (t, J 7.6 Hz, 
Ar-CH), 7.59 – 7.53 (m, Ar-CH), 7.33 – 7.22 (m, Ar-CH), 7.09 – 7.01 (m, C(4)H 
major isomer & C(4)H minor isomer), 3.91 (s, C(1)H2 major isomer), 3.55 (s, C(1)H2 
minor isomer); 13C NMR (100 MHz, d6-DMSO, two isomers, some signals are 
coincident) % 171.2 (C=O major isomer), 166.7 (C=O minor isomer), 147.8 (Ar-CH), 
147.7 (Ar-CH), 147.7 (Ar-CH), 144.6 (Ar-CH), 140.9 (Ar-C), 135.6 (Ar-C), 135.5 
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(Ar-C), 135.5 (Ar-C), 134.6 (Ar-CH), 133.7 (Ar-CH), 133.5 (Ar-CH), 133.5 (Ar-
CH), 132.5 (Ar-CH), 132.0 (Ar-CH), 130.4 (Ar-CH), 130.1 (Ar-CH), 129.9 (Ar-
CH), 129.5 (Ar-CH), 129.4 (Ar-CH), 129.2 (Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-
CH), 126.6 (Ar-CH), 126.4 (Ar-CH), 124.5 (Ar-CH), 41.1 (C(1) minor isomer), 38.5 
(C(1) major isomer); m/z ($ve ion electrospray) 308.1 ([M$H]$, 100%), (+ve ion 
electrospray) 332.1 ([M+Na]+, 100%); (Found 310.1187, C17H16N3O3, ([M+H]+), 
requires 310.1186). 
 
(9E)-N’-((E)-3-(5-Nitrofuran-2-yl)allylidene)benzohydrazide. (86) 
 
1
2
3
4
5
6
7
N
H
8O
N
O
NO2
 
 
(E)-3-(5-nitro-2-furyl)acrylaldehyde (123 mg, 0.74 mmol) was added under nitrogen 
to a solution of benzhydrazide (100 mg, 0.74 mmol) in anhydrous MeOH (1 mL). 
The reaction mixture was stirred at rt overnight and then Et2O (5 mL) was added to 
allow further precipitation to occur. The solid was filtered and washed with Et2O (10 
mL) and pentane (10 mL) yielding the title compound (112 mg, 53%) as a yellow 
solid. Mp 226–227 °C; (max (evaporated film)/cm$1 3339 (brw, N-H), 2965 (w, C-H), 
1652 (s, C=O), 1631 (m, C=C), 1597 (w, C=C), 1574 (w, C=C), 1548 (w, C=C), 
1532 (m, C=C), 1509 (w, C=C); 1H NMR (400 MHz, d6-DMSO) % 11.98 (1H, s, 
NH), 8.26 (1H, d, J 8.1 Hz, C(2)H), 7.90 (2H, d, J 7.3 Hz, 2 & Ar-CH), 7.76 (1H, d, J 
3.9 Hz, C(7)H), 7.62 – 7.51 (3H, m, 3 & Ar-CH), 7.17 (1H, d, J 3.9 Hz, C(6)H), 7.14 
– 7.07 (2H, m, C(3)H & C(4)H); 13C NMR (100 MHz, d6-DMSO, some signals are 
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coincident) % 163.2 (C(1)), 154.9 (C(8)), 151.4 (C(5)), 147.9 (C(2)), 133.1 (Ar-C), 
132.0 (Ar-CH), 130.7 (C(3)), 128.5 (Ar-CH), 127.7 (Ar-CH), 123.9 (C(4)), 115.4 
(C(7)), 113.5 (C(6)); m/z ($ve ion electrospray) 284 (100%, [M$H]$), (+ve ion 
electrospray) 286 ([M+H]+, 70%), 308 ([M+Na]+, 100%); (Found 286.0834, 
C14H12N3O4, ([M+H]+), requires 286.0822). 
 
5.2.4 Click Eeyarestatins 
 
Methyl 2-(3-(4-chlorophenyl)-4-(1-hydroxy-3-(prop-2-ynyl)ureido)-5,5-
dimethyl-2-oxoimidazolidin-1-yl)acetate. (87) 
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1,1-Carbonyldiimidazole (495 mg, 3.05 mmol) was added under an atmosphere of 
nitrogen to a solution of propargylamine (168 mg, 3.05 mmol) in freshly distilled 
THF (10 mL). The reaction mixture was stirred at 50 °C for 1.5 h then the mono-
adduct, 68 (500 mg, 1.53 mmol) was added. The reaction mixture was stirred for a 
further 17 h at 50 °C then allowed to cool to rt. Diethyl ether (10 mL) was added and 
precipitated solid was collected by filtration, washed with diethyl ether (20 mL) and 
pentane (20 mL) and then dried to give the crude product as a cream solid (619 mg). 
Purification by flash column chromatography (SiO2, PE:EtOAc, 2:1) yielded the title 
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compound as a colourless solid (434 mg, 69%). Mp 177–179 °C; (max (evaporated 
film)/cm$1 3291 (brm, O-H), 3238 (m, N-H), 2962 (m, C-H), 2933 (m, C-H), 2857 
(m, C-H), 1738 (s, C=O), 1703 (s, C=O), 1644 (s, C=C), 1524 (s, C=C), 1495 (s, 
C=C); 1H NMR (300 MHz, CDCl3) % 7.59 (2H, d, J 7.0 Hz, 2 & Ar-CH), 7.50 (1H, 
brs, NH or OH), 7.24 (2H, d, J 7.0 Hz, 2 & Ar-CH), 6.31 (1H, t, J 5.7 Hz, NH), 6.05 
(1H, s, C(4)H), 4.39 (1H, d, J 18.1 Hz, C(18)HaHb), 3.99 (2H, dd, J 5.7 & 2.5 Hz, 
C(13)H), 3.67 (3H, s, CO2CH3), 3.60 (1H, d, J 18.1 Hz, C(18)HaHb), 2.20 (1H, t, J 
2.5 Hz, C(15)H), 1.32 (3H, s, C(17)H3 or C(18)H3), 1.27 (3H, s, C(17)H3 or 
C(18)H3); 13C NMR (75 MHz, CDCl3, some signals are coincident) % 172.4 (C(19)) 
158.3 (C(2) or C(12)), 156.7 (C(2) or C(12)) 136.9 (Ar-C) 128.8 (Ar-C) 128.7 (Ar-
CH), 121.4 (Ar-CH), 80.2 (C(14)), 75.2 (C(4)), 70.7 (C(15)), 58.9 (C(5)), 52.9 
(CO2CH3), 40.2 (C(18)), 29.5 (C(13)), 25.4 (C(16) or C(17)), 19.2 (C(16) or C(17)), 
m/z ($ve ion electrospray) 409 ([M$H]$, (37Cl), 35%), 407 ([M$H]$, (35Cl), 100%), 
(+ve ion electrospray) 433 ([M+Na]+, (37Cl), 25%)431 ([M+Na]+, (35Cl), 100%); 
(Found 431.1106, C18H2135ClN4NaO5 ([M+Na]+), requires 431.1093). 
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1-(3-(4-Chlorophenyl)-1-(2-hydrazinyl-2-oxoethyl)-5,5-dimethyl-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-(prop-2-ynyl)urea. (89) 
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Hydrazine solution 62% in water (0.6 mL, 619 mg, 12.37 mmol) was added to a 
solution of methyl ester, 87 (200 mg, 0.489 mmol) in anhydrous MeOH (2 mL). The 
reaction mixture was stirred at rt for 2.5 h. Then EtOAc (20 mL) and water (10 mL) 
were added and two phases were separated. The product was extracted further from 
aqueous layer using EtOAc (2 x 20 mL). The combined organic layers were washed 
with water several times and dried over Na2SO4 then filtered and concentrated under 
reduced pressure. This yielded the title product (196 mg, 98%) as a white solid. Mp 
100–102 °C; (max (evaporated film)/cm$1 3297 (brm, O-H), 2971 (w, C-H), 2933 (w, 
C-H), 2876 (brw, C-H), 1668 (s, C=O), 1495 (s, C=C); 1H NMR (500 MHz, CD3OD) 
% 7.64 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.32 (2H, d, J 8.8 Hz, 2 & Ar-CH), 6.01 (1H, s, 
C(4)H), 4.05 (1H, d, J 17.4 Hz, C(18)HaHb), 3.93–3.92 (2H, m, C(13)H2), 3.80 (1H, 
d, J 17.4 Hz, C(18)HaHb), 2.50 (1H, brs, C(15)H), 1.36 (3H, s, C(16)H3 or C(17)H3), 
1.32 (3H, s, C(16)H or C(17)H); 13C NMR (75 MHz, CD3OD) % 171.5 (C(19)), 
161.3 (C(2) or C(12)), 158.5 (C(2) or C(12)), 138.8 (Ar-C), 130.2 (Ar-C), 129.9 (Ar-
CH), 125.4 (Ar-C), 122.6 (Ar-CH), 86.5 (C(14)), 77.4 (C(4)), 71.9 (C(15)), 61.1 
(C(5)), 42.4 (C(18)), 30.4 (C(13)), 25.7 (C(16) or C(17)), 19.3 (C(16) or C(17)); m/z 
($ve ion electrospray) 409 ([M$H]$, (37Cl), 50%) 407 ([M$H]$, (35Cl), 100%), (+ve 
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ion electrospray) 433 ([M+Na]+, (37Cl), 40%) 431 ([M+Na]+, (35Cl), 100%); (Found 
431.1195, C17H2135ClN6NaO4 ([M+Na]+), requires 431.1205). 
 
1-(3-(4-Chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(5-nitrofuran-2-
yl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-hydroxy-3-
(prop-2-ynyl)urea. (91) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (25 mg, 0.147 mmol) was added under nitrogen 
to a solution of acyl hydrazide, 89 (60 mg, 0.77 mmol) in anhydrous MeOH (0.6 
mL). The reaction mixture was stirred at rt overnight until a yellow precipitate forms. 
Ether (5 mL) was added to allow further precipitation to occur. The solid was filtered 
and washed with Et2O and pentane yielding the title compound (33.5 mg, 49%) as a 
yellow solid. Mp 159–161 °C; (max (evaporated film)/cm$1 3293 (brm, O-H), 3148 
(brm, N-H), 2971 (m, C-H), 2908 (m, C-H), 2848 (m, C-H), 1673 (s, C=O), 1663 (s, 
C=O), 1516 (m, C=C), 1493 (s, C=C); 1H NMR (500 MHz, CDCl3) % 9.90 (1H, brs, 
NH or OH), 8.92 (1H, brs, NH or OH), 7.60 (2H, d, J 8.9 Hz, 2 & Ar-CH), 7.37 (2H, 
d, J 8.9 Hz, 2 & Ar-CH), 7.33 (1H, d, J 3.6 Hz, C(25)H), 7.26 (1H, m, obscured by 
chloroform peak at 7.27, C(20)H), 6.92 (1H, dd, J 15.9 and 9.8 Hz, C(21)H), 6.52 
(1H, d, J 3.6 Hz, C(24)H), 6.01 (1H, s, C(4)H), 5.84 (1H, t, J 5.7 Hz, NH), 5.53 (1H, 
brd, J 15.9 Hz, C(22)H), 4.71 (1H, d, J 18.5 Hz, C(18)HaHb), 4.07 (1H, d, J 18.5 Hz, 
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C(18)HaHb), 3.91 (2H, m,  C(13)H), 2.09 (1H, brs, C(15)H), 1.38 (3H, s, C(16)H3 or 
C(17)H3), 1.25 (3H, s, C(16)H3 or C(17)H3); 13C NMR (100 MHz, d6-DMSO, two 
isomers, some signals are coincident) % 169.8 (C=O), 165.4 (C=O), 159.0 (C=O), 
158.9 (Ar-C), 157.0 (Ar-C), 155.6 (Ar-C), 154.8 (Ar-C), 154.7 (Ar-C), 154.6 (Ar-C), 
151.4 (Ar-C), 151.3 (Ar-C), 147.2 (Ar-CH), 143.7 (Ar-CH), 138.2 (Ar-C), 138.0 
(Ar-C), 130.2 (Ar-CH), 130.1 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 128.3 (Ar-
CH), 126.5 (Ar-C), 126.1 (Ar-C), 124.2 (Ar-CH), 124.0 (Ar-CH), 123.2 (Ar-CH), 
120.1 (Ar-CH), 120.0 (Ar-CH), 115.4 (C(24) major isomer), 115.4 (C(24) minor 
isomer), 113.6 (C(25) minor isomer), 113.4 (C(25) major isomer), 82.3 (C(14) major 
isomer), 81.9 (C(14) minor isomer), 74.9 (C(4) major isomer), 74.8 (C(4) minor 
isomer), 72.5 (C(15) major isomer), 72.2 (C(15) minor isomer), 58.8 (C(5) minor 
isomer), 58.6 (C(5) major isomer), 41.5 (C(18) minor isomer), 40.2 (C(18) major 
isomer), 28.9 (C(13) minor isomer), 28.8 (C(13) major isomer), 26.9 (C(16) or 
(C(17) major isomer), 26.2 (C(16) or (C(17) minor isomer), 19.2 (C(16) or (C(17) 
major isomer), 18.7 (C(16) or (C(17) minor isomer); m/z (-ve ion electrospray) 558 ( 
[M$H]$, (37Cl), 65%,), 556 ( [M$H]$, (35Cl), 100%,), (+ve ion electrospray) 582 
([M+Na]+, (37Cl), 30%), 580 ([M+Na]+, (35Cl), 100%); (Found 580.1326, 
C24H2435ClNaN7O7, [M+Na]+, requires 580.1318).  
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1-(3-(4-Chlorophenyl)-1-(2-((E)-2-((E)-3-(furan-2-yl)allylidene)hydrazinyl)-2-
oxoethyl)-5,5-dimethyl-2-oxoimidazolidin-4-yl)-1-hydroxy-3-(prop-2-yn-1-
yl)urea. (92) 
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By using the similar procedure described for 91, acyl hydrazide 89 (134 mg, 0.312 
mmol) and 2-furanacrolein (80 mg, 0.622 mmol) provided the title compound as a 
pale yellow solid (82.7 mg, 49%). Mp 177.4 °C (dec); (max (solid state)/cm$1 3415 
(w, O-H), 3270 (w, N-H), 3132 (brw, N-H), 3125 (brw, C-H), 3079 (brw, C-H), 
2928 (w, C-H), 2882 (w, C-H), 1698 (m, C=O), 1662 (s, C=O), 1645 (w, C=O), 
1605 (w, C=C), 1526 (m, C=C), 1496 (s, C=C); 1H NMR (400 MHz, CDCl3) % 9.54 
(1H, brs, NH or OH), 8.98 (1H, brs, NH or OH), 7.58 (2H, d, J 9.0 Hz, 2 & Ar-CH), 
7.44 (1H, d, J 1.7 Hz, C(26)H), 7.33 (2H, d, J 9.0 Hz, 2 & Ar-CH), 7.29 (1H, m, 
partly obscured by chloroform peak, C(20)H), 6.61 (1H, dd, J 15.8 & 9.6 Hz, 
C(21)H), 6.45 (1H, dd, J 3.3 & 1.7 Hz, C(25)H), 6.42 (1H, d, J 3.3 Hz, C(24)H), 
6.00 (1H, s, C(4)H), 5.93 (1H, brt, J 5.6 Hz, NHCH2CCH), 5.87 (1H, d, J 15.8 Hz, 
C(22)H), 4.74 (1H, d, J 18.4, C(18)HaHb), 4.06 (1H, d, J 18.4, C(18)HaHb), 3.99 
(2H, dd, J 5.6 & 2.5 Hz, C(13)H), 2.09 (1H, t, J 2.5 Hz, C(15)H), 1.36 (3H, s, 
C(16)H3 or C(17)H3), 1.26 (3H, s, C(16)H3 or C(17)H3); 13C NMR (100 MHz, d6-
DMSO, two isomers, some signals are coincident) % 169.5 (C=O), 165.0 (C=O), 
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164.5 (C=O), 159.0 (Ar-C), 158.9 (Ar-C), 157.1 (Ar-C), 157.1 (Ar-C), 157.0 (Ar-C), 
155.7 (Ar-C), 155.7 (Ar-C), 151.8 (Ar-C), 151.7 (Ar-C), 157.7 (Ar-C), 157.6 (Ar-
C), 148.6 (Ar-CH), 145.2 (Ar-CH), 145.2 (Ar-CH), 144.5 (Ar-CH), 144.4 (Ar-CH), 
144.3 (Ar-CH), 138.3 (Ar-C), 138.1 (Ar-C), 128.4 (Ar-CH), 128.3 (Ar-CH), 126.5 
(Ar-CH), 126.5 (Ar-CH), 126.1 (Ar-CH), 125.7 (Ar-CH), 122.9 (Ar-CH), 122.9 
(Ar-CH), 122.8 (Ar-CH), 120.1 (Ar-CH), 119.9 (Ar-CH), 112.6 (C(24) minor 
isomer), 112.5 (C(24) major isomer), 112.0 (C(25) major isomer), 111.7 (C(25) minor 
isomer), 82.4 (C(14) major isomer), 82.0 (C(14) minor isomer), 74.9 (C(4) major 
isomer), 74.8 (C(4) minor isomer), 72.7 (C(15) major isomer), 72.3 (C(15) minor 
isomer), 58.9 (C(5) minor isomer), 58.6 (C(5) major isomer), 41.6 (C(18) minor 
isomer), 40.2 (C(18) major isomer), 28.9 (C(13) minor isomer), 28.9 (C(13) major 
isomer), 27.0 (C(16) or C(17) major isomer), 26.1 (C(16) or C(17) minor isomer), 
19.3 (C(16) or C(17) major isomer), 18.6 (C(16) or C(17) minor isomer); m/z ($ve ion 
electrospray) 513 ([M$H]$, (37Cl), 100%), 511 ([M$H]$, (35Cl), 100%); (Found 
511.1505, C24H2435ClN6O5, ([M$H]$), requires 511.1497). 
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Methyl 2-(3-(4-chlorophenyl-4-(3-(4-ethynylphenyl)-1-hydroxyureido)-5,5-
dimethyl-2-oxoimidazolidin-1-yl)acetate. (88) 
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1,1-Carbonyldiimidazole (495 mg, 3.05 mmol) was added under nitrogen to a 
solution of 4-ethynylaniline (358 mg, 3.05 mmol) in freshly distilled THF (6 mL). 
The reaction mixture was stirred at 50 °C for 1.5 h then 68 (500 mg, 1.53 mmol) was 
added. The reaction mixture was stirred for 17 h at 50 °C then cooled down to rt. The 
solvent was then removed under reduced pressure to give a crude yellow solid. The 
product was purified by flash column chromatography 2:1 PE:EtOAc yielding title 
compound as a white solid (321 mg, 45%). Mp 179–181 °C; (max (evaporated 
film)/cm$1 3295 (brm, O-H), 2977 (w, C-H), 2965 (w, C-H), 2868 (w, C-H), 1737 
(m, C=O), 1695 (s, C=O), 1674 (s, C=O), 1582 (m, C=C), 1520 (s, C=C), 1497 (s, 
C=C); 1H NMR (400 MHz, CDCl3) % 8.35 (1H, brs, NH or OH), 8.01 (1H, brs, NH 
or OH), 7.69 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.63 (2H, d, J 8.6 Hz, 2 & Ar-CH), 7.45 
(2H, d, J 8.6 Hz, 2 & Ar-CH), 7.24 (2H, d, J 8.8 Hz, 2 & Ar-CH), 6.20 (1H, s, 
C(4)H), 4.37 (1H, d, J 18.2 Hz, C(23)HaHb), 3.56 (1H, d, J 18.2 Hz, C(23)HaHb), 
3.48 (3H, s, CO2CH3), 3.04 (1H, s, C(20)H), 1.35 (C(21)H3 or C(22)H3), 1.27 
(C(21)H3 or C(22)H3);  13C NMR (100 MHz, CDCl3) % 171.2 (C(24), 156.8 (C(2) or 
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C(12)), 155.7 (C(2) or C(12)), 139.3 (2 & Ar-C), 136.8 (2 & Ar-C), 132.9 (2 & Ar-
CH), 128.7 (2 & Ar-CH), 121.0 (2 & Ar-CH), 118.5 (2 & Ar-CH), 83.7 (C(19)), 76.4 
(C(20)), 74.5 (C(4)), 59.1 (C(5)), 52.9 (CO2CH3), 40.2 (C(23)), 25.3 (C(21) or 
C(22)),  19.2 (C(21) or C(22))  m/z ($ve ion electrospray) 471 ([M$H]$, (37Cl), 
25%), 469 ([M$H]$, (35Cl), 100%), (+ve ion electrospray) 495 ([M+Na]+, (37Cl), 
40%), 493 ([M+Na]+, (35Cl), 100%); (Found 493.1260, C23H2335ClNaN4O5, 
([M+Na]+), requires 493.1249). 
 
1-(3-(4-Chlorophenyl)-1-(2-hydrazinyl-2-oxoethyl)-5,5-dimethyl-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-(4-ethynylphenyl)urea. (90) 
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Hydrazine solution 62% in water (0.278 mL, 287 mg, 5.74 mmol) was added to a 
solution of methyl ester, 88 (90 mg, 0.191 mmol) in anhydrous MeOH (1 mL). The 
reaction mixture was stirred at rt for 1.5 h. Then EtOAc (10 mL) and water (10 mL) 
were added and two phases were separated. The product was extracted further from 
aqueous layer using EtOAc (2 x 10 mL). The combined organic layers were washed 
with water several times and dried over MgSO4 then filtered and concentrated under 
reduced pressure. This yielded the title product (85 mg, 94%) as a white solid. Mp 
 176 
188–190 °C; (max (evaporated film)/cm$1 3288 (brw, O-H), 3218 (w, N-H), 3154 (w, 
N-H), 2110 (w, C,C), 1699 (m, C=O), 1683 (s, C=O), 1672 (s, C=O), 1583 (w, 
C=C), 1519 (s, C=C), 1495 (s, C=C); 1H NMR (400 MHz, CD3OD) % 7.70 (2H, d, J 
8.8 Hz, 2 & Ar-CH), 7.50 (2H, d, J 8.8 Hz, 2 & Ar-CH), 7.40 (2H, d, J 8.8 Hz, 2 & 
Ar-CH), 7.33 (2H, d, J 8.8 Hz, 2 & Ar-CH), 6.14 (1H, s, C(4)H), 4.09 (1H, d, J 17.1 
Hz, C(23)HaHb), 3.82 (1H, d, J 17.1 Hz, C(23)HaHb), 2.42 (1H, s, C(20)H),  1.41 
(3H, s, C(21)H3 or C(22)H3), 1.35 (3H, s, C(21)H3 or C(22)H3); 13C NMR (100 
MHz, CD3OD) % 171.5 (C(24)), 158.7 (C(2) or C(12)), 158.4 (C(2) or C(12)), 141.2 
(Ar-C), 140.2 (Ar-C), 138.8 (Ar-C), 133.9 (Ar-C), 133.7 (2 & Ar-CH), 129.9 (2 & 
Ar-CH), 122.5 (2 & Ar-CH), 121.4 (2 & Ar-CH), 84.4 (C(19)), 78.1 (C(20)), 77.0 
(C(4)), 61.1 (C(5)), 42.4 (C(23)), 25.7 (C(21) or C(22)), 19.4 (C(21) or C(22)); m/z 
($ve ion electrospray) 471 ([M$H]$, (37Cl) 30%), 469 ([M$H]$, (35Cl), 100%); 
(Found 493.1371, C22H2335ClN6NaO4, ([M+Na]+), requires 493.1362). 
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1-(3-(4-Chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(5-nitrofuran-2-
yl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-3-(4-
ethynylphenyl)-1-hydroxyurea. (93) 
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(E)-3-(5-nitro-2-furyl)acrylaldehyde (33 mg, 0.198 mmol) was added under nitrogen 
to a solution of acyl hydrazide, 90 (85 mg, 0.198 mmol) in anhydrous MeOH (1 
mL). The reaction mixture was stirred at rt for 17 h until a yellow precipitate formed. 
The solid was filtered and washed with pentane (3 & 5 mL) yielding the title 
compound as a yellow solid (56.5 mg, 50%). Mp 275 °C (dec); (max (evaporated 
film)/cm$1 3292 (brm, O-H), 3281 (m, N-H), 3245 (m, N-H), 2919 (w, C-H), 1674 
(s, C=O), 1581 (m, C=C), 1556 (w, C=C), 1520 (s, C=C), 1497 (s, C=C); 1H NMR 
(400 MHz, CDCl3) % 9.93 (1H, brs, NH or OH), 9.46 (1H, brs, NH or OH), 7.73 
(1H, brs, NH or OH), 7.69 (2H, d, J 9.1 Hz, 2 & Ar-CH), 7.38 (2H, d, J 9.1 Hz, 2 & 
Ar-CH), 7.30 (4H, m, 4 & Ar-CH), 7.25 (1H, m, obscured by chloroform peak at 
7.27, C(25)H), 7.16 (1H, d, J 3.8 Hz, C(30)H), 6.94 (1H, dd, J 15.8 & 9.6 Hz, 
C(26)H), 6.32 (1H, d, J 3.8 Hz, C(29)H), 6.13 (1H, s, C(4)H), 5.47 (1H, d, J 15.8 
Hz, C(27)H), 4.77 (1H, d, J 18.5 Hz, C(23)HaHb), 4.11 (1H, d, J 18.5 Hz, 
C(23)HaHb), 3.04 (1H, s, C(20)H), 1.43 (3H, s, C(21)H3 or C(22)H3), 1.30 (3H, s, 
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C(21)H3 or C(22)H3); 13C NMR (100 MHz, d6-DMSO, two isomers, some signals 
are coincident) % 169.9 (C=O), 165.4 (C=O), 156.4 (Ar-C), 156.3 (Ar-C), 155.8 (Ar-
C), 155.7 (Ar-C), 154.9 (Ar-C), 154.8 (Ar-C), 151.4 (Ar-C), 151.4 (Ar-C), 147.1 
(Ar-CH), 143.9 (Ar-CH), 139.8 (Ar-C), 139.6 (Ar-C), 138.3 (Ar-C), 138.1 (Ar-C), 
132.1 (Ar-CH), 130.4 (Ar-CH), 130.2 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 
127.7 (Ar-C), 126.6 (Ar-C), 126.3 (Ar-C), 124.1 (Ar-CH), 123.3 (Ar-CH), 120.2 
(Ar-CH), 120.0 (Ar-CH), 119.7 (Ar-CH), 119.5 (Ar-CH), 115.6 (C(29) minor 
isomer), 115.5 (C(29) major isomer), 113.6 (C(30) minor isomer), 113.6 (C(30) 
major isomer), 83.8 (C(19) , 79.7 (C(20) minor isomer), 79.7 (C(20) major isomer), 
74.4 (C(4) major isomer), 74.4, (C(4) minor isomer) 58.9 (C(5) minor isomer), 58.7 
(C(5) major isomer), 41.6 (C(23) minor isomer), 40.3 (C(23) major isomer), 26.8 
(C(21) or C(22) major isomer), 26.4 (C(21) or C(22) minor isomer), 19.3 (C(21) or 
C(22) major isomer), 19.1 (C(21) or C(22) minor isomer); m/z ($ve ion electrospray) 
620 ([M$H]$, (37Cl), 25%), 618 ([M$H]$, (35Cl), 100%); (Found 642.1488, 
C29H2635ClNaN7O7, ([M+Na]+), requires 642.1474). 
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Methyl 2-(4-(hydroxyamino)-5,5-dimethyl-3-(naphthalen-1-yl)-2-
oxoimidazolidin-1-yl)acetate. (95) 
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A solution of 1-naphthyl isocyanate (846 mg, 5 mmol) in freshly distilled THF (6 
mL) was added drop-wise, under nitrogen, at 0°C, to a solution of oxime, 67 (870 
mg, 5 mmol) in freshly distilled THF (44 mL). The reaction mixture was stirred at rt 
overnight and then concentrated to afford a mixture of compounds 96 and 72 (1.5:1 
ratio; 1H NMR). This was then purified by flash column chromatography PE:EtOAc 
2:1 yielding title compound as a white solid (750 mg, 44%). Mp 127–129 °C; (max 
(evaporated film)/cm$1 3323 (brm, O-H), 3272 (m, N-H), 2969 (w, C-H), 1751 (s, 
C=O), 1677 (s, C=O), 1597 (w, C=C), 1559 (w, C=C), 1533 (w, C=C), 1508 (w, 
C=C), 1499 (w, C=C); 1H NMR (400 MHz, CDCl3) % 7.97 (1H, d, J 7.8 Hz, Ar-
CH), 7.88 (1H, d, J 8.9 Hz, Ar-CH), 7.82 (1H, d, J 8.3 Hz, Ar-CH), 7.55–7.47 (4H, 
m, 4 & Ar-CH), 5.30 (1H, brs, NH or OH), 5.05 (1H, brs, NH or OH), 4.48 (1H, s, 
C(4)H), 4.17 (1H, d, J 17.7 Hz, C(18)HaHb), 3.92 (1H, d, J 17.7 Hz, C(18)HaHb), 
3.75 (3H, s, CO2CH3), 1.51 (3H, s, C(16)H3 or C(17)H3), 1.41 (3H, s, C(16)H3 or 
C(17)H3); 13C NMR (100 MHz, CDCl3) % 170.8 (C(19)), 157.5 (C(2)), 134.2 (Ar-
C), 133.6 (Ar-C), 131.8 (Ar-C), 128.2 (Ar-CH), 127.9 (Ar-CH), 126.3 (2 & Ar-CH), 
125.7 (Ar-CH), 125.4 (Ar-CH), 120.7 (Ar-CH),  81.9 (C(4)), 58.9 (C(5)), 52.0 
(CO2CH3), 40.4 (C(18)), 26.3 (C(16) or C(17)), 19.8 (C(16) or C(17)); m/z (+ve ion 
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electrospray) 366.1 ([M+Na]+, 100%); (Found 366.1419, C18H21NaN3O4, ([M+Na]+), 
requires 366.1424). 
 
Methyl 2-(4-(1-hydroxy-3-(prop-2-ynyl)ureido)-5,5-dimethyl-3-(naphthalen-1-
yl)-2-oxoimidazolidin-1-yl)acetate.  (96) 
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1,1-Carbonyldiimidazole (477 mg, 2.94 mmol) was added under nitrogen to a 
solution of propargyl amine (162 mg, 2.94 mmol) in freshly distilled THF (6 mL). 
The reaction mixture was stirred at 50 °C for 1.5 h then mono-adduct, 96 (504 mg, 
1.47 mmol) was added. The reaction mixture was stirred overnight at 50 °C then 
cooled down to rt. Et2O (6 mL) was added to favour further precipitation. The solid 
was then filtered, washed with Et2O and pentane and dried yielding the crude product 
as a cream solid. Product was purified by flash column chromatography (SiO2, 2:1 
PE:EtOAc) yielding title compound as a white solid (271 mg, 44%). Mp 83–84 °C; 
(max (evaporated film)/cm$1 3412 (m, O-H), 3291 (brm, N-H), 3055 (m, C-H), 2971 
(m, C-H), 2951 (m, C-H), 2920 (m, C-H), 2858 (m, C-H), 1752 (m, C=O), 1675 (s, 
C=O), 1597 (m, C=C), 1574 (w, C=C), 1516 (s, C=C); 1H NMR (400 MHz, CDCl3) 
% 8.12 (1H, brs, OH), 7.92 (1H, d, J 8.2 Hz, Ar-CH), 7.79 (1H, d, J 7.9 Hz, Ar-CH), 
7.71 (1H, d, J 8.2 Hz, Ar-CH), 7.59 (1H, d, J 7.0 Hz, Ar-CH), 7.48–7.39 (2H, m, 2 & 
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Ar-CH), 7.27 (1H, t, J 7.9 Ar-CH), 6.14 (1H, brt, J 5.7 NH), 5.83 (1H, s, C(4)H), 
4.14 (1H, d, J 18.1 Hz, C(22)HaHb), 3.82 (1H, d, J 18.1 Hz, C(22)HaHb), 3.63 (3H, 
s, CO2CH3), 3.57 (2H, m, C(17)H2), 2.02 (1H, s, C(19)H), 1.50 (3H, s, C(20)H3 or 
C(21)H3) 1.23 (3H, s, C(20)H3 or C(21)H3); 13C NMR (100 MHz, CDCl3) % 172.0 
(C(30)), 158.6 (C(2) or C(16)), 158.3 (C(2) or C(16)), 134.2 (Ar-C), 132.2 (Ar-C), 
130.7 (Ar-C), 128.3 (Ar-CH), 128.0 (Ar-CH), 126.4 (Ar-CH), 125.8 (2 & Ar-CH), 
125.3 (Ar-CH), 122.2 (Ar-CH), 79.9 (C(18)), 77.7 (C(4)), 70.5 (C(19)), 59.7 (C(5)), 
52.4 (CO2CH3), 40.6 (C(22)), 29.1 (C(17)), 26.1 (C(20) or C(21)), 19.5(C(20) or 
C(21)); m/z (-ve ion electrospray) 423 ([M$H]$, 100%), (+ve ion electrospray) 447 
([M+Na]+; (Found 447.1651, C22H24NaN4O5, ([M+Na]+), requires 447.1639). 
 
1-(1-(2-Hydrazinyl-2-oxoethyl-5,5-dimethyl-3-(naphthalen-1-yl)-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-(prop-2-ynyl)urea.  (97) 
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An aqueous solution of hydrazine (62%, 0.621 mL, 12.80 mmol) was added to a 
solution of methyl ester, 96 (271 mg, 0.640 mmol) in anhydrous MeOH (2 mL). The 
reaction mixture was stirred at rt for 2.5 h. Then EtOAc (20 mL) and water (10 mL) 
were added and two phases were separated. The product was extracted further from 
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the aqueous layer using EtOAc (2 x 20 mL). The combined organic layers were 
washed with water several times and dried over Na2SO4 then filtered and 
concentrated under reduced pressure. This yielded the title product (250 mg, 92%) as 
a white solid. Mp 141–143 °C; (max (evaporated film)/cm$1 3296 (brs, O-H), 3056 (s, 
N-H), 2978 (m, C-H), 2929 (m, C-H), 2868 (m, C-H), 1669 (s, C=O), 1597 (m, 
C=C), 1520 (s, C=C); 1H NMR (400 MHz, CD3OD) % 7.91 (1H, d, J 8.1 Hz, Ar-
CH), 7.78 (1H, d, J 8.1 Hz, Ar-CH), 7.73 (1H, d, J 8.1 Hz Ar-CH), 7.60 (1H, d, J 
7.0 Hz), 7.46–7.34 (2H, m, 2 & Ar-CH), 7.12–7.08 (1H, m, Ar-CH), 5.80 (1H, s, 
C(4)H), 3.97 (1H, d, J 17.2 Hz, C(22)HaHb), 3.75 (1H, d, J 17.2 Hz, C(22)HaHb), 
3.53 (2H, m , C(17)H2), 3.18 (1H, brt, NH or OH), 2.36 (1H, brs, C(19)H), 1.47 
(3H, s, C(20)H3 or C(21)H3), 1.32 (3H, s, C(20)H3 or C(21)H3); 13C NMR (100 
MHz, CD3OD) % 171.6 (C(23)), 161.9 (C(2) or C(16)), 160.5 (C(2) or C(16)), 136.7 
(Ar-C), 136.0 (Ar-C), 132.4 (Ar-C), 130.2 (Ar-CH), 129.6 (2 & Ar-CH), 128.0 (Ar-
CH), 127.3 (Ar-CH), 126.7 (Ar-CH), 123.6 (Ar-CH), 81.3 (C(18)), 79.4 (C(4)), 72.0 
(C(19)), 61.6 (C(5)), 41.9 (C(22)), 30.1 (C(17)), 26.5 (C(20) or C(21)), 20.1 (C(20) 
or C(21)); m/z (-ve ion electrospray) 423 ([M$H]$, 100%), (+ve ion electrospray) 
447 ([M+Na]+, 100%); (Found 423.1774, C21H23N6O4, ([M$H]$), requires 
423.1781). 
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Methyl 2-(3-bromophenyl)acetate. (102) 
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3-Bromophenylacetic acid (1.0 g, 4.7 mmol) was dissolved in MeOH (10 mL), 
concentrated sulphuric acid (0.1 mL, 3.6 mmol) was added, and the resulting solution 
was heated under reflux for 16 h. The reaction mixture was concentrated under 
reduced pressure and the residue was partitioned with DCM (10 mL) and saturated 
sodium hydrogen carbonate solution (10 mL) and layers separated. The organic layer 
was dried over MgSO4, filtered and concentrated under reduced pressure and the 
resulting oil was purified by flash column chromatography (EtOAc/PE 1:1) to yield 
the title compound as a colourless oil (1.05 g, 99%) [Lit82 oil]; (max (evaporated 
film/cm$1)  3061 (w, C-H), 2998 (w, C-H), 2952 (m, C-H), 2841 (w, C-H), 2153 (w, 
C-H), 1739 (s, C=O), 1596 (m, C=C), 1570 (s, C=C); 1H NMR (400 MHz, CDCl3) % 
7.45 – 7.44 (1H, brs, C(6)H), 7.41 (1H, dt, J 7.1 & 1.9, Ar-CH), 7.23 – 7.17 (2H, m, 
2 & Ar-CH), 3.70 (3H, s, OCH3), 3.60 (2H, s, C(7)H2); 13C NMR (125 MHz, CDCl3) 
% 171.3 (C(8)), 136.0 (Ar-C), 132.3 (Ar-CH), 130.2 (Ar-CH), 130.0 (Ar-CH), 127.9 
(Ar-CH), 122.4 (Ar-C), 52.14 (CH3), 40.6 (C(7)); m/z (GC/MS) 230 ([M]+, (79Br), 
80%), 232 ([M]+, (81Br), 79%); (Found 227.9786, C9H979BrO2, ([M]+), requires 
227.9780). 
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Methyl 2-(3-iodophenyl)acetate. (105) 
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3-Iodophenylacetic acid (500 mg, 1.9 mmol) was dissolved in MeOH (5 mL), 
concentrated sulphuric acid (0.08 mL, 1.5 mmol) was added, and the resulting 
solution was heated under reflux for 16 h. The reaction mixture was concentrated 
under reduced pressure and the residue was partitioned between DCM (5 mL) and 
saturated sodium hydrogen carbonate solution (5 mL) and layers separated. The 
organic layer was dried over MgSO4, filtered and concentrated under reduced 
pressure and the resulting oil was purified by flash column chromatography 
(EtOAc/PE 1:1) to yield the title compound as a colourless oil (527 mg, 95%). (max 
(evaporated film/cm$1) 3054 (w, C-H), 2998 (w, C-H), 2949 (m, C-H), 2840 (w, C-
H), 1739 (s, C=O), 1590 (s, C=C), 1565 (s, C=C); 1H NMR (400 MHz, CDCl3) % 
7.56 (1H, brs, C(6)H), 7.52 (1H, d, J 7.7 Hz C(2)H), 7.16 (1H, d, J 7.7 Hz, C(4)H), 
6.97 (1H, t, J 7.7, C(3)H), 3.61 (3H, s, OCH3), 3.48 (2H, s, C(7)H2); 13C NMR (100 
MHz, CDCl3) % 171.4 (C(8)), 138.2 (C(6)), 136.2 (C(2)), 136.1 (C(5)), 130.2 (C(3)), 
128.6 (C(4)), 94.4 (C(1)), 52.2 (CH3), 40.5 (C(7)); m/z (GC/MS) 276 ([M+, 100%); 
(Found 275.9648, C9H9IO2, ([M]+), requires 275.9642). 
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Methyl (2-(3-(2-(trimethylsilyl)ethynyl)phenyl)acetate. (103) 
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To a solution of 105 (250 mg, 0.91 mmol) and ethynyltrimethylsilane (133 mg, 1.36 
mmol) in freshly distilled THF (2.5 mL) under an atmosphere of nitrogen, freshly 
distilled triethylamine (2.5 mL, 2.16 mmol) was added followed by 
bis(triphenylphosphine)palladium(II) dichloride (64 mg, 0.091 mmol) and copper(I) 
iodide (17 mg, 0.091 mmol). The reaction mixture was stirred at rt for 18 h then 
filtered and concentrated under reduced pressure. The product was extracted with 
EtOAc (55 mL) washed with saturated NaHCO3 (3 & 25 mL) and brine (3 & 25 mL) 
and dried over MgSO4. The product was purified by flash column chromatography 
(SiO2: 20:1 Hexane:DCM then increasing polarity to 5:1 Hexane:DCM, Rf 0.16) to 
give the title compound as a colourless oil (216 mg, 97%). (max (evaporated 
film/cm$1) 3094 (w, C-H), 3057 (w, C-H), 3024 (w, C-H), 2992 (w, C-H), 2956 (s, 
C-H), 2898 (w, C-H), 2841 (w, C-H), 2154 (s, C,C), 1740 (s, C=O), 1602 (m, 
C=C), 1579 (w, C=C); 1H NMR (400 MHz, CDCl3) % 7.17 (1H, brs, C(6)H),  7.15 
(1H, dt, J 7.1 & 1.8 Hz,  Ar-CH), 7.05 – 6.99 (2H, m, 2 & Ar-CH), 3.46 (3H, s, 
OCH3), 3.36 (2H, s, C(7)H2), 0.02 (9H, s, (CH3)3Si); 13C NMR (100 MHz, CDCl3) % 
171.6 (C(8)), 134.0 (Ar-CH), 132.8 (Ar-CH), 130.6 (Ar-CH), 129.5 (Ar-C), 128.4 
(Ar-CH), 123.4 (Ar-C), 104.7 (C(9)), 94.4 (C(10)), 52.1 (OCH3), 40.8 (C(7)), -0.09 
((CH3)3Si); m/z (+ve ion electrospray) 269 ([M+Na]+, 100%); (Found 269.0974, 
C14H18NaO2Si, ([M+Na]+), requires 269.0968). 
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Methyl 2-(3-ethynylphenyl)acetate. (106) 
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To a stirred solution of 103 (289 mg, 1.17 mmol) in freshly distilled MeCN (6 mL) 
under an atmosphere of nitrogen, TBAF (1.5 mL of a 1 M solution in THF, 5.05 
mmol) was added. The solution was stirred at rt for 18 h then concentrated under 
reduced pressure. The residue was partitioned between water (40 mL) and EtOAc 
(40 mL) and layers separated. The organic layer was washed with water (3 & 20 mL) 
and brine (3 & 20 mL), dried over MgSO4 and concentrated under reduced pressure 
to yield a crude product. Purification by flash column chromatography (SiO2: 5:1 
Hexane:DCM, Rf 0.20) gave the title compound as a colourless oil (150 mg, 74%). 
(max (evaporated film/cm$1) 3288 (s, C-H), 3030 (w, C-H), 2997 (w, C-H), 2952 (m, 
C-H), 2922 (w, C-H), 2846 (w, C-H), 2102 (w, C,C), 1734 (w, C=O), 1600 (w, 
C=C), 1580 (w, C=C); 1H NMR (400 MHz, CDCl3) % 7.35 (1H, brs, C(6)H), 7.35 – 
7.32 (1H, m, Ar-CH), 7.24 – 7.20 (2H, m, 2 & Ar-CH), 3.63 (3H, s, OCH3), 3.54 (2H, 
s, C(7)H2), 3.00 (1H, s, C(10)H); 13C NMR (100 MHz, CDCl3) % 171.5 (C(8)), 134.1 
(Ar-C), 133.0 (Ar-CH), 130.9 (Ar-CH), 129.8 (Ar-CH), 128.6 (Ar-CH), 122.4 (Ar-
C), 83.3 (C(9)), 77.40 (C(10)),  52.1 (OCH3), 40.8 (C(7)); m/z (+ve ion electrospray) 
175 ([M+H]+, 100%); (Found 197.0581, C11H10NaO2, ([M+Na]+), requires 
197.0573). 
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2-(3-Ethynylphenyl)acetohydrazide. (107) 
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To a solution of 106 (150 mg, 0.862 mmol) in MeOH (4 mL), an aqueous solution of 
hydrazine (62%, 1.045 mL, 21.55 mmol) was added. The reaction was stirred at rt 
for 2 h then concentrated under reduced pressure. The residue was partitioned 
between water (20 mL) and EtOAc (20 mL) and the layers separated. The organic 
layer was further washed with water (3 & 20 mL), dried over MgSO4 and 
concentrated under reduced pressure to give a crude product. Purification by flash 
column chromatography (SiO2: EtOAc:PE 4:1, Rf 0.24) gave the title compound as 
colourless crystals (115 mg, 77%). Mp 79 – 81 °C; (max (evaporated film/cm$1) 3299 
(s, N-H or alkyne C-H), 3284 (s, N-H or alkyne C-H), 3239 (s, N-H), 3197 (s, N-H), 
3030 (s, C-H), 2879 (w, C-H), 1668 (s, C=O), 1652 (m, C=C), 1637 (s, C=C), 1616 
(s, C=C), 1575 (m, C=C), 1557 (m, C=C); 1H NMR (500 MHz, CD3OD) % 7.40 (1H, 
brs, C(6)H), 7.33 (1H, dt, Ar-CH), 7.29 – 7.24 (2H, m, 2 & Ar-CH), 3.48 (1H, s, 
C(10)H), 3.43 (2H, s, C(7)H2); 13C NMR (125 MHz, CD3OD) % 172.7 (C(8)), 137.2 
(Ar-C), 133.7 (C(6)), 131.6 (Ar-CH), 130.7 (Ar-CH), 129.8 (Ar-CH), 124.0 (Ar-C), 
84.4 (C(9)), 79.0 (C(10)), 41.5 (C(7)); m/z (GC/MS) 174 ([M]+, 20%); (Found 
174.0783, C10H10N2O, ([M]+), requires 174.0788). 
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(12E)-2-(3-Ethynylphenyl)-N’-((E)-3-(5-nitrofuran-2-
yl)allylidene)acetohydrazide. (99) 
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To a stirred solution of 107 (72 mg, 0.621 mmol) in freshly distilled MeOH (3 mL) 
under an atmosphere of nitrogen, (E)-3-(5-nitro-2-furyl)acrylaldehyde (114 mg, 
0.683 mmol) was added. The reaction solution was stirred at rt for 18 h until a 
precipitate was formed. The solid was filtered and washed with cold MeOH (3 & 10 
mL) and Et2O (3 & 10 mL) to give the title compound as a yellow solid (70 mg, 53%). 
Mp 192 °C (dec); (max (evaporated film/cm$1) 3030 (w, N-H), 2933 (w, C-H), 2911 
(w, C-H), 2857 (w, C-H), 2836 (w, C-H), 1663 (s, C=O), 1659 (s, C=C), 1575 (w, 
C=C) 1559 (m, C=C), 1505 (w, C=C); 1H NMR (400 MHz, CDCl3) % 8.83 (1H, brs, 
NH), 7.51 – 7.47 (2H, m, C(11)H & Ar-CH), 7.42 – 7.30 (4H, m, C(16)H & 3 & Ar-
CH), 7.15 (1H, dd, J 16.4 & 9.1 Hz, C(12)H), 6.66 (1H, d, J 16.4 Hz, C(13)H), 6.64 
(1H, brs, C(15)H), 4.01 (2H, s, C(7)H2), 3.08 (1H, s, C(10)H); 13C NMR (100 MHz, 
d6-DMSO, two isomers, some signals are coincident) % 172.1 (C=O), 166.4 (C=O), 
154.9 (Ar-C), 154.9 (Ar-C), 151.3 (Ar-C), 146.8 (Ar-CH), 143.6 (Ar-CH), 136.0 
(Ar-C), 135. (Ar-C), 132.8 (Ar-CH), 132.4 (Ar-CH), 130.5 (Ar-CH), 130.4 (Ar-CH), 
130.2 (Ar-CH), 130.0 (Ar-CH), 129.9 (Ar-CH), 129.8 (Ar-CH), 129.0 (Ar-CH), 
128.7 (Ar-CH), 128.6 (Ar-CH), 128.2 (Ar-CH), 126.8 (Ar-CH), 125.9 (Ar-CH), 
123.8 (Ar-CH), 123.2 (Ar-CH), 121.7 (Ar-C), 121.5 (Ar-C), 115.4 (C(16) major 
isomer), 115.4 (C(16) minor isomer), 113.4 (C(15) minor isomer), 113.4 (C(15) 
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major isomer), 83.5 (C(9) major isomer), 83.4 (C(9) minor isomer), 80.8 (C(10) 
minor isomer), 80.7 (C(10) major isomer), 40.6 (C(7) minor isomer), 38.1 (C(7) 
major isomer); m/z  (+ve ion electrospray) 346 ([M+Na]+, 100%); (Found 346.0802, 
C17H13N3NaO4, ([M+Na]+), requires 346.0799). 
 
2-Phenylacetic acid. (109) 
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To a solution of methylphenylacetate (5.00 g, 33 mmol) in THF (100 mL) under an 
atmosphere of nitrogen, LiOH (100 mL of a 1 M solution in water, 100 mmol) was 
added. The solution was stirred at rt for 4 h then concentrated under reduced 
pressure. The residue was partitioned between water (100 mL) and DCM (100 mL) 
and the layers separated. To the aqueous layer 1M HCl (-50 mL) was added until a 
precipitate was formed, which was filtered and dried under vacuum to give the title 
compound as colourless crystals (3.76 g, 83%). Mp 76 – 79 °C (Lit105 76 – 76.5 °C); 
(max (evaporated film/cm$1) 3089 (brm, O-H), 3062 (m, C-H), 3032 (m, C-H), 2976 
(m, C-H), 2922 (m, C-H), 2733 (w, C-H), 2652 (w, C-H), 2555 (w, C-H), 1699 (s, 
C=O), 1602 (w, C=C), 1497 (m, C=C); 1H NMR (400 MHz, CDCl3) % 9.76 (1H, brs, 
CO2H), 7.38 – 7.30 (5H, m, 5 & Ar-CH), 3.67 (2H, s, C(7)H2); 13C NMR (100 MHz, 
CDCl3) % 178.0 (C(8)), 133.2 (C(5)), 129.4 (2 & Ar-CH), 128.6 (2 & Ar-CH), 127.3 
(Ar-CH), 41.0 (C(7)); m/z ($ve ion electrospray) 135 ([M$H]$, 100%); (Found 
135.0457, C8H7O2, ([M$H]$), requires 135.0452). 
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2-(4-Iodophenyl)acetic acid. (110) 
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To a stirred solution of iodine (1.25 g, 4.94 mmol) and 109 (3.36 g, 24.7 mmol) in 
glacial acetic acid (45 mL), a mixture of HNO3 (1.10 mL of a 70% solution) and 
concentrated H2SO4 (4.42 mL) was added drop-wise over 30 minutes. The reaction 
mixture was stirred at 60 °C for 1.5 h then cooled to rt and allowed to stir for a 
further 18 h. After the allotted time most of the iodine colour had disappeared AND 
the resulting solution was poured onto ice (110 g) to form a white precipitate, which 
was filtered under vacuum to give a crude product. Recrystallisation from hexane 
gave the title compound as colourless crystals (2.92 g, 45%). Mp 135 – 137 °C 
(Lit106 135 °C); (max (evaporated film/cm$1) 3401 (brs, O-H), 3320 (s, C-H), 3235 (m, 
C-H), 3186 (m, C-H), 1699 (s, C=O), 1653 (m, C=C), 1637 (w, C=C), 1616 (w, 
C=C), 1559 (w, C=C), 1505 (w, C=C) ; 1H NMR (400 MHz, CDCl3) % 7.67 (2H, d, J 
8.3 Hz, C(1)H & C(3)H), 7.04 (2H, d, J 8.3 Hz, C(4)H & C(6)H), 3.60 (2H, s, 
C(7)H2); 13C NMR (100 MHz, CDCl3) % 176.6 (C(8)), 137.7 (C(1) & C(3)), 132.8 
(C(5)), 131.3 (C(4) & C(6)), 93.0 (C(2)), 40.4 (C(7)); m/z ($ve ion electrospray) 261 
([M$H]$, 100%); (Found 260.9406, C8H6IO2, ([M$H]$), requires 260.9418). 
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Methyl 2-(4-iodophenyl)acetate. (111) 
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Acid, 110 (1.66 g, 6.35 mmol) was dissolved in MeOH (9 mL), concentrated sulfuric 
acid (0.27 mL, 1.5 mmol) was added, and the resulting solution was heated under 
reflux for 16 h. The reaction mixture was concentrated under reduced pressure and 
the residue was partitioned between DCM (20 mL) and saturated sodium hydrogen 
carbonate solution (20 mL) and the layers were separated. The organic layer was 
dried over MgSO4, filtered and concentrated under reduced pressure giving the title 
product as a colourless oil (1.67 g, 95%). (max (evaporated film/cm$1) 3023 (m, C-H), 
2998 (m, C-H), 2949 (s, C-H), 2840 (w, C-H), 1734 (s, C=O), 1627 (w, C=C), 1589 
(w, C=C), 1565 (w, C=C), 1522 (w, C=C); 1H NMR (400 MHz, CDCl3) % 7.66 (2H, 
d, J 8.0 Hz, C(1)H & C(3)H), 7.04 (2H, d, J 8.0, C(4)H & C(6)H), 3.70 (3H, s, 
OCH3), 3.58 (2H, s, C(7)H2); 13C NMR (100 MHz, CDCl3) % 171.4 (C(8)), 137.6 
(C(1) & C(3)), 133.5 (C(5)), 131.3 (C(4) & C(6)), 92.6 (C(2)), 52.2 (OCH3), 40.6 
(C(7)); m/z (GC/MS) 276 ([M]+, 100%); (Found 275.9637, C9H9IO2, ([M]+), requires 
275.9642). 
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Methyl (2-(4-(2-(trimethylsilyl)ethynyl)phenyl)acetate. (112) 
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To a solution of 111 (500 mg, 1.81 mmol) and ethynyltrimethylsilane (266 mg, 2.72 
mmol) in freshly distilled THF (5 mL) under an atmosphere of nitrogen, freshly 
distilled triethylamine (5 mL, 4.31 mmol) was added followed by 
bis(triphenylphosphine)palladium(II) dichloride (127 mg, 0.18 mmol) and CuI (34 
mg, 0.18 mmol). The reaction mixture was stirred at rt for 18 h then filtered and 
concentrated under reduced pressure. The product was extracted with EtOAc (100 
mL) washed with saturated NaHCO3 (3 & 50 mL) and brine (3 & 50 mL) and dried 
over MgSO4. The product was purified by flash column chromatography (SiO2: 20:1 
Hexane:DCM then increasing polarity to 5:1 Hexane:DCM) to give the title 
compound as a colourless oil (429 mg, 96%). Rf 0.16; (max (evaporated film/cm$1) 
3024 (w, C-H), 2997 (w, C-H), 2955 (m, C-H), 2900 (w, C-H), 2836 (w, C-H), 2158 
(m, C,C), 1740 (s, C=O), 1507 (m, C=C); 1H NMR (400 MHz, CDCl3) % 7.43 (2H, 
d, J 8.2 Hz, C(1)H & C(3)H), 7.22 (2H, d, J 8.2 Hz, C(4)H & C(6)H), 3.69 (3H, s, 
OCH3), 3.62 (2H, s, C(7)H2), 0.25 (9H, s, (CH3)3Si); 13C NMR (100 MHz, CDCl3) % 
171.5 (C(8)), 134.3 (C(5)), 132.1 (C(1) & C(3)), 129.1 (C(4) & C(6)), 121.9 (C(2)), 
104.7 (C(9)), 94.2 (C(10)), 52.1 (OCH3), 41.0 (C(7)), -0.08 ((CH3)3Si); m/z ($ve ion 
electrospray) 245 ([M$H]$, 100%), (+ve ion electrospray) 269 ([M+Na]+, 100%); 
(Found 247.1156, C14H19O2Si, ([M+H]+), requires 247.1149). 
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Methyl 2-(4-ethynylphenyl)acetate. (113) 
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To a stirred solution of 112 (429 mg, 1.74 mmol) in freshly distilled MeCN (6 mL) 
under an atmosphere of nitrogen, TBAF (2.19 mL of 1 M solution in THF, 7.56 
mmol) was added. The solution was stirred at rt for 18 h then concentrated under 
reduced pressure. The residue was partitioned between water (80 mL) and EtOAc 
(80 mL) and layers separated. The organic layer was washed with water (3 & 40 mL) 
and brine (3 & 40 mL), dried over MgSO4 and concentrated under reduced pressure 
to yield a crude product. Purification by flash column chromatography (SiO2: 5:1 
Hexane:DCM, Rf 0.20) gave the title compound as a colourless oil (250 mg, 83%). 
(max (evaporated film/cm$1) 3282 (s, C-H), 3032 (m, C-H), 3000 (m, C-H), 2952 (s, 
C-H), 2843 (w, C-H), 2108 (w, C,C), 1737 (s, C=O), 1610 (w, C=C), 1565 (w, 
C=C), 1509 (s, C=C); 1H NMR (400 MHz, CDCl3) % 7.46 (2H, d, J 8.1 Hz, C(1)H & 
C(3)H), 7.25 (2H, d, J 8.1 Hz, C(4)H & C(6)H), 3.70 (3H, s, OCH3), 3.64 (2H, s, 
C(7)H2), 3.08 (1H, s, C(10)H); 13C NMR (100 MHz, CDCl3) % 171.5 (C(8)), 134.7 
(C(5)), 132.3 (C(1) & C(3)), 129.3 (C(4) & C(6)), 120.9 (C(2)), 83.4 (C(9)), 77.4 
(C(10)), 52.1 (OCH3), 41.0 (C(7)); m/z (+ve ion electrospray) 175 ([M+H]+, 45%), 
197 ([M+Na]+, 100%); (Found 175.0756, C11H11O2, ([M+H]+), requires 175.0754). 
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2-(3-Ethynylphenyl)acetohydrazide. (114) 
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To a solution of 113 (118 mg, 0.68 mmol) in MeOH (3 mL), an aqueous solution of 
hydrazine (62%, 0.97 mL, 1.00 g, 19.97 mmol) was added. The reaction was stirred 
at rt for 2 h then concentrated under reduced pressure. The residue was partitioned 
between water (15 mL) and EtOAc (15 mL) and the layers were separated. The 
organic layer was further washed with water (3 & 15 mL), dried over MgSO4 and 
concentrated under reduced pressure to give a crude product. Purification by flash 
column chromatography (SiO2: EtOAc:PE 3:1, Rf 0.24) gave the title compound as 
colourless crystals (117 mg, 99%). Mp 79 – 81 °C; (max (evaporated film/cm$1) 3333 
(s, N-H or alkyne C-H), 3294 (m, N-H or alkyne C-H), 3202 (w, N-H), 3030 (w, C-
H), 2954 (w, C-H), 1736 (w, C=O), 1651 (m, C=C), 1642 (s, C=C), 1616 (s, C=C), 
1525 (m, C=C), 1505 (w, C=C); 1H NMR (300 MHz, CD3OD) % 7.38 (2H, d, J 7.9 
Hz, C(1)H & C(3)H), 7.25 (2H, d, J 7.9Hz, C(4)H & C(6)H), 3.44 (2H, s, C(7)H2), 
3.43 (1H, s, C(10)H); 13C NMR (100 MHz, CD3OD) % 172.6 (C(8)), 137.5 (C(5)), 
133.1 (C(1) & C(3)), 130.2 (C(4) & C(6)), 122.4 (C(2)), 85.6 (C(9)), 78.7 (C(10)), 
41.6 (C(7)); m/z (GC/MS) 175 ([M+H]+, 20%); (Found 174.0788, C10H10N2O, 
([M]+), requires 174.0788). 
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(12E)-2-(4-Ethynylphenyl)-N’-((E)-3-(5-nitrofuran-2-
yl)allylidene)acetohydrazide. (100) 
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To a stirred solution of 114 (81 mg, 0.462 mmol) in freshly distilled MeOH (2 mL) 
under an atmosphere of nitrogen, (E)-3-(5-nitro-2-furyl)acrylaldehyde (85 mg, 0.509 
mmol) was added. The reaction solution was stirred at rt for 18 h until a precipitate 
was formed. The solid was filtered and washed with cold MeOH (3 & 10 mL) and 
Et2O (3 & 10 mL) to give the title compound as a yellow solid (50 mg, 34%). Mp 202 
°C (dec); (max (evaporated film/cm$1) 3391 (brs, N-H), 3283 (s, C-H), 2938 (w, C-H), 
1663 (s, C=O), 1581 (w, C=C), 1556 (w, C=C), 1505 (w, C=C); 1H NMR (400 
MHz, CDCl3) % 8.73 (1H, brs, NH), 7.49 (1H, d, J 8.8 Hz, C(11)H), 7.47 (2H, d, J 
7.6 Hz, C(1)H & C(3)H), 7.37 (1H, d, J 3.5 Hz, C(16)H), 7.33 (2H, d, J 7.6 Hz, 
C(4)H & C(6)H), 7.15 (1H, dd, J 16.2 & 8.8 Hz, C(12)H), 6.66 (1H, d, J 16.2 Hz, 
C(13)H), 6.64 (1H, d, J 3.5 Hz, C(15)H); 13C NMR (100 MHz, d6-DMSO, two 
isomers, some signals are coincident) % 172.0 (C=O), 166.3 (C=O), 154.9 (Ar-C), 
154.6 (Ar-C), 151.3 (Ar-C), 146.8 (Ar-CH), 143.6 (Ar-CH), 136.7 (Ar-C), 136.5 
(Ar-C), 136.4 (Ar-C), 136.4 (Ar-C), 136.3 (Ar-C), 131.7 (Ar-CH), 131.6 (Ar-CH), 
131.6 (Ar-CH), 131.5 (Ar-CH), 130.5 (Ar-CH), 130.2 (Ar-CH), 129.9 (Ar-CH), 
129.5 (Ar-CH), 123.8 (Ar-CH), 123.2 (Ar-CH), 120.1 (Ar-C), 119.9 (Ar-C), 115.4 
(C(15) major isomer), 115.4 (C(15) minor isomer), 113.5 (C(16) major isomer), 113.4 
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(C(16) minor isomer), 83.5 (C(9) major isomer), 83.4 (C(9) minor isomer), 80.7 
(C(10) minor isomer), 80.5 (C(10) major isomer), 40.9 (C(7) minor isomer), 38.4 
(C(7) major isomer); m/z (+ve ion electrospray) 246 ([M+Na]+, 100%); (Found 
322.0833, C17H12N3O4, ([M$H]$), requires 322.0851). 
 
5.2.5 Click chemistry 
 
2-[2-(2-Hydroxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate. (116) 
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Triethylene glycol (1.00 g, 6.66 mmol) was dissolved in anhydrous pyridine (10 mL) 
and cooled to 0 °C. p-Toluenesulfonyl chloride (1.26 g, 6.66 mmol) in anhydrous 
pyridine (5 mL) was then added drop-wise to the stirred solution. The reaction 
solution was stirred for 4 h then ice water (15 mL) was added and the mixture was 
stirred for a further 1 h. The product was extracted with chloroform (3 x 20 mL), 
washed with water (3 x 20 mL), dried over magnesium sulfate and concentrated under 
reduced pressure. Flash column chromatography (EtOAc) gave the title product as a 
colourless oil (1.244 g, 61%). Rf 0.48; (max (evaporated film)/cm$1 3421 (brm, O-H), 
2875 (m, C-H), 1718 (w), 1653 (w, C=C), 1646 (w, C=C), 1597 (m, C=C); 1H NMR 
(400 MHz, CDCl3) % 7.72 (2H, d, J 7.03 Hz, C(8)H and C(12)H), 7.28 (2H, d, J 7.03 
Hz, C(9)H and C(11)H), 4.08–4.07 (2H, m, TEG CH2), 3.62–3.61 (4H, m, 2 & TEG 
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CH2), 3.52 (4H, m, 2 & TEG CH2), 3.49–3.48 (2H, m, TEG CH2), 2.74 (1H, brs, 
OH), 2.37 (3H, s, C(13)H3); 13C NMR (100 MHz, CDCl3, some signals are 
coincident) % 144.72 (C(10)), 132.58 (C(7)), 129.66 (C(8) and C(12)), 127.72 (C(9) 
and C(11)), 72.29 (TEG CH2), 70.47 (TEG CH2), 70.00 (TEG CH2), 69.04 (TEG 
CH2), 68.40 (TEG CH2), 61.38 (TEG CH2), 21.40 (C(13));  m/z (+ve ion 
electrospray) 305 ([M+H]+, 100%); (Found 305.1060, C13H21O6S, ([M+H]+), 
requires 305.1053). 
 
2-[2-(2-Azidoethoxy)ethoxy]ethanol. (117) 
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Monotosylated triethylene glycol, 116 (500 mg, 1.646 mmol) was dissolved in dry 
DMF (25 mL). Sodium azide (535 mg, 8.231 mmol) was added under nitrogen and 
the mixture heated to 70 °C for 17 h. Water (12 mL) was added and the reaction 
mixture cooled to rt. The product was extracted with EtOAc (3 x 15 mL), organic 
layer was washed with water  (3 x 15 mL) dried over magnesium sulphate and 
concentrated under reduced pressure. Crude oil was purified by flash column 
chromatography (EtOAc) to give title product as a colourless oil (167 mg, 54%). Rf  
0.45; (max (evaporated film)/cm$1 3433 (brs, O-H), 2920 (s, C-H), 2876 (s, C-H), 
2103 (s, N3), 1646 (m); 1H NMR (400 MHz, CDCl3) % 3.70 (2H, t, J 4.6 Hz, TEG 
CH2OH), 3.66–3.64 (6H, m, 3 & TEG CH2), 3.58 (2H, t, J 4.6 Hz, TEG 
CH2CH2N3), 3.37 (2H, t, J 5.1 Hz, CH2N3), 2.69 (1H, brs, OH); 13C NMR (100 
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MHz, CDCl3) % 72.4 (C(2)), 70.4 (C(3)), 70.2 (C(4)), 69.8 (C(5)), 61.5 (CH2OH), 
50.4 (CH2N3);  m/z (+ve electrospray) 198.0 ([M+Na]+, 100%); (Found 198.0860, 
C6H13NaN3O3, ([M+Na]+), requires 198.0849). 
 
Methyl 2-(3-(4-chlorophenyl)-4-(1-hydroxy-3-((1-(2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)ureido)-5,5-dimethyl-
2-oxoimidazolidin-1-yl)acetate. (118) 
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The ester, 87 (10 mg, 0.024 mmol) and triethylene glycol azide (8.4 mg, 0.048 
mmol) were suspended in a solution of tert-butanol:water 1:1 (1.5 mL). A freshly 
made up solution of sodium ascorbate (2.4 µL of a 1 M solution) followed by a 
freshly made up solution of copper sulphate (0.8 µL of a 0.3 M solution) were the 
added to the stirred mixture. (The copper sulfate was recrystallised from water first 
then the resulting crystals made up the solution to ensure its purity). The mixture was 
stirred for 18 h (monitored by TLC) and the product was extracted with chloroform 
(3 x 5 mL) and washed with brine (5 mL and water (5 mL). The organic layer was 
dried over MgSO4 and concentrated under reduced pressure to yield the product as a 
colourless oil (14.3 mg, 93%). (max (evaporated film)/cm$1 3360 (brm, O-H), 2925 
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(m, C-H), 2876 (m, C-H), 1752 (m, C=O), 1701 (s, C=O), 1653 (s, C=O), 1596 (w, 
C=C), 1521 (m, C=C), 1500 (s, C=C); 1H NMR (400 MHz, CDCl3) % 7.70 (1H, s, 
C(18)H), 7.53 (2H, d, J 8.9 Hz, 2 & Ar-CH), 7.14 (2H, d, J 8.9 Hz, 2 & Ar-CH), 6.75 
(1H, brt, J 5.8 Hz, NH), 6.03 (1H, s, C(4)H), 4.42 (2H, m, TEG CH2), 4.35 (2H, m, 
partly obscured by multiplet at 4.42), C(13)H2), 4.06 (1H, d, J 17.7 Hz, 
C(27)HaHb), 3.82 (1H, d, partly obscured by triplet at 3.78, C(27)HaHb), 3.78 (2H, 
t, J 4.9 Hz TEG CH2), 3.68 (3H, s, CO2CH3), 3.59 (2H, m, TEG CH2) 3.54 (4H, m, 
2 & TEG CH2), 3.43 (2H, m, TEG CH2), 1.29 (3H, s, C(25)H3 or C(26)H3), 1.27 
(3H, s, C(25)H3 or C(26)H3); 13C NMR (100 MHz, CDCl3, some signals are 
coincident) % 170.9 (C(28)), 159.0 (C(2) or C(12)), 156.4 (C(2) or C(12)), 145 
(C(14)), 137.1 (Ar-C), 128.5 (2 & Ar-CH), 128.1 (Ar-C), 123.4 (C(18)), 120.6 (2 & 
Ar-CH), 75.0 (C(4)), 72.2 (TEG CH2), 70.2 (TEG CH2), 69.9 (TEG CH2), 69.0 
(TEG CH2), 61.3 (TEG CH2), 58.9 (C(5)), 52.4 (CO2CH3), 50.0 (TEG CH2), 40.6 
(C(27)), 35.1 (C(13)), 26.1 (C(25) or C(26)), 19.3 (C(25) or C(26));  m/z ($ve ion 
electrospray) 584 ([M$H]$, (37Cl), 40%), 582 ([M$H]$, (35Cl), 100%), (+ve ion 
electrospray) 608 ([M+Na]+, (37Cl), 30%), 606 ([M+Na]+, (35Cl), 100%); (Found 
584.2235, C24H3535ClN7O8, ([M+H]+), requires 584.2230). 
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1-(3-(4-Chlorophenyl)-5,5-dimethyl-1-(2-((E)-2-((E)-3-(5-nitrofuran-2-
yl)allylidene)hydrazinyl)-2-oxoethyl)-2-oxoimidazolidin-4-yl)-1-hydroxy-3-((1-
(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)urea. (119) 
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Alkyne ES, 91 (10 mg, 0.018 mmol) and triethylene glycol azide (3 mg, 0.017 
mmol) were suspended in a solution of tert-butanol:water 1:1 (1.5 mL). A freshly 
made up solution of sodium ascorbate (1.8 µL of a 1 M solution) followed by a 
freshly made up solution of copper sulphate (0.6 µL of a 0.3 M solution) were the 
added to the stirring mixture. The mixture was stirred for 36 h and the product was 
extracted with chloroform (3 x 5 mL) and washed with brine (5 mL and water (5 
mL). The organic layer was dried over MgSO4 and concentrated under reduced 
pressure to yield the product as an orange oil (12.9mg, 96%). (max (evaporated 
film)/cm$1 3384 (brm, O-H), 2929 (m, C-H), 2868 (m, C-H), 2101, (m, -N-N=N-), 
1696 (m, C=O), 1684 (s, C=O), 1675 (m, C=O), 1653 (s, C=C), 1559 (m, C=C), 
1522 (m, C=C), 1507 (m, C=C); m/z ($ve ion electrospray) 733 ([M$H]$, (37Cl), 
50%), 731 ([M$H]$, (35Cl), 100%), (+ve ion electrospray) 757 ([M+Na]+, (37Cl), 
50%), 755 ([M+Na]+, (35Cl), 100%); (Found 755.2288, C30H3735ClNaN10O10, 
([M+Na]+), requires 755.2275). 
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5.3 Synthesis of Cotransin 
5.3.1 Solution phase synthesis of Cotransin 
 
(S)-Methyl 2-(methylamino)propanoate-N-MeAla-OMe. (130) 
 
H 1
N 2
3
4
OMe
O
 
 
To a solution of Boc-Ala-OH (1 g, 5.29 mmol) stirring in THF/DMF (10:1, 11 mL) 
was added MeI (4.28 g, 30.15 mmol) followed by sodium hydride dispersion (60% 
dispersion in oil) pre-washed with PE (0.543 g, 11.31 mmol) slowly. A reflux 
condenser fitted with a drying tube containing Drierite. was attached and the 
reaction mixture was stirred at 80 °C for 24 h. The solvent was removed under 
vacuum from the resulting yellow mixture then ether (20 mL) was added and 
evaporation repeated to remove MeI. The product was extracted with ether (3 & 20 
mL), washed with water (3 & 20 mL) dried over MgSO4 and concentrated under 
vacuum to give the corresponding methyl ester. This crude product was immediately 
treated with a 37% solution of HCl in acetic acid for 2 h at rt and concentrated under 
reduced pressure.  The crude product was dissolved in water (25 mL), washed with 
ether (2 & 10 mL) then evaporated to dryness and stored overnight under vacuum 
over P2O5 to yield the title compound as pale yellow oil (776 mg, 96%). [!]D21 +7.20 
(c 1.0 in MeOH); (max (evaporated film)/cm$1 3370 (brw, N-H), 2947 (brm, C-H), 
2736 (brm, C-H), 2457 (brw, C-H), 1733 (s, C=O), 1628 (w), 1571 (w); 1H NMR 
(400 MHz, CDCl3) % 9.96 (1H, brs, NH), 9.72 (1H, brs, NH), 3.97 (1H, q, J 5.8, 12.9 
Hz, C(2)H), 3.84 (3H, s, CO2CH3), 2.8 (3H, t, J 7.4 Hz, C(4)H), 2.88 (3H, d, J 7.4 
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Hz, C(3)H); 13C NMR (100 MHz, CDCl3) % 169.0 (C(1)), 56.1 (C(2)), 53.3 
(CO2CH3), 30.8 (C(4)), 14.2 (C(3)); m/z (+ve ion electrospray) 118 ([M+H]+, 
100%); (Found 118.0875, C5H11NO2, ([M+H]+), requires 118.0863). 
 
(S)-Methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-N,4-
dimethylpentanamido)propanoate. (131) 
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O
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To a solution of Boc-Leu-OH monohydrate (497 mg, 1.99 mmol) and 130 (350 mg, 
2.99 mmol) in DCM/DMF (5:1, 15 mL, 0.1 M) at 0 °C was added HOAt (407 mg, 
2.99 mmol), EDCI (765 mg, 3.99 mmol) and NaHCO3 (251 mg, 2.99 mmol). The ice 
bath was removed and the reaction allowed to warm to rt and then stirred overnight. 
The reaction mixture was quenched with HCl (1 M, 20 mL), the organic layer diluted 
with EtOAc (25 mL) and layers separated. The organic layer was washed with HCl 
(1 M, 20 mL), saturated NaHCO3 (2 & 20 mL) and brine (2 & 20 mL) then dried over 
MgSO4, filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (SiO2, 4:1, PE:EtOAc) gave the title compound as a white 
crystalline solid (457 mg, 72%). Rf 0.28; Mp 141.9 – 142.4 °C; (max (solid state)/cm$1 
3296 (brw, N-H), 2958 (brw, C-H), 2871 (brw, C-H), 1746 (m, C=O), 1721 (s, 
C=O), 1711 (s, C=O), 1503 (m); 1H NMR (400 MHz, CDCl3, major isomer) % 5.27 – 
5.21 (2H, m, NH & C(2)H), 4.67 (1H, m, C(4)H), 3.69 (3H, s, CO2CH3), 2.99 (3H, s, 
C(10)H3), 1.80 -1.70 (1H, m, C(6)H), 1.46 – 1.39 (14H, m, C(CH3)3, C(9)H3 & 
C(5)H2), 0.99 (3H, d, J 6.7 Hz, C(7)H3 or C(8)H3), 0.93 (3H, d, J 6.7 Hz, C(7)H3 or 
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C(8)H3); 13C NMR (100 MHz, CDCl3) % 173.4 (CON(CH3)CH), 172.1 (CO2CH3), 
155.6 (CO2C(CH3)3), 79.4 (CO2C(CH3)3), 52.2 (CO2CH3), 52.0 (C(2)), 48.9 (C(4)), 
42.2 (C(5)), 30.9 (C(10)), 28.3 (CO2C(CH3)3), 24.5(C(6)), 23.4 (C(7) or C(8)), 21.7 
(C(7) or C(8)), 14.2 (C(9)); m/z (+ve ion electrospray) 353 ([M+Na]+, 100%); 
(Found 353.2044, C16H30N2NaO5, ([M+Na]+), requires 353.2047). 
 
(S)-Methyl 2-((S)-2-amino-N,4-dimethylpentanamido)propanoate. (132) 
 
N
1234
5 OMe6
O
7
8
9
10
O
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HCl-EtOAc (4 M, 7 mL) was added to neat methyl ester, 131 (239 mg, 0.75 mmol) 
at 0 °C for 1.5 h. Volatiles were removed with a stream of nitrogen and the sample 
was further dried under high vacuum to yield the title compound as colourless 
crystals (166 mg, 96%). This compound can be used in the subsequent reactions 
without further purification. 
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(S)-Methyl 2-(methylamino)-3-phenylpropanoate-N-MePhe-OMe. (134) 
 
H
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By using the similar procedure described for 130, Boc-Phe-OH (1.0 g, 3.77 mmol) 
provided the title compound as a pale yellow oil (0.770 g, 89%). [!]D21 +24.0 (c 1.0 
in MeOH) [lit107 [!]D20 +24.9 (c 0.3 in CHCl3)]; (max (evaporated film)/cm$1 3366 
(brw, N-H), 3027 (brw, C-H), 2955 (brw, C-H) 2747 (brm, C-H), 2692 (brm, C-H), 
2434 (brm, C-H), 1737 (s, C=O), 1633 (w, C=C), 1604 (w, C=C), 1569 (w, C=C); 1H 
NMR (400 MHz, CDCl3) % 10.44 (1H, brs, NH), 9.47 (1H, brs, NH), 7.38 – 7.27 
(5H, m, 5 & Ar-H), 4.02 (1H, brs, C(2)H), 3.68 (3H, s, CO2CH3), 3.59 (1H, d, J 12.2 
Hz, C(3)HaHb), 3.37 (1H, q, J 5.8, 12.2 Hz, C(3)HaHb), 2.76 (3H, brs, C(10)H3); 13C 
NMR (100 MHz, CDCl3) % 168.1 (C(1)), 133.9 (C(4)), 129.2 (2 & Ar-CH), 128.9 (2 
& Ar-CH), 127.7 (C(7)), 62.6 (C(2)), 53.1 (CO2CH3), 35.8 (C(3)), 32.3 (C(10)); m/z 
(+ve ion electrospray) 194 ([M+H]+, 100%); (Found 194.1179, C11H16NO2, 
([M+H]+), requires 194.1176). 
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(S)-Methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-N,4-dimethylpentanamido)-3-
phenylpropanoate. (135)  
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To a solution of Boc-Leu-OH monohydrate (120 mg, 0.482 mmol) and 134 (102 mg, 
0.530 mmol) in DCM/DMF (5:1, 5 mL, 0.1M) at 0 °C was added HOAt (72 mg, 
0.530 mmol), EDCI (185 mg, 0.964 mmol) and NaHCO3 (45 mg, 0.530 mmol). The 
ice bath was removed and the reaction allowed to warm to rt and then stirred 
overnight. The reaction mixture was quenched with HCl (1 M, 10 mL), the organic 
layer was diluted with EtOAc (15 mL) and the layers separated. The organic layer 
was washed with HCl (1 M, 10 mL), saturated NaHCO3 (2 & 10 mL) and brine (2 & 
10 mL) then dried over MgSO4, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (SiO2, 3:1, PE:EtOAc) gave the title 
compound as a white crystalline solid (371 mg, 76%). Rf 0.35; Mp 117.5 – 119.5 °C; 
(max (solid state)/cm$1 3383 (w, N-H), 3028 (w, C-H), 2977 (w, C-H), 2949 (w, C-H), 
2917 (w, C-H), 2874 (w, C-H), 1730 (m, C=O), 1703 (s, C=O), 1644 (s, C=O), 1584 
(m, C=C), 1516 (w, C=C); 1H NMR (400 MHz, CDCl3, major isomer) % 7.24 – 7.09 
(5H, m, 5 x Ar-CH), 5.11 (1H, dd, J 10.1 & 5.3 Hz, C(2)H), 4.97 (1H, brd, J 9.5 Hz, 
NH), 4.45 (1H, ddd, J 9.5, 9.5 & 4.1 Hz, C(4)H), 3.65 (3H, s, CO2CH3), 3.30 (1H, 
dd, J 14.5 & 5.3 Hz, C(9)HaHb), 2.97 (1H, dd, J 14.5 & 10.1, C(9)HaHb), 2.83 (3H, s, 
C(16)H), 1.67 – 1.57 (1H, m, C(6)H), 1.37 – 1.34 (11H, m, C(CH3)3 & C(5)H2), 0.88 
(3H, dd, J 6.3 Hz, C(7)H3 or C(8)H3), 0.84 (3H, dd, J 6.3 Hz, C(7)H3 or C(8)H3); 13C 
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NMR (100 MHz, CDCl3 major isomer) % 173.4 (CON(CH3)CH), 171.0 (CO2OCH3), 
155.4 (CO2C(CH3)3), 136.7 (C(10)), 128.8 (2 & Ar-CH), 128.4 (2 & Ar-CH), 126.7 
(C(13)), 79.3 (CO2C(CH3)3), 58.8 (C(2)), 52.2 (C(4)), 48.7 (CO2OCH3), 42.2 (C(5)), 
34.4 (C(16)), 32.9 (C(9)), 28.2 (CO2C(CH3)3), 24.5 (C(6)), 23.3 (C(7) or C(8)), 21.6 
(C(7) or C(8)); m/z (+ve ion electrospray) 429 ([M+Na]+, 100%); (Found 429.2363, 
C22H34N2NaO5, ([M+Na]+), requires 429.2360). 
 
(S)-2-((S)-2-((Tert-butoxycarbonyl)amino)-N,4-dimethylpentanamido)-3-
phenylpropanoic acid. (136) 
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Methyl ester 135 (200 mg, 0.49 mmol) was dissolved in t-BuOH:H2O (2:1, 0.1 M) 
and cooled to 0 °C. Lithium hydroxide monohydrate  (24 mg, 0.99 mmol) was added 
and the mixture was stirred for 1.5 h after which HCl (1 M) was added until pH 
reached 1-2. The product was extracted with EtOAc (3 & 10 mL) and the combined 
extracts dried over MgSO4, filtered and concentrated under reduced pressure to yield 
the free acid as colourless crystals (190 mg, 98%). This compound can be used in the 
subsequent reactions without further purification. 
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5.4 Biochemical experiments. 
 
5.4.1 General methods 
Materials 
!1-Antitrypsin antibody was purchased from Calbiochem, anti-!-tubulin antibody 
was obtained from Abcam and the anti-ubiquitin P4D1 monoclonal antibody was 
obtained from Santa Cruz Biotechnology inc. (Santa Cruz, CA, USA) and secondary 
antibodies were purchased from Licor Biosciences. Proteasome inhibitor II (ZLLF-
CHO; Benzyloxycarbonyl)-Leu-Leu-phenylalaninal) was obtained from Merck 
Biosciences. Alexa488 azide was obtained from Invitrogen. T7 and SP6 RNA 
polymerases, rNTPs, RNasin ribonuclease inhibitor, amino acids and nuclease 
treated rabbit reticulocyte lysate were obtained from Promega. DNA and RNA 
purification kits were obtained from Qiagen. All other reagents were obtained from 
Sigma.  
The linear transcription template for ppCec was provided by Nick Johnson in the 
High lab in the pTNT vector and the mRNA transcript of pPL was provided by 
Quentin in the High lab. Canine pancreatic ER microsomes and mRNA for pre-
procecropin and pre-prolactin were prepared by the High lab according to published 
protocols.108,109 All ES compounds were synthesised as previously described and 
solubilised at a concentration of 10 mM in DMSO giving a stock solution and stored 
at $80 °C prior to use. 
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Cell Culture 
HeLa cells were cultured in DMEM (Sigma) supplemented with 10% fetal bovine 
serum (FBS) and 2 mM L-glutamine. HepG2 cells were cultured in DMEM 
supplemented with 10% FBS only. 
 
Splitting cells 
Growth media was aspirated and replaced with warm phosphate buffered saline 
(PBS, 10 mL) then aspirated again. Warm trypsin (3 mL) was then added and the 
flask returned to 37 °C for 5-15 mins. Gentle tapping every few minutes dislodged 
cells from the surface. Complete media (7 mL) was added to the trypsinised cells and 
the solution resuspended to break up any cell clumps by pipetting against the side of 
the flask 3 times. The cells were split at a 1:3 or 1:4 dilution into 6 or 12 well dishes 
for use in experiments or 1:10 into a new flask for maintenance.  
 
Semi-intact cell preparation 
HeLa cells in a 12-well dish were washed twice with ice-cold PBS then incubated in 
ice-cold 1& KHM buffer (110 mM KOAc, 2 mM Mg(OAc)2, 20 mM HEPES, pH 
7.2; 0.5 mL per well) containing digitonin (40 µg/mL) for 10 mins. The cells were 
washed twice with 1& KHM buffer (0.5 mL per well) then incubated in ice-cold 1& 
HEPES buffer (238 g/L HEPES in H2O, pH 7.5, 0.5 mL per well) on ice for 10 mins. 
The cells were washed again with 1& KHM buffer and incubated with 1& KHM 
buffer (0.2 mL/well) containing CaCl2 (1 mM) and calcium-dependant monococcal 
nuclease (10 µg/mL) at RT for 12 mins. The solution was aspirated and the cells 
incubated in 1& KHM buffer (0.2 mL/well) containing ethylene glycol tetraacetic 
acid (EGTA, 4 mM) to chelate Ca2+ and inactivate the nuclease. 
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TCA precipitation 
1/10 of the total volume of 100% trichloroacetic acid (TCA) was added to each 
sample, mixed thoroughly and left on ice for 30 mins. Each sample was centrifuged 
at 4 °C for 30 minutes at 14,000 rpm in a microfuge and the supernatant removed. 
Each pellet was washed with 1 mL of acetone, centrifuged for 15 mins at 14,000 rpm 
in a microfuge and the supernatant removed. The pellets were dried at 95 °C for 5 
mins then 1& SDS-PAGE sample buffer (100 µL) and DTT (1 M, 10 µL) were 
added. 
 
SDS-PAGE and sample analysis 
SDS-PAGE gels were performed using the Laemmli method110, which involved the 
solubilsation of samples in 1& SDS sample buffer and denaturation at 37 °C for 1 h 
before electrophoresis with 8, 10, 12 or 18% tris-glycine acrylamide separating gels. 
For radiolabelled samples, gels were dried and exposed to phosphorimager plate 
(Fuji), then scanned using a Fujifilm LAS-3000 system. Quantitative analysis of 
pixel intensity on phosphorimages was carried out using AIDA v4.0 software. 
 
Western Blotting 
Proteins were transferred to a nitrocellulose membrane (Licor Biosciences) in 1& 
transfer buffer (0.025 M Tris-HCl, pH 8.3, 0.192 M glycine and 0.0013 M SDS, 20% 
(V/V) MeOH) at 30 mAmps for required time (2.5 h for ubiquitin, 1 h for all other). 
After this time the membrane was blocked for 1 h at rt in a solution containing 4.5 
mL of 1& TBS (0.02 M Tris-HCl, pH 7.6, and 0.15 M NaCl) and 500 µL of 10& 
blocking buffer (Sigma). The membrane was then blotted with a relevant antibody 
for 18 h at 4 °C (P4D1 mouse ubiquitin was used 1:500, !-tubulin, albumin and !1-
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AT were used 1:3000) in a solution containing 1& TBS (4.5 mL) and 10& blocking 
buffer (500 µL). The membrane was then washed four times with 1& TBS (5 mL) 
and then the blot was incubated for 1 h at rt in a solution containing 1& TBS (4.5 
mL), 10& blocking buffer (500 µL) and the corresponding secondary antibody (all 
secondary antibodies were used 1:5000). The membrane was washed with 1& TBS 
four times and bands visualised using an Odyssey-SA (Licor Biosciences) infra-red 
scanner. Bands were quantified using Odyssey software. 
 
Data analysis and statistics 
Graphs and statistical analyses were prepared using Microsoft Excel 2004 for 
Macintosh.  
 
5.4.2 Measurement of Cell Viability (MTT assay) 
Approximately 10,000 HeLa cells were plated into each well of a 96 well plate and 
grown for 24 h. Old media was aspirated and replaced with 200 µL of media 
containing 2, 4, 8, 16, 32 and 64 µM concentrations of ES compounds or DMSO 
solvent control in triplicate (i.e. 3 wells per treatment condition) or in triplicate with 
fresh media in the blanks. The cells were incubated for a further 16 h then the media 
was aspirated and the cells washed twice with PBS. A 0.05 µg/mL solution of MTT 
(Sigma) was prepared in 9 mL of DMEM (without phenol red) was added (100 µL 
per well) and the cells incubated for 2 h. The MTT media was aspirated and DMSO 
(100 µL) was added to each well and the plate was agitated for 15 minutes. The 
absorbance of the DMSO solubilised product was measured at 570 nm using a 
Synergy H1 hybrid reader spectrophotometer (BioTek, USA) and the data compiled 
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using Gen5 software (Biotek, USA). Cell viability was determined measuring the 
absorption at 570 nm and calculating the mean of triplicate samples and expressing 
as a percentage against the mean absorption of DMSO treated cells. Standard 
deviation for ESI and ES35 was calculated from three sets of data. 
 
5.3.3 Vacuolisation and accumulation of polyubiquitin conjugates 
HeLa cells were plated into 6-well dishes and left to grow until 60-70% confluent. 
Cells were treated with PSII (10 µM), ESI, ES35, ES40, ES326, ES328, ES47, ES24, 
ES24 Click para or ES24 Click meta at 8 µM or ES47 at 16 µM at 37°C for 8 h. An 
Olympus IX51 Inverted microscope was used to take pictures of live cells. Cells 
were then washed with PBS twice and then lysed 1& SDS sample buffer (62.5 mM 
Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.0025% Bromophenol blue; 100 µl per 
well of a 6 or 12-well dish). Cells were solubilised at RT overnight and insoluble 
material was sonicated using a Diagenode bioruptor at high speed for 5 mins at 4°C. 
Denaturation of proteins was performed at 37 °C for 1 hour or at 70 °C for 10 
minutes and samples centrifuged at 14800 rpm in a microfuge for 5 mins. Samples 
were analysed by SDS-PAGE and western blotting. 
 
5.4.4 In vitro translocation assay 
The analysis of translocation inhibition involved two types of assay post-translational 
translocation and co-translational translocation: 
Post-translational translocation: Cell free translation was performed by taking 240 µl 
of a translation mixture (200 µL rabbit reticulocyte lysate supplemented with 6.25 
µL of amino acids ($methionine), 2.5 µL of RNasin, 25 µL of water and 19 µL of 
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35S Methionine/Cysteine (22 µCi/mL)) and incubating at 30 °C for 15 mins in the 
presence of an in vitro synthesised mRNA transcript of ppCec (24 µL). Translation 
was stopped upon the addition of puromycin (1 mM, 12 µL) and further incubation 
for 5 mins, this generated the 35S labelled ppCec. The translation mixture was added 
to a 12 well dish (20 µL per well) containing freshly prepared semi-permeabilsed 
HeLa cells that had been treated with 10 µM PSII, 8 µM ESI, ES35, ES326, ES328, 
ES47, ES40, ES24, ES24 Click para, ES24, Click meta or 16 µM ES47 for 1 h. Cells 
were then incubated at 30 °C for 1 h to allow post-translational translocation of 
ppCec across the ER membrane of the semi-permeablised cells.  
 
Co-translational translocation: Translation reactions were assembled as above but on 
ice to prevent translation and the in vitro synthesised mRNA transcript of pre-
prolactin (pPL) was added. This mixture was then added to freshly prepared semi-
permeabilised HeLa cells that had been treated with PSII (10 µM), ES35, ESI, ES40, 
ES24 Click para or ES24 Click meta at 8 µM for 1 h. Cells were then incubated with 
the translation reaction for 1 h at 30 °C to allow co-translational translocation of pPL 
to occur. 
 
In both post- and co-translational translocation assays the translation mixture was 
aspirated and the cells were washed with 1& KHM buffer. The cells and associated 
radiolabelled proteins were then solubilised in 2& SDS-PAGE sample buffer (40 µL) 
and incubated at 37 °C for 30 min. The samples were analysed by SDS-PAGE using 
18% acrylamide gels followed by dried gel phosphorimaging. 
 
 213 
5.4.5 Protein secretion from HepG2 cells 
Normal media was aspirated from each well of a 6-well dish and washed twice with 
PBS and cells incubated with starvation media (DMEM lacking methionine and 
cysteine supplemented with 2 mM glutamine) containing ESI, ES35, ES40, ES326, 
ES328, ES47, ES24, ES24 Click para, ES24 Click meta at 8 µM, DMSO 10 µM, or 
Brefeldin A (5 µg/mL, Sigma) for 30 mins at 37 °C. The starvation media was 
aspirated and replaced with 1 mL pulse media per well (Starvation media containing 
2 µL/mL, 22 µCi/mL, 35S methionine/cysteine) containing the same compounds. The 
cells were incubated for a further 1 h at 37 °C to allow metabolic labelling of cellular 
proteins (“Pulse” period). The pulse media was then aspirated and the cells washed 
twice with PBS and then incubated with chase media (1 mL per well, normal DMEM 
without FBS) containing the same compounds for a further 1.5 h at 37 °C. During 
this ‘Chase’ period, the radiolabelled secretory proteins synthesised during the pulse 
period, were transported along the secretory pathway and released into the media.  
The chase medium was collected and centrifuged at 4 °C for 5 mins at 10,000 rpm in 
a microfuge and the supernatant TCA precipitated. The samples were analysed by 
SDS-PAGE using a 10% acrylamide gel and radioactive proteins were visualised by 
phosphorimaging. The cells were harvested in 1& SDS-PAGE sample buffer (200 
µL), and analysed as above. Cell lysates were also analysed by SDS-PAGE using an 
8% acrylamide gel and immunoblotting with !-tubulin and ubiquitin antibodies of 
the cell samples. The secretion of !1-anti-trypsin and albumin into the media was 
specifically analysed by SDS-PAGE using a 12% acrylamide gel and 
immunoblotting of the TCA precipitation samples. 
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5.4.6 Click chemistry 
ESI Click, ES35 Click, ES47 Click or ESIB Click (250 µM) were incubated with 
canine pancreatic rough microsomes (10 µL) at 0 °C for 1 h. To ES-treated 
microsomes the following reagents were added in order: 1% SDS (10% stock in 
H2O), Alexa 488-N3 (50 µM), tris(carboxyethyl)phosphine (TCEP, 1 mM), TBTA 
(100 µM in 4:1 tert-BuOH/H2O) and lastly CuSO4 (1 mM). Reactions were mixed 
gently and incubated at rt for 2 h. 6& SDS-PAGE sample buffer (5 µL) was added, 
the samples were incubated at 70 °C for 10 minutes and the reactions resolved by 
SDS-PAGE on 12% acrylamide gels (BioRad). The gels were scanned for 
fluorescence (480 nm) using a Fujifilm LAS-3000 system. 
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